



BRUSSELS LIFETECH



Brussels**LifeTech**
Powered by BEA






FOREWORD

The process of innovation in the “Life Technologies” sector involves an interdisciplinary approach aroused by a dynamic network between the academic laboratories and the entrepreneurial world in the medical technologies, biotech and pharma field. The Brussels-Capital Region, on a concentrate space, gather an important expertise as well for new developments integrating the last communication technologies as for clinical research. This brochure gives an overview of the academic area, companies, support organizations and incubators active in the “Life Technologies” sector in the Brussels-Capital Region. Are you looking for new partnership or have any project of implementation in the Brussels area, do not hesitate to contact either directly the companies, the universities, the institutions or the Brussels LifeTech Cluster.





CONTENTS

11

Research Area Landscape

23

Companies Involved in Medical
Technologies Field

61

Companies Involved in Biotechnology
& Pharma Fields

87

Companies Involved in Expertise & Services
Fields

115

Incubators

121

Brussels Support Organizations

140

Index



BRUSSELS LIFETECH

The Brussels-Capital Region with its central position in northern Europe has a population of one million (around 10% of the Belgian population). Even though the Region covers 161 km² (0,5% of the Belgian territory), it represents 15% of the global healthcare activity in Belgium comprising as well hospitals, private doctors, universities and industries. The dynamism of the Brussels Life Technologies sector results from a close collaboration between universities, the industry and the support of the Regional Institutions. The presence in a small area of three main universities, a broad network of hospitals linked with these universities, is a favourable environment for the development of Life Technologies activities in the Brussels-Capital Region.





Brussels **LifeTech**
Powered by BEA

THE BRUSSELS LIFETECHNOLOGIES SECTOR

Companies In Brussels

The Brussels-Capital Region gathers more than 300 companies active in "Life Technologies" (biotech, pharma, medical technologies), 110 of these companies are active in R&D, production or expertise and services linked to these sectors. In this catalogue, you have an overview of 84 of these companies: 35 (42%) active in medical technologies, 12 (14%) in Pharma, 12 (14%) in biotech and 25 (30%) in expertise & services.

Focus On Two Specific Themes



European trends, in matters of clusters, is to focus on topics to consolidate the majority of regional actors. Considering these trends the Cluster will focus on two priority themes. The mapping of the Brussels actors, the critical mass and the market interpenetration leads the Brussels LifeTech Cluster to consider cross-cutting thematics: the “clinical trials” and “telemetry”.

Clinical trial

The theme “clinical trials” meets the common goals of CROs, many actors of “medical devices” and “pharma” and “hospitals” active in this field. According to a study by Deloitte, some 9% of European clinical trials on new drugs are made in Belgium, placing our country in the lead. On average, 540 clinical trials are conducted each year in Belgium. Between 2006 and 2008, the number of studies has jumped 17%.

Telemetry

The “telemetry” includes the technologies that collect, organize and share clinical data needed to assess the patient’s condition, diagnosis and determine treatment. It allows diagnosis and “remote patient monitoring.”

The combination of sub-sectors of “diagnosis” and “data transfer” together represent 61% of value-added businesses in medical devices in the Brussels-Capital Region and allow the “telemetry” (remote patient monitoring) to be a driver of development of medical technologies in

Brussels.

Global trends, growth and ageing population increasing the needs of chronic patients monitoring (nearly 50% occupancy of hospital beds in Europe), involve the improvement of new methods of diagnosis and monitoring of patients, making telemetry the technology trend for the future of medical care.

The “telemetry” could interest both companies involved in the “medical diagnosis” and companies active in the “management” and “data transfer”. The fact that one of the four markets in this theme is the “clinical trials” ensure transferability between them and the “telemetry”.

Research In Brussels

In Brussels, the presence of 3 main universities, “ULB (Université Libre de Bruxelles)”, “UCL (Université catholique de Louvain)” and the “VUB (Vrije Universiteit Brussel)”, one “Haute Ecole”, the “Meurice Institute” and “5 university hospitals”, including almost 3.000 researchers in life sciences, has provided a favorable environment for the development of LifeTech companies. The financing of research in the Brussels-Capital Region is supported by INNOVIRIS (the Brussels Institute for Research and innovation).

Incubators In Brussels

Incubation infrastructures have been created on the initiative of the Brussels-Capital Region in order to help start-ups and spin-offs.

BLSI (The Brussels Life Science Incuba-



tor) is located on the UCL site and provide specific accommodation for start-ups: offices, laboratories and logistic facilities. Moreover, start-ups will benefit from the UCL support structure: SOPARTEC and its Vives investments fund, the Research Management Office of UCL and the Vésalius Scientific Park.

EEBIC (The Erasmus European Business & Innovation Centre) created in 1992 offers more than 6.000 m² of premises, from offices to equipped laboratories, and a comprehensive administrative infrastructure which enables start-ups and spin-offs to grow up. The EEBIC team provides managerial advices, from the preparation of a business plan to intellectual property protection, in order to support pioneering projects development.

Solvay Campus has opened its largest research and development site to start-ups. Solvay Campus offers spaces for research, the necessary backing for their activity, particularly favorable conditions of accommodation, within the framework of an agreement where the start-up retains its full independence and the intellectual property rights on its research.


Financing Possibilities

The Brussels Regional Investment Agency (SRIB), Business Angels Connect, the Participation Fund, the Warranty Fund, Venture Capital providers and business oriented banks offer different possibilities of funding start-ups and fast growing companies. The Brussels Regional Authorities have created efficient financial mechanisms in order to support the scientific research and the technological development efforts of the companies in the Brussels area: subsidies or interest

less loans can be obtained for R&D activities (InnovIris).

The Brussels Lifetech Cluster

The Brussels LifeTech Cluster is an initiative of the the Brussels Enterprise Agency. The Brussels LifeTech Cluster's mission is to support the life technologies sector in the Brussels-Capital Region. Our objective is to ensure that the life technologies remain a strong driver of economic growth in the region, attracting new R&D companies, investors, and service & technology providers. The Brussels LifeTech Cluster brings together companies with innovative, R&D-driven activities in the life technologies (biotechnological, pharmaceutical or medical technologies sectors) that are based in Brussels but also academic research institutes and support organisations.



The main objective of the cluster is the visibility of the Brussels know-how, stimulating innovation, encouraging international partnerships and generating synergies between the players.

Mission

The mission of the Brussels LifeTech Cluster is to:

- stimulate, accelerate and develop the competitiveness of the companies and “start-ups” mainly on our priority thematics promote and facilitate international marketing of the cluster members.
- stimulate “added value” interactions between the cluster members to create synergies, complementarities and all relevant collective initiatives.
- create, with all regional partners, an adequate environment for innovation and the development of the sector.

Business Development Support

Among the cluster activities, the Brussels LifeTech Cluster develops different kinds of services for the Brussels biotech, pharma or medical technologies players: technology and commercial partnerships, strategic information, project validation, industry-university collaboration, participation to international events, communication tools development, ...

Think Europe, Act From Brussels

Many people know Brussels as the political capital of Europe and the centre of many of the European institutions. Decisions affecting the life of 450 million people are taken here every day, and this is why Brussels has also become the home of many multinational headquarters. But other important factors have made Brussels one of the world’s leading business centers. It is located at the heart of the wealthiest and most populated area of Europe. Sixty percent of the EU purchasing power lies in a 300 miles radius. Brussels International Airport is located 12 km from the city center and the new rapid train network (TGV) provides rapid rail services to Paris, London, Amsterdam and Frankfurt. Brussels is a city of 1 million inhabitants with an astonishing variety of cultures, styles and nationalities. Unlike other European capitals, it is large enough to be cosmopolitan and yet small enough to allow its inhabitants to enjoy all the advantages of a human size city. Geographically, economically and thanks to its outstanding quality of life, Brussels has convinced numerous overseas investors, from SME’s to international headquarters to set up their company in this unique region.

More information about the cluster activities and services:

www.brussellslifetech.com



@BruLifeTech



Brussels LifeTech



RESEARCH AREA LANDSCAPE

In the Research Area Landscape, Research Institutions are key vehicles for technology transfer. With three main universities, a broad network of hospital linked with these universities and research centers, the Brussels-Capital Region, in a restricted area, developed an important potential in research activities.



The Université catholique de Louvain (UCL) has a longstanding world-renowned expertise in Life technologies.

ILLUSTRATIVE RESEARCH TOPIC AT UCL

Health and life sciences are considered by UCL to be one of the areas of strategic research. The research projects are conducted jointly by several Institutes, in which teams of outstanding quality collaborate around a core field of research. Furthermore, UCL institutes are supported by technological platforms and facilities. This particular organization optimizes the coordination between research groups, which thereby increases their chances of success.

Many UCL research projects in life sciences are led in collaboration with the UCL academic hospitals "St-Luc" (Woluwe-St-Lambert) and "Mont-Godinne", and through a network of 35 healthcare institutions.

- De Duve Institute (<http://www.deduveinstitute.be>) Research teams give special attention to medical benefits resulting from basic findings. cancer immunology, biochemistry or signal transduction.
- Institute of Neuroscience (<http://www.uclouvain.be/ions.html>) aims to improve the knowledge of our nervous system and neurological illness.
- Experimental and Clinical research Institute (<http://www.uclouvain.be/irec.html>) gathers clinical and fundamental research to better understand diseases and to set up new therapies.
- Louvain Drug Research Institute (<http://www.uclouvain.be/en-ldri.html>) complete drugs development, from the conception of active molecules to their formulation, and optimization of their use.

- Institute of Health and Society (<http://www.uclouvain.be/irss.html>). Integration of health issues in regards to some social aspects.
- Institute of Life Science (<http://www.uclouvain.be/en-isv.html>) exploring the basic mysteries of life in the fields of biochemistry, molecular and cell biology, microbiology, genetics and physiology.
- Institute of Information and Communication Technologies, Electronics and Applied Mathematics (<http://www.uclouvain.be/en-352437.html>), outstanding level of competence in bioengineering, computational biology and bioinformatics, high-density DNA micro-array and next generation sequencing, biomedical data analysis, medical imaging, new biosensors, modeling of biological and physiological systems
- Institute of Mechanics, Materials and Civil Engineering (<http://www.uclouvain.be/en-immc.html>), new biomaterials, biomechanics and surgical robotics, contributes to the evolution of medicine and surgery.
- Earth and Life Science Institute (<http://www.uclouvain.be/eli.html>) studies agronomy, applied microbiology, environmental science and biodiversity.

UCL research institutes are also supported by state-of-art facilities, which bring together technical and administrative staff around a coherent set of scientific and technical equipment (<http://www.uclouvain.be/373687.html>). This broad approach to the UCL research potential can be supplemented with booklets detailing the research projects by themes. To date eight themes in relation with life/medical science have been published: biomedical engineering, biotechnology and biomedical applications, cancerology, food science and

nutrition, applied biology, agriculture and environment, materials, ICT and nanotechnologies (<http://www.uclouvain.be/349.html>).

TECHNOLOGICAL TRANSFERS AT UCL

Beyond teaching and research UCL fulfills a third mission, known as “Services to the Society”. Economic exploitation of knowledge and technological transfers are as crucial for UCL as for the Society. However, despite their common interest in innovation and economic growth, the processes of innovation are lengthy, very complex and expensive.

To meet these challenges the Louvain Technology Transfer Office or “LTTO” (<http://ltto.com/>) has been set up, which associates the teams of the UCL Research Administration Department of UCL and Sopartec, the UCL technology transfer company. As a result the LTTO is a single desk where academic researchers and UCL partners can find a full range of integrated services in the fields of technological transfer.

The LTTO also collaborates with the entrepreneurial world with an aim to developing innovation inside companies. The LTTO helps them to know what UCL technologies may best meet their need for development and which UCL team is the best to work with.

UCL takes part in an impressive economic exploitation of knowledge by supporting the creation of spin-off companies. The development of research spin-offs is a longstanding success story at UCL. To date 46 spin-offs have been built up following technologies developed at UCL, which represent over 2,400 jobs created. Several of these spin-offs are related to life/health sciences, such as IBA (sterilization-radiotherapy). In order to favour the continuous development of spin-offs the UCL has set up two company incubators. These structures host and support young entrepreneurs and researchers in their efforts to build innovative companies. The Brussels Life Science Incubator (<http://www.blsincubator.be/>) located at the UCL biomedical campus, is dedicated to life/health science. It benefits both from the top-level expertise of a number of UCL specialists and of the activities of several scientific platforms. The second incubator, known as the “Centre d’Entreprise et d’Innovation” (<http://www.ceilln.be/>) is hosted at the Louvain-la-Neuve campus.

For more information on research and development activities:

**The Université catholique de Louvain (UCL)
Research Management Office
Place de l’Université, 1
B - 1348 Louvain-la-Neuve
(Belgium)**

Phone: +32 10 47 24 97

Fax: +32 10 47 48 30

**E-mail
info-adre@listes.uclouvain.be**

www.uclouvain.be/en-recherche.html

UCL

ULB and its connections with hospitals

The Erasme Hospital is the academic medical center of the Université Libre de Bruxelles (ULB). It originally opened its doors in 1977 and currently employs around 3 000 staff. Every year, 300 medical students and many other nursing and physical therapy students are educated or receive practical work experience at the Erasme Hospital. ULB has yet also developed strong links with several important hospitals in the Brussels Region: the Institut des tumeurs Jules Bordet, the Brugmann University Hospital, the Queen Fabiola Children's University Hospital, the Saint-Pierre University Hospital and the hospitals in the IRIS Sud network. ULB also strongly benefits from a vast hospital training network in both provinces of Brabant and Hainaut in the south of Belgium.

ULB health and biotechnology thematic campuses

The "pôle santé" already gathers on the Erasme Campus scientific and teaching activities from the Faculty of Medicine, the faculty of Motricity Sciences, the Public Health School as well as the Erasme Hospital. Both the Faculty of Pharmacy and the Institut des tumeurs Jules Bordet will move to the Erasme Campus in the coming years.

The Biopark Charleroi Brussels South gathers four institutes and research centers specialized in biomedical sciences: the Institute for Molecular Biology and Medicine, the Institute for Medical Immunology, the Center for Microscopy and Molecular Imaging and the Vegetal Biotechnology Laboratory.

This exceptional environment mixing health-care, research and teaching provides a wide range of expertise and value creation activities among which:

Molecular Biology

The Faculty of Science and the Faculty of Medicine at the ULB conduct both experimental and clinical research. Laboratory experiments are used to explain clinical observations while clinical activities take advantage of the output of fundamental research. Such an approach can help understanding the physiological roles of receptors and their ligands and implications in various pathologies; the study of intercellular communication enables ideal targets to be identified for the development of novel therapeutic agents in such varied fields as neuropsychiatry, endocrinology, inflammatory diseases and the treatment of AIDS; research finds applications in the development of new vaccines, in the rational design of new medicines and the development of new therapeutic approaches such as immunotherapy and gene therapy.

Oncology

The Jules Bordet Institute is a leading Belgian institution that is entirely devoted to screening, diagnosis and treatment of cancer whilst at the same time exercising a scientific, clinical and pedagogical activity for many cancer-related health problems. The research activities conducted in Institut des tumeurs Jules Bordet have led over recent years to several value creation activities (patents and spin-off).

Immunology

Research activities in immunology cover vari-

ous fields including immunosuppression, organ transplants, immunodeficiency, new pathologies, cell marking and cancer therapies. ULB research units in immunology participate in international networks and contribute to the development of new economic activities. They are for example taking an active interest in fields such as Cancer Immunotherapy, in the relationship between cell metabolism and immune response, in the identification and characterization of new vaccine adjuvants or in the immune system in early life.

Pharmaceutical Research

The Faculty of Pharmacy includes research units working in the field of medical sciences, biochemistry, therapeutic chemistry, pharmaceutical microbiology and related sciences. Research units in the Faculty have numerous research contracts with pharmaceutical industries to develop new medicines and to improve their conservation. The University hospital infrastructures also provide the necessary environment to conduct clinical research for the private sector.

Public Health Research

The Public Health School develops activities in several fields related to public health: occupational medicine, industrial hygiene and the environment, community health, hospital and medico-social sciences, age-related problems and the health economy. It undertakes numerous research projects in Belgium, at the European level and in developing countries, especially in the following areas: epidemiological monitoring, toxicology, hospital planning, adolescent health, etc. Research units in the School also conduct studies on the influence of the working environment (noise, vibrations, temperature and lighting) on workers' health and wellbeing as well as on the health risks and acceptable exposure levels to various substances present in the environment.

For more information on research and development activities:

Université Libre de Bruxelles (ULB)
Research Department
Technology Transfer Office (TTO)
Avenue F.D Roosevelt, 50
CP161
B - 1050 Brussels (Belgium)

Contact persons-
Laurent INGRASSIA
Scientific Advisor

Phone: +32 2 650 23 09
Fax: +32 2 650 35 12

E-mail
laurent.ingrassia@ulb.ac.be

Frédéric DE CONINCK
Business developer

Phone: +32 2 650 30 27
Fax: +32 2 650 35 12

E-mail
frederic.de.coninck@ulb.ac.be

www.ulb.ac.be/rech/docs/ulbinter-uk.html

The Vrije Universiteit Brussel (VUB) is a dynamic and modern university with two parkland campuses in the Brussels Capital Region. The main campus in Etterbeek is home to seven faculties. The medical campus is located close to the university hospital, UZ Brussel in Jette. So is the healthcare campus of its association partner EhB (Erasmus University College Brussels). Together they form the Universitaire Associatie Brussel (UAB).

High quality education and research are central issues. More than 150 research teams are working on both VUB campuses. Our research teams are internationally recognised in many disciplines of fundamental and applied research. Thanks to this expertise and its strategic location, the VUB is your ideal partner for renowned research with an outlook on Europe and the world.

www.vub.ac.be

The Vrije Universiteit Brussel supports all R&D activities in the process leading from scientific discovery and exploration of new knowledge up to invention and development, including the interface with the regional and worldwide industrial and economic actors, the non-profit sector, the policy makers and governments.

Building relations with industry is crucial: giving a tangible impact to our R&D by transferring results to industry, government and society is a priority taken care of by the Technology Transfer Interface (TTI). Contract research, protection of intellectual property, license agreements, spin-off guidance, it all passes through the TTI, the unique entry point for industry, that knows how and where to find the right researchers to answer your

questions.

www.vubtechtransfer.be

CROSSTALKS, the university and industry network of the Vrije Universiteit Brussel, is one of the tools bridging the gap between the academic and the industrial worlds. Since we live in a fast-moving and rapidly evolving society, long-term visions are fundamental, but scarce. The short-term agendas of decision-makers in the political, corporate, non-profit and academic worlds do not enable them. This is exactly where CROSSTALKS can make a difference. CROSSTALKS aims at creating an open and constructive exchange dynamic by hosting thematic encounters which go beyond the limitations of specific disciplines and which encourage active participation of key players from all levels of society.

<http://crosstalks.vub.ac.be>

LifeTech research at the Vrije Universiteit Brussel

Researchers at the Vrije Universiteit Brussel are at the cutting edge of science in many disciplines.

The list below of biopharma and medtech research is far from complete:

- Cancer related genes
- Stem cell research
- Proteins for signal transmission
- Molecular genetics of bacteria
- Peptides for tumour diagnosis and therapy
- New fertilisation and reproduction techniques
- Diabetes research
- Dendritic cells as therapeutic cancer vaccine
- Biophotonics or light-based technologies used in medicine and life sciences

- Experimental in vitro toxicology
- Functional starter cultures for improved food quality, safety and healthiness
- Neuropharmacology
- Medical imaging
- Advanced rehabilitation technology and science (ALTACRO – step rehabilitation robot)
- And many more

Many of the laboratory activities and efforts at the VUB are oriented towards application in the university hospital. The UZ Brussel is internationally recognized for its expertise in reproductive medicine, oncology, diabetes, cardiovascular diseases, medical imaging and is well-known for its Children's Hospital.

A lot of the high quality research performed at the Vrije Universiteit Brussel also results in collaboration projects with the biomedical and pharmaceutical industry as well as in the establishment of university spin-offs. In Brussels two spin-offs are active: BruCells that specializes in the development of new cancer vaccines and Beta-Cell, a biotech company that arose from the Diabetes Research Center of the Vrije Universiteit Brussel and that develops novel cell therapy and other products related to diabetes.

For a complete overview of all the research teams in Lifetech and Medtech go to the directory under "Brussels LifeTech cluster" on: www.brussellslifetech.com

Or go to the search engine of the VUB for the research units and their activities: www.vub.ac.be/english/infoabout/research/index.php

For more information on research and development activities

The Vrije Universiteit Brussel (VUB)
Research & Development Dept
Technology Transfer Interface
Pleinlaan, 2
B - 1050 Brussels (Belgium)

Phone: +32 2 629 22 07
Fax: +32 2 629 21 08

www.vub.ac.be/technologytransfer

E-mail
rd.interface@vub.ac.be

Contact person
Sonja HAESEN
Head Technology Transfer Interface

CROSSTALKS - University and Industry

Network of the Vrije Universiteit Brussel

<http://crosstalks.vub.ac.be>

For the scientific and clinical research at the UZ Brussel

UZ Brussel
Laarbeeklaan 101
B - 1090 Brussels (Belgium)

Phone: +32 2 476 36 30

www.uzbrussel.be

Contact person
Bart STRAGIER
Research Manager UZ Brussel
E-mail
bart.stragier@vub.ac.be

Capitalizing on more than 40 researchers experts in Life Sciences, the “Meurice Institute”, part of the Haute Ecole Lucia de Brouckère, actively participates to broadly applied research with future-oriented and innovative strategy including economic valorization through existing spin-off companies.

Major research bioengineering units conducted in Meurice Institute are:

The “BIOTECHNOLOGY UNIT” (BTU) is an applied research centre is composed by the Microbial engineering and Chemical engineering departments.

BTU's thematics for innovative research achievements, strategic collaborations and technology transfers are:

- Isolation of natural strains of industrial interest (enzymes secretion, xenobiotics metabolism)
- Microbial starters production for food and bioepuration-technology
- Purification of recombinant proteins produced by genetically modified microorganisms (E. coli, L. lactis, P. pastoris, S. cerevisiae, etc)
- Development of fermentation processes with high biomass concentration
- Downstream processing development (UF, centrifugation, cell lysis, etc)
- Formulation by drying processes, immobilisation/coating of biological products and stability studies during storage
- Development of new processes in fermentation (batch, fed-batch, continuous process) for the food, environmental and pharmaceutical sectors with free or encapsulated living cells

- Production of natural antagonistic substances: organic acids, bacteriocins, biofungicides
- Computer-based design and liquid flows simulation of bioreactors
- Environmental technologies: specific biodegradating micro-organisms production, innovative bioprocesses for waste water and polluted air treatment

The “BREWING SCIENCES AND FERMENTATION TECHNOLOGY UNIT” is active in research in fermentation.

Research activities include:

- Selection of industrial yeasts (brewing purpose, bioethanol production, etc)
- Yeast as eucaryotic model for cosmetic or pharmaceutical studies
- Microbial produced aromatic substances
- Natural antioxidants extraction from yeast
- Organoleptical stable fermented beverages
- Nutritional characterization of beer
- Development of new fermentation technologies
- Process improvement such as beer filtration

The “FOOD TECHNOLOGY UNIT” helps companies during the assessment of physical/chemical food and non-food products control. With the help of advanced analysis equipments, this unit is active in aromas and odours analysis, microbiological control, new products development, nutritional products, etc.

The Food Technology Unit encompasses 3 lab's .

1. The laboratory for flavour analysis is ac-

tive in VOC's analysis by GC-MS sniffing for food or chemical products, etc.

2. The laboratory for food processing and analysis (member of IUPAC) provides skills in:

- Product research and development (formulation), new additives, ingredients, etc
- Product analysis
- Qualitative Analysis on micro-organisms by PCR-RT and ELISA*
- Allergens detection in foodstuff *

3. The laboratory of Sensory Technologies Analysis (LSTA) evaluates beverages, cosmetics, foods, fragrances, health care products, packaging, paints, etc using sensory analysis according to the AFNOR NF V 09-105 standards.

In addition LSTA provides expertise and competencies in:

- Behavioural studies (medical and paramedical studies) for sensory preferences of elderly people
- Effects of zinc deficiency on sensory perceptions
- Effect of cancer treatment on food preferences

The “**MICROBIOLOGY UNIT**” validates the efficiency of new products such as cleaning and disinfectant solutions, conservative factors developed by the food, the “soft drinks” and the brewery industries and the cosmetic field.

Tests are performed according to the European standards EN 1276, EN 1650 and C.O.L.I.P.A. standards.

The “**NATURAL SUBSTANCES UNIT**” analyzes protein pathways in order to solve medical diseases. Researches are conducted in collaboration with RUG, ULB-Erasme (department of cyclotron), Institut Bordet (department of mammary oncology or department of melanoma cells) using ChemTech 90 solid phase peptide synthesizer, the Fmoc-chemistry method and the electrospray mass spectrometry for analysis and sequencing.

The **RESEARCH AND INFORMATION CENTER ON FOOD INTOLERANCES AND HYGIENE (CIRIHA)** provides expertise mainly in food intolerances analysis and in reduction of cardiovascular risks related to food practices.

For more information on research and development activities:

**InduTec - Transfer Technology
Centre for the Brussels
(Belgium) Industrial
Engineering Institutes**

**Avenue Nellie Melba, 73
B - 1070 Brussels (Belgium)**

Phone: +32 2 534 33 79

Fax: +32 2 534 33 95

**Contact person
Cédéric DOUTRELEPONT**

**E-mail
doutrelepont@indutec.be**

www.indutec.be



Capitalizing on more than 40 researchers and experts, the HEPHS extensively participates in applied and fundamental research projects with the industrial world at Belgian and international levels.

The Institut Supérieur d'Ergothérapie et de Kinésithérapie (ISEK) department are active, for more than 80 years in Ergotherapy and Physiotherapy.

Research units

Anatomical Biomechanics and Morphology Unit

Study of the mechanical behaviour of the pelvic floor, especially of pelvic straits before and after muscular pre-stressing. Studies include anatomical description, clinical implications, mechanical and dynamic modelling in particular of the levator ani muscle.

- Modelling of the biomechanics of arterial and venous flows
- Clinical study of the consequences of episiotomy. The study evaluates the anatomical variations of the pudendal nerve in order to detect pain, lesions etc. and to find out new physiotherapeutic techniques coping with pain
- Numerical modelling of anatomical structures in order to understand the mechanisms of a lesion
- Analysis and considerations of the biomechanical and anatomical evolution of bipedalism
- Software and hardware developments allowing human volumes analysis

Lymphology and Phlebology Unit

- Study of the physiology of lymphatic oedemas using NMR imaging (MRI).

- Analysis of in vivo human imaging and correlation with the images observed after injection of lymphatics in piglets
- Study of the cardiac function (haemodynamic and cardio-pulmonary parameters) in cardiac patients by using pressotherapy techniques, multilayer bandages and manual lymphatic drainage

Environmental and Occupational Physiology Unit

The main objective of the unit is to better understand the human efficiency under normal and extreme occupational activities and in stressful situations in order to improve human efficiency in such situations.

- Study of the Diffusing capacity of the Lung for Carbon Monoxide (DLCO), the Functional Residual Capacity (FRC) and, the Flow Mediated Dilation (FMD) in young smoker, passive smokers and non smokers populations.
- Evolution of respiratory noises (turbulences) during mucus-clearing sessions in mucoviscidosis patients.
- Physiological parameters study in extreme environments like microgravity, confined environments (in collaboration with aerospace agencies), hyperand hypobaric situations, hot and cold environments, etc
- Physiological parameters studies of airplane pilots exposed to radiations (in collaboration with the Nuclear Physics and radiation Laboratory)
- Physiological parameters studies of extreme athletes (like apnea divers and extreme triathletes)
- Stress level analysis of airplane pilots, children at school and, professionals at work

Two research units located in the ISIB (Institut Supérieur Industriel de Bruxelles) are active in nuclear physics and applied researches.

Nuclear Physics and Radiation Laboratory

For more than 20 years the laboratory has developed a national and international expertise in radiation and nuclear physics, nuclear engineering and, radiation protection. In particular, the lab is involved in:

- Study of the exposure of the public to naturally occurring radioactivity, especially the study of the pollution of buildings by radon, second main cause of lung cancer
- Metrology and simulation of ionising rays, including the application of spectrum deconvolution
- Applications of radioactive tracers in the car industry
- Medical physics. Using the Monte Carlo simulation as well as measurements, the lab has performed a dosimetric study of Sr-Y (Strontium – Yttrium) sources used in endovascular brachytherapy. It is currently involved in similar studies for other brachytherapy sources

In addition, trainings in radioprotection are provided to paramedical professionals and experts (according to the Arrêté Royal / Koninklijk besluit of July 20, 2001 art 53.2 and 73.2).

IT and Electronics Unit

This unit is active in development and implementation of IT and electronics applications, devices, and solutions. In the medical domain, the unit studies and develops (in collaboration with the Anatomical Biomechanics and Morphology Unit) innovative tools/methods for the assessment of the physiological and cardiovascular state by means of non-invasive measurement methods such as echography imaging, plethysmography, ... Currently, the unit develops advanced image processing software for Flow Mediated Dilation (FMD) evaluation.

For more information on research and development activities:

**InduTec - Transfer Technology
Centre for the Brussels
(Belgium) Industrial
Engineering Institutes**

**Avenue Nellie Melba, 73
B - 1070 Brussels (Belgium)**

Phone: +32 2 534 33 79

Fax: +32 2 534 33 95

**Contact person
Cédéric DOUTRELEPONT**

**E-mail
doutrelepont@indutec.be**

www.indutec.be



COMPANIES INVOLVED IN MEDICAL TECHNOLOGIES FIELD



**Rue de Ransbeek, 310
B - 1120 Brussels (Belgium)**

Phone: +32 2 770 27 80

Fax: +32 2 770 37 50

www.2ingis.eu

Contact person
Philippe DE MOYER

E-mail
philippe.demoyer@2ingis.eu

Date of establishment
1991

Number of employees
10

Market
Medtech companies

Activities in Brussels
Headquarter
Manufacturer
Research & Development

Corporate description

2INGIS brings Technology and Know-How to Dental Professionals so that they can offer their patients a new smile using dental implants thanks to the simple, predictable and sure 2INGIS Guide System.

2INGIS S.A. was established in 1991 by P. De Moyer Building upon the expertise in prosthetic solutions, the company quickly set itself apart in the marketplace by providing its clients with substantial technology and scientific support. The company has its own R&D department since 1999 which, after years of in-depth research, has developed new technologies that make the placing of implants (using with surgical guides) predictable, easier, safer and quicker. Several of these technologies have been patented. Today, 2INGIS is working very closely with several International industrial partners and University Dental Centers to assert its high level of technology. The precision, aesthetics and quality of 2INGIS products have enabled it to become one of the leading European companies in its field thanks to technology that enables predictable outcome.

Technology description

The company makes the following products: radiological guides, analyzing and planning service, surgical guides, surgical tool planning, prosthetic solutions on implants, maxillofacial and orthodontic solutions.

The 2INGIS specializations:

- Surgical planning service on implants maxillofacial and orthodontic solutions
- Services (via Internet) complementing computer-aided implant positioning solution
- Radiological and surgical guides
Development of an innovative new pre-implant planning technology which enables prosthesis
- Optimization, creation and assembly placement in the mouth
- Training

ELECTROMECHANICAL MEDICAL TECHNOLOGY - COMMUNICATION AND
INFORMATION TECHNOLOGIES: DIAGNOSTIC AND TELEMEDICINE

Corporate description

Biomedical Systems is a global provider of centralized diagnostic services for the pharmaceutical and medical device industries. The international headquarters are based in St.Louis, Missouri, USA and the European headquarters in Brussels.

Established in 1975, Biomedical Systems has contributed in more than 1000 clinical research trials at more than 11.000 research centres in 75 countries. Biomedical Systems centralized services include the collection and analysis of data for cardiac safety and medical imaging and pulmonary function assessment.

Since our first clinical trial in 1985, Biomedical Systems has assisted some of the world's largest pharmaceutical and biotechnology companies to complete clinical trials (phase I to IV) for drugs that make a global impact. Many companies and contract research organizations depend on Biomedical Systems' pharmaceutical Services because of our experience (we currently operate in more than 60 countries), our reliance on the best available technology, and our unrelenting dependability.

Technology description

Software package for Holter analyses.

Services Description

Our services include Centralized Digital ECG, Spirometry, Holter Monitoring, Ambulatory Blood Pressure Monitoring, Cardiac Event Monitoring, Pulse Oximetry, Peak Flow with Electronic Diary and since 2004, Central Medical Imaging Assessments for clinical studies.

Innovative aspects

Equipped with all new techniques.

**Chaussée de Wavre, 1945
B - 1160 Brussels (Belgium)**

Phone: +32 2 661 20 70

Fax: +32 2 661 20 71

www.biomedsys.com

E-mail

brussels@biomedsys.com

Date of establishment

1975

Number of employees

90

Market

Army
Biotech or pharma companies
Healthcare Organization
Hospitals, nursing home
Physicians/Doctors
Cardiologists in private
practice
Clinical Trial

Distribution

Direct (own sales force)
Indirect (independent dealer)

Activities in Brussels

Research & Development
(R&D)
Service company
Supplier/Distributor

BRACING CENTER

TECHNICAL AIDS FOR DISABLED: ORTHOPAEDIC TECHNOLOGY (BANDAGES, WALKING AND MOBILITY AIDS, PHYSIOTHERAPEUTIC MOBILITY AIDS, REHABILITATION EQUIPMENT AND DEVICES

Rue Walcourt, 150 b4
B - 1070 Brussels (Belgium)

Phone: +32 2 520 58 98

Fax: +32 2 522 93 84

www.bracing-center.be

Contact person

Baudouin BERTRAND

E-mail

bbertrand@bracingcenter.be

Date of establishment

1998

Number of employees

1

Market

Orthopaedics firms
Hospitals and clinics

Prescribing doctors
specialising in: orthopaedics,
surgery, neurology,
physiotherapy, paediatrics,
sports medicine, rehabilitation

Activities in Brussels

Production
Distribution/Sales
Research & Development
(R&D)

Corporate description

Bracing Center focuses on specialists from the world of medicine surgeons, orthopaedic specialists, rheumatologists, physiotherapists, sports medicine and rehabilitation. From 1998, Bracing center apply the GII product range in Belgium, specialized in products for the knee, including both customized and pre-fabricated appliances. Our technicians are on the road to provide better customer service. In addition to high-quality products, they are also able to listening carefully to the patients using the product. Bracing Center's activity focuses on the lower limbs, the knee, the foot: soles, lumbar supports and foot supports, FAG orthopaedic immobilization splints, JPF knee supports and specially DRE AM BRACE which support and improve a drop foot gait. Bracing Center seek out new products and licenses, constantly in search of innovations to improve the quality of life of each patient.

Technology description

Contribution to the development of new therapeutic technique in the treatment of dangling feet. Elimination of the inevitable constraints of conventional foot supports by means of a dynamic heel brace.

Products description

Manufacture, distribution and application of orthopaedic equipment (bandages, walking and mobility aids, physiotherapeutic mobility aids, rehabilitation equipment and devices, wheelchairs).

Innovative aspects

Feature of brace: dynamic as it moves freely in one direction and is curbed in the other. This results in less effort and tiredness and more safety, avoiding falls for patients with a dangling foot. If the foot does not feel constrained it may remain in alignment with the movement when the patient walks up or down a slope or stairs.



ELECTROMECHANICAL MEDICAL TECHNOLOGY: ELECTROCARDIOGRAPHY (ECG) - COMMUNICATION AND INFORMATION TECHNOLOGIES: DIAGNOSTIC AND TELEMEDICINE

Corporate description

For over 42 years, **Cardionics** has provided quality, reliable and cost-effective solutions in the field of computerized ECG. Our core business focuses on ECG devices and software.

Cardionics is present at every step: from the development to the distribution but also, training and after-sales services. Since 2000, Cardionics has broadened its activities in providing software's dedicated to Clinical Trials from phase I to phase IV.

Technology description

Portable and PC based ECG equipments for hospitals, private cardiologists and clinical trials (pharmaceutical companies & CRO's).

Specific ECG software's for private cardiologists: ECG analysis, interpretation and validation.

For clinical trials: QT dispersion, transmission, validation and export under PDF, JPEG, TIF and XML file.

Specific ECG software's for hospitals: computerized interpretation, validation, export in the medical file, centralization on the hospital server, automatic billing. Cardionics software's are compliant to all regulations (including 21 CFR part 11).

Products description

Development, production, distribution and technical services of electrocardiograms equipments.

The CarTouch is a portable ECG device with memory and several transfer modes.

The CarTouch can read a RFID card containing the patient ID:

- Memorizes up to 50 ECG's
- High-resolution ECG
- Light and easy to use
- Records 12 leads simultaneously
- Patient identification via card or keyboard
- 12-leads LCD screen

The CardioPlug is a USB ECG recorder allowing 12 leads acquisition. We tailor ECG network solutions for hospitals by providing the acquisition devices and software that fully integrate the existing HIS.

**Rue Gabrielle Petit, 4 b2
B - 1080 Brussels (Belgium)**

Phone: +32 2 426 75 75

Fax: +32 2 426 40 40

www.cardionics.eu

Contact persons

Bernard GRAUX

Stephan RAMPENBERGH

E-mail

bernard.graux@cardionics.eu

stephan.rampelbergh@cardionics.eu

Date of establishment

1969

Number of employees

9

Market

Biotech or pharma companies
Healthcare Organization
Physicians/Doctors

Distribution

Direct (own sales force)

Indirect (independent dealer)

Activities in Brussels

Headquarter

Manufacturer

Research & Development (R&D)

CHEMICAL PRODUCTS R. BORGHGRAEF

HOSPITAL HARDWARE: LABORATORY EQUIPMENT, CLEANING, DESINFECTING,
HAND DESINFECTION

Rue Bollinckx, 271/273
B - 1190 Brussels (Belgium)

Phone: +32 2 332 15 66

Fax: +32 2 332 08 05

www.rbs-cp.be

Contact person
Serge BORGHGRAEF

E-mail
serge.borghgraef@rbs-cp.be

Date of establishment
1960

Number of employees
15

Market
Healthcare Organization
Homecare
MedTech companies
Biotech or pharma companies
Hospitals, nursing homes

Distribution
Direct (own sales force)
Indirect (independent dealer)

Activities in Brussels
Headquarter
Manufacturer
Research & Development
(R&D)

Corporate description

Manufacturing of cleaning and disinfecting agents for cleaning and decontaminating surgical and dental instruments in hospitals, clinics, dentisteries, etc.

Adapted solutions are available for various cleaning processes: manual cleaning, immersion, ultrasonic cleaning, washers disinfectors, etc.

In laboratories (analyses, control, R&D, teaching hospitals, etc.), **RBS** products are used to clean glassware and laboratory equipment made of plastic and stainless steel.

RBS products are also used in the pharmaceutic, cosmetic and biotechnology industries to clean production equipment.

RBS range includes alkaline, neutral and acidic detergents designed to offer quality, efficiency and performance at low working concentrations. RBS products have been developed taking into account the environmental dimension and the most recent regulations on the matter, thanks notably to the use of biodegradable surfactants. Chemical Products is also marketing a new products range for hand hygiene including RBS HDS GEL, an hydro-alcoholic gel for hand disinfection (bactericidal, fungicidal and active against Influenza A H1N1).



ALLOYS - DENTISTRY TOOLS

Corporate description

Company producing mainly dental alloys intended for export throughout the world. Other products are currently being examined.

CMD is also linked with other companies:

PRO dental, Pierre Ravets Organization

Established in 1972, active in the field of manufacture, creation and R&D of new dental alloys. Main products: Vio Ceram Ni, Vio Ceram Cr, Vio Chrome 35, etc.

www.prodental.be

MAIL-DENT, dental diffusion

Established in 2001, active in e-business.

The Website allows:

- to consult the offers and innovations of various suppliers on only one site
- to obtain information on dental manufacturers and importers

www.onlinedental.net

Inter Medic-All

Established in 1987, active in the field of manufacture of dental alloys for export.

www.ima.be

Dentex International

Established in 1976, cooperative company organizing, in Belgium and abroad, fairs and seminars to inform on the medico-dental sector.

www.dentex.be

Promodent

Established 1984, specialized in oral rehabilitation with dental implants and accessories.

**Rue des Carburants, 50
B - 1050 Brussels (Belgium)**

Phone: +32 2 340 17 10

Fax: +32 2 340 17 10

www.cmd dental.be

Contact person

Pierre RAVETS

E-mail

info@cmd dental.be

Date of establishment

1976

Number of employees

1

Market

Army
Healthcare Organization
Hospitals, nursing homes
Dentist
Dental lab's
Clinic dental
University

Distribution

Direct (own sales force)
Indirect (independent dealer)

Activities in Brussels

Service company
Supplier/Distributor
Parent company
Production
Distribution/Sales
Research & Development



**Rue des Mélézes 69
B - 1050 Brussels (Belgium)**

Phone: +32 495 57 40 70

Fax: +32 2 344 59 40

www.cyrpa.com

Contact persons

Elsa KERVELLA

Rocio HERNANDEZ VICIANA

E-mail

e.kervella@cyrpa.com

r.hernandez@cyrpa.com

Date of establishment

2010

Number of employees

2

Market

Hospitals, nursing homes

Physicians/Doctors

Distribution

Indirect (independent dealer)

Activities in Brussels

Headquarter

Corporate description

CYRPA Medical Security is a company based in Brussels and Paris and is a leader in design, development and distribution of innovative products in the radiotherapy field.

Our product range is called CYRPA HIT® : fixed or mobile laser systems, all motorised and automated, for a perfect adaptation to each CT scanner/linear accelerator room.

Adapted to each customer's need, the HIT system optimizes the time spent treating patients and improves the usability for the professionals operating the equipment.

The CYRPA systems offer many innovations :

- Choice of colour, red or green, for each laser beam, switchable at anytime by the operator
- Automated adjusting and calibrating with the Smart Phantom® : less than 10 minutes to have a perfectly adjusted CT scanner room, with delivery of a weekly quality CYRPA certificate
- Positioning accuracy : 0,1mm
- Automatic and real time verification of the positioning
- CE Certified
- Services adapted to each customer
- Integration of the customer's needs with the CYRPASoft® Software
- Wireless connection through radio network : no cables
- Complete integration of the control electronics in the lasers : more space in the control room

We have already installed in France, Spain and Azerbaidjan, and we are focussing on other European Countries but also Brazil and USA. Our main clients are Cancer Center, clinics and hospital with a radiotherapy department.

Our technology is unique and we are always on the look for other innovations. We are currently developing a new device, similar to the SmartPhantom, that will allow the automatic calibration of the laser system in the linear accelerator.



COMMUNICATION AND INFORMATION TECHNOLOGIES; DATA BASES,
ELCTRONIC PATIENT RECORD (EPR), DOCUMENT MANAGEMENT,
DIGITALIZATION AND INDEXATION OF DOCUMENTS

Corporate description

Founded in 1989, Data Innovations (DI) is the world's largest, most successful clinical and blood laboratory middleware company. With offices in the United States, Belgium, Brazil, China, France, and the United Kingdom, DI is the only middleware company with a true global scope. Through our over 40 industry business partnerships and directly with laboratory end users, we have installed over 6.500 middleware systems in 63 countries.

Technology description

Based on a large experience of the interfacing medical devices and providing management software, Data Innovations proposes to manufacturers of analytical instruments to provide dedicated workstations with all functionalities to manage the work around the analysers, handle and validate results.

Products description

Laboratory production Manager (LPM-V5) and Instrument Manager (IM) enable the laboratory to carefully examine the results before transferring them to the biologist and afterwards to the recipient, in complete security and confidence.

Going beyond simple connectivity, LPM V5 and IM also handles sample routers and robotic sample transport systems. Existing LPM and IM users do not have to re-learn a whole new software product if they move to a robotic sample transport system and can keep using their existing interface and rule base.

Innovative aspects

Based on a solid foundation including most of required functionalities (90 to 95%). Embedding modules developed by the manufacturer embedded as exclusive library (e.g. expert System, maintenance, etc). Reducing time to the market delay (3 months). Limiting the investment in development of software to just a few days custom design (30 to 60 days). Reducing the level of risk of software development. Including all the experience acquired during 20 years. Allowing manufacturer to concentrate on very specific topics requiring experience and expertise.

**Avenue Jacques Brel, 34
B - 1200 Brussels (Belgium)**

Phone: +32 2 770 62 22

Fax: +32 2 775 91 96

www.datainnovations.com

Contact person

Robert J. ROTHSTEIN

E-mail

europe-sales@datainnovations.com

Date of establishment

1982

Number of employees

17

Market

Biotech or pharma companies
Healthcare Organization
Hospitals, nursing homes
Medtech companies

Distribution

Direct (own sales force)
Indirect (independent dealer)

Activities in Brussels

Manufacturer
Research & Development (R&D)
Service company
Subsidiary
Supplier/Distributor

DDD (DIGITAL DENTAL DESIGN)

DENTAL TECHNOLOGY: DENTAL PROSTHESES, DENTAL COSMETICS, CROWNS, BRIDGES

Avenue Brugmann, 416
B - 1180 Brussels (Belgium)

Phone: +32 2 734 93 13

Fax: +32 2 735 36 69

www.dentaldesign.eu

Contact person
Pierre CHELALA

E-mail
ddu@skynet.be

Date of establishment
1998

Activities in Brussels
Headquarter
Production
Research & Development (R&D)

Corporate description

The first **Dental Design laboratory** was established in 1991 by Pierre Chelala, offering aesthetic dental ceramic prostheses to local clientele of dentists.

In 2002 opened the second laboratory in Paris offering same range of products. Today most of the labor work in a standard dental laboratory is made in an artisanal way, from pouring the model of plaster in the dentist impression mold, to waxing, investing and casting the metal of the framework before cosmetic layering.

With the arrival of new material for the framework (cosmetic's support) such as zirconium oxide, for aesthetic and biocompatibility reason, a switch occurred towards a new method based on CAD CAM technology. This method represents only around 10 to 15% of the market.

Noticing an increasing demand on for this technology, and needs of reduction in costs, improvements in precision and quality allowing the dental lab to offer competitive prices to his dentists clients, has driven us to develop a unique new project based on digital and high technological innovations that respond on those needs. The distribution system is ensured through developing a network of dental laboratories within Europe. The DDD marketing and communication system is customized for each dental lab of the network in his region to develop his business and promote his activity on all DDD promotional tools and DDD website. In the concept also training and technical support are offered to all members in order to maintain their know-how and skills on high level.

Market

Dental Laboratories, Dentists, Stomatologists, Dental Clinics, Hospitals, etc

Technology description

Our new concept is based on increasing the productivity and the profitability of each lab member, reducing his costs on materials and labor by eliminating few steps of the ordinary process but certainly with increasing the quality of the product and reducing the remake stage.



DIGITAL DENTAL DESIGN
1st european dental labs network

Corporate description

Manufacture

Over twenty-five years' experience in the manufacture of diamond-tipped and carbide rotary precision instruments : rotary instruments coated or impregnated with diamonds (galvanic or sintering) and carbide cutters. Cutters and disks for grinding, cutting and polishing. Diamond-tipped polishing pastes. Main applications in dental field, dental surgeries, among dental technicians, also for glass, crystal, jewellery and craft work. We also manufacture coated and sintered diamond disks and wheels for industrial application (ceramic, hard metal, stones, ...)

Distribution

We also distribute a complete range of polishing tool, innovative abrasives and mounted abrasives stones.

Certification

We have had IS P certification since 1998. We current hold ISO 9001/2000 and EC certification for our instruments intended for medical use.

Commercial policy and agents

Our distribution channels focus on the end user.

Our approach depends chiefly on sales through local agents who visit users.

Our priorities: value for money, short lead times, flexibility, service and personal contact ensuring a direct link with the market and its development.

We are seeking agents for all parts of the world that are not already covered by our current network. All requests are welcome.

Technology description

- Electroplated or sintered diamond burs & discs
- Tungsten carbide
- Polishers
- Abrasive instruments

Products description

Diamond tipped and tungsten carbide rotary instruments for the dental, glass, stone and mechanics sectors.

Innovative aspects

The only Belgian manufacturer of diamond and carbide precision rotary instruments.

Rue des Anciens Etangs, 42
B - 1190 Brussels (Belgium)

Phone: +32 2 343 65 30

Fax: +32 2 346 28 72

www.dumont-instruments.com

Contact person

Charles D'UDEKEM

E-mail

info@dumont-instruments.com

Date of establishment

1978

Number of employees

18

Market

Dentists and dental
laboratories (denture
laboratories)
Industrial applications

Our clients

Consumer (mass market)
Hospitals, nursing homes

Distribution

Direct (own sales force)
Indirect (independent dealer)

Activities in Brussels

Headquarter
Manufacturer
Research & Development
(R&D)
Supplier/distributor

Domaine Latour de Freins
Rue Engeland, 555
B - 1180 Brussels (Belgium)

Phone: +32 2 541 30 52

Fax: +32 2 538 65 51

www.episearch.be

Contact person

André-Robert GRIVEGNEE

E-mail

agrive@bordet.be

Date of establishment

2000

Market

Consumer (mass market)

Activities in Brussels

Research & Development
(R&D)

Corporate description

EPIsearch asbl was created in January 2000 by a group of doctors and researchers of Brussels-Capital Region. EPIsearch is an association which has as principal objective to promote research and development projects in the field of the public health by applying innovating technologies in particular in the spheres of activities related on the medical imagery and epidemiology. The strategy of EPIsearch is systematically to make call in its activities to specialized university networks (Committee of scientific follow-up), by integrating personalities recognized at the international level.

Very quickly, EPIsearch was seen entrusting significant missions in the field of the public health such as for example: epidemiologic investigations in the cardiovascular field, in the field of environmental health, the tracking and treatment of the cancer of centre and the development of tools for tissue characterization based on the ultrasonic imagery in the field of cancer (ovaries, prostate, thyroid, ...). After the development of the concept of Telemammography within the framework of the tracing routine of the cancer of centre in Area of Brussels, EPIsearch ensures the deployment of the last centers of first reading as well as a study on the installation of the concept of virtual hospital based on telemedicine.

Technology description

The solution suggested is articulated round two concepts: the platform of Management of Medical Contents [integration DICOM-Pacs- + HL7-Laugh + XDS] the digitizer of anatomopathology DICOM High Definition; diagnosis quality, streaming technology, DICOM integration + LAUGH

Market

The solutions suggested by EPIsearch as regards archives, quality control of anatomopathologic guard and its potential of development in telemedicine ensure an access to quality care with controlled costs. The objective of this research project is to lead to the creation of a European centre of digital anatomopathology. his center will make it possible to bind the anatomopathology to the other elements of the file of the same patient imagery, medical information, clinical biology). The services will be marketed at the European and international level. At the end of the research and development project, five pilot sites will be operational in four countries (Belgium/Brussels, Luxemburg, Switzerland and France).

WELLNESS:RELAXATION MUSIC

Corporate description

The founders of Fonda-Mental® S.A. have been working in the field of research and manufacture of relaxation software and hardware since 1985.

The company designs and produces the Biosphere music, an internationally known label of music for wellness (zen, jazzy, lounge, ethnic atmospheres and nature sounds) sold in retail shops on interactive displays.

Fonda-Mental also distributes an innovative sound system for shops, waiting rooms, wellness centers, spas, decoration or natural products shops, etc.

The premises of Fonda-Mental ® S.A. (company with capital of € 130,000) are located in Brussels (Belgium) at the heart of Europe.

Technology description

The technology developed induces a state of deep relaxation and a general sense of wellbeing.

Services description

- Music for wellness and nature sounds (CD's)
- New sound system for public spaces

Research & Development (R&D)

- Interactive displays for shops
- New sound system for public spaces (24 hours zen music royalty free)

**Avenue Lambeau, 13
B - 1200 Brussels (Belgium)**

Phone: +32 2 732 46 66

Fax: +32 2 732 49 33

www.biosphere.com

Contact person

Pascale VAN WEERT

E-mail

pascale@fondamental.com

Date of establishment

1990

Market

Hospitals, nursing homes
Biotech or Pharma companies
Healthcare organization

Distribution

Direct (own sales force)

Activities in Brussels

Manufacturer
Parent company
Production
Distribution/Sales
Research & Development (R&D)



**Rue du Moniteur, 9
B - 1000 Brussels (Belgium)**

Phone: +32 2 219 11 03

Fax: + 32 2 219 32 15

www.fse-export.com

Contact person

Hervé MARQUIS

E-mail

hmarquis@fse-export.com

Date of establishment

2006

Number of employees

12

Activities in Brussels

Headquarter

Corporate description

FSE is a young, dynamic, and flexible partner for development projects. FSE's aim is to work in close co-operation with public authorities, the private sector, and major international financial institutions to prepare, monitor and execute projects which can improve conditions of living and the economic development in all emerging nations.

Over the years, the team at FSE has developed a thorough experience of international trade, logistics, project management, and financing in international competitive bidding, national tenders, privately funded projects, and bi- or multilateral loans and grants.

In many countries throughout Europe, Africa, and Asia, FSE has earned a reputation as a service company capable of respecting its commitments in terms of price, quality, deadlines and pre- or aftersales support.

Market

HEALTH

- Medical Laboratories
- Medical and Hospital Equipment
- Turn-key Medical Clinics
- Mobile Medical Centres
- Epidemic control

EDUCATION AND RESEARCH

- Teaching Materials For Higher Education
- Equipment for Technical Education Centres
- Basic and Applied Research Laboratories

ANIMAL HEALTH

- Veterinary Research Laboratories
- Veterinary Disease Control Laboratories
- Campaigns Against Animal Diseases
- Artificial Insemination Centers

Technology description

FSE supplies both basic technologies (e.g. for primary health care), as state-of-the-art technology for advanced research centres, universities, centres of excellence, etc.



TECHNICAL FOR AIDS DISABLED - ORTHOPAEDIC TECHNOLOGIES: INSOLES, ORTHOTICS, SHOE, LASTS, CAD/CAM

Corporate description

IDEAS specializes in producing measurement and CAD CAM systems for the production of made to measure insoles, orthotics and shoe lasts. It has customers in over 25 countries across the world to which it exports its products which have been 100% designed and assembled in Belgium using a maximum of Belgian products and suppliers.

The company was created in 1989 to take over a university research project based on the medical applications of CAD CAM (computer aided manufacture, computer aided design). The owner manager, Dr Stéphane Huberty, won the Brussels Young Entrepreneur of the Year Award in 1993 for his project of using CAD CAM to make made to measure shoes for "Mr and Mrs Everybody".

Today, IDEAS sells its products to podiatrists, O&P Labs, orthopaedists and shoemakers who wish to use the highest quality measurement and CAD CAM technology to produce precise made to measure insoles, Orthotics and shoe lasts.

Technology description

Devices for measuring the human body (especially the foot).
2D and 3D CAO software programs to design orthopaedic lasts and soles in 3D.
Digitally controlled machine tools for the CAM of shoe lasts and orthopaedic insoles.

Products description

Measurement and computer-aided design and production systems to produce insoles and shoe lasts.

Market

Manufacturers of insoles (chiropodists, bandage makers, orthopaedic specialists, orthopaedic technicians) and shoe lasts (last makers, orthopaedic or other shoes, luxury, mass produced, etc).
CAD/CAM + measurement devices for the production of made-to-measure insoles and shoe last.

**Avenue de Fré, 151
B - 1180 Brussels (Belgium)**

Phone: +32 2 686 04 40

Fax: +32 2 686 04 41

www.ideas.be

Contact person
Stéphane HUBERTY

E-mail
info@ideas.be

Date of establishment
1989

Activities in Brussels
Parent company



**Rue Maurice Liétart, 60
B - 1150 Brussels (Belgium)**

Phone: +32 477 87 12 24

Fax: +32 2 731 49 48

www.imagilys.com

Contact person

Laurent HERMOYE

E-mail

hermoye@imagilys.com

Date of establishment

2005

Market

Clinical neuroradiology
Neurosurgical planning

Activities in Brussels

Headquarter
Production
Research & Development
(R&D)

Corporate description

Imagilys is a SME based in Brussels. It was created in July 2005 by Dr. Laurent Hermoye. It offers services, software, and hardware in the field of advanced magnetic resonance imaging (MRI) of the brain.

Its main mission is to provide complete and user-friendly systems, readily useable in clinical routine.

Its second mission is to perform applied research to develop future clinical techniques. This second mission is fostered by national and international collaborations with research institutes.

Its potential clients are public or private hospitals willing to provide their patients with state-of-the-art medical care. Radiology and neurosurgery departments are its main interlocutors.

Although its techniques can be used worldwide, Imagilys focuses mainly on Europe, the Middle East and Asia.

Services description

- Functional magnetic resonance imaging (fMRI): paradigms, stimulation systems, MR sequences optimization, user-friendly analysis software, test of the whole system in clinical practice, teaching
- Diffusion Tensor Imaging (DTI): MR sequences optimization, analysis software, test in clinical practice, teaching
- Perfusion imaging (PWI): MR sequence optimization, analysis software, test in clinical practice, teaching
- Neurosurgical navigation: pre and intraoperative imaging, integration of advanced techniques, technical and medical assistance for the use of the navigation system
- Deep brain stimulation (DBS) that uses electrical stimulation of deep brain nuclei to attenuate the symptoms of motor and psychiatric disorders

Innovative aspects

- State-of-the-art MR imaging of the brain
- Complete and user-friendly systems readily useable in clinical routine
- Research and development of future applications



COMMUNICATION AND INFORMATION TECHNOLOGIES: DATA BASES,
ELECTRONIC PATIENT RECORD (EPRI), DOCUMENT MANAGEMENT,
DIGITALIZATION AND INDEXATION OF DOCUMENTS

Corporate description

Market leader in outsourcing of document processing, **IFY** is committed to manage (on behalf our customers) incoming mails of heterogeneous and unstructured documents.

We increase our customer productivity thanks to our processes, our flexibility and quality.

Thanks to our Docflow "Document Production Management" tool based on advanced technology, we have industrialized the process from mailing room to file output.

Our offer includes scanning services, indexation, classification and data capture through Human Character Recognition & OCR, electronic signature and various format conversion.

Input for You owns and operates the largest scanning center in Belgium, based in Brussel with a daily capacity exceeding 400 000 sheets per day. Input for You is an ISO 9001 Quality Management Systems and ISO 27001 Information Security Management Systems certified company.

Market

- Mass scanning of active and archived files including patient, client and business folders, administrative documents or daily correspondence
- Digitalisation of the daily mails included invoices, contracts, business documents
- Indexation, classification and data capture of produced images
- Delivery in any electronic format and on any commercial support
- We can also advise on best practices and assist in designing and planning dematerialization projects

Our clients

Healthcare Organization, Physicians/Doctors, Biotech or pharma companies, Hospitals, Social Security Institutions, Mutuality companies, Utility and Telecom market, Government Institutions, Insurance and Banking.

Innovative aspects

With our capability to scan and index more than 300.000 pages per day, we can eliminate hospital archives in a very short time and free valuable space for higher value usages.

We are certified both ISO 9001:2008 Quality Management and ISO 27001 Data Security and offer therefore best quality and highest security to our customers.

Scanning can be done either on site or in own premises

**Chaussée de Gand, 1434
B - 1082 Brussels (Belgium)**

Phone: +32 2 464 25 62

Fax: +32 2 426 89 44

www.inputforyou.be

Contact persons

Stephan CORNELIS
Marie DEL MARMOL

E-mail

stephan.cornelis@inputforyou.be
marie.delmarmol@inputforyou.be

Date of establishment
2006

Number of employees
5

Activities in Brussels

Headquarter
Production
Research & Development (R&D)

**input
for you.**

Document Processing Services

KISANO BELGIUM

Domaine Latour de Freins
Rue Engeland, 555
B - 1180 Bruxelles

Phone: +32 2 600 50 19
Fax: +32 2 600 50 45

www.kisanogroup.com

Contact persons

Serge ROVENNE
Antoine DUCHATEAU

E-mail

sro@kisanogroup.com
adu@kisanogroup.com

Date of establishment
2005

Number of employees
6

Market

Biotech or pharma companies
Healthcare Organization
Hospitals, nursing homes
Physicians/Doctors

Distribution

Indirect (independent dealer)

Activities in Brussels

Headquarter
Research & Development
(R&D)
Service company



Corporate description

KISANO was created in 2006 with the vision to build an application able to give access or to send cheaply, simply and via Internet any medical image from any point to any point without having to centralise anywhere the flow and by being completely agnostic of the material used to create or store the image. The initial domain of application would be the breast screening cancer programs. The first commercial release was launched in 2010.

In October 2010, after a thorough analysis of KISANO and a deep due diligence, the Swiss breast cancer screening federation decided to use KISANO in his nationwide numeric breast screening cancer new program. The KISANO product was then extended for the enabling of archiving images and was combined with a specific workflow application. By the beginning of 2012, 40 hospitals have already been installed and are running in production and by 2015 horizon, through such program, KISANO will be installed in around 125 hospitals across the whole Switzerland. Based on this success, KISANO decided to expand to 2 other domains of applications: KISANO ECHANGE Teleradiology and KISANO ECHANGE Prescribers [numeric link between medical institutions and prescribers]. KISANO also realizes integration with national eID and Digital Certificate Services. In both these domains, KISANO signed business in 2011 across Belgium and Switzerland and is now gaining a lot of interest. At the end of 2011, KISANO decided to develop a 4th domain, which is the "Mobile radiology" embarked in busses; and by the beginning of 2012, a 5th and a 6th domain were developing: KISANO MED-TECH Pharma and KISANO GESTION.

Clients

KISANO is in production in 50 hospitals, radiology centers and medical centers across Switzerland and Belgium. About 500 general practitioners are also connected to the KISANO platform. About 3000 medical images and mammograms go through the platform each day.

Product & Main competitive advantages

The product is also called KISANO and was designed and developed between 2006 and 2010. The product is 100% written in Java. KISANO requires 2 to 3 days to be implemented, integrated and run live.

The first key strength of the product is its "peer to peer" architecture that offers maximum flexibility, contrary to all competitive offering that requires a heavy and rigid centralised deal flow. The second is its simplicity, requiring very few installation and integration efforts at a very attractive value for money pricing.

MEC (MEDICAL ELECTRONIC CONSTRUCTION) R&D

RESPIRATORY AND CARDIO-RESPIRATORY EQUIPMENTS (SPIROMETRY, BODYPLETHYSMOGRAPHY, DIFFUSION, CARDIO PULMONARY EXERCISE TEST), GASTRO-ENTEROLOGY EQUIPMENTS (BREATH TEST MONITORS H2 CH4 & CO2)

Corporate description

Founded in 1984, MEC sprl Brussels Belgium grew up in the forefront of spirometry, pulmonary function testing and electronic cardio respiratory devices distribution. In 2002, the company was certified ISO 9001 / EN ISO 13485 and started to manufacture its own innovative software and hardware technology to design and develop CE approved medical devices in close collaboration and partnership with universities. MEC products assortments are well designed by experienced clinicians and technical team. MEC product are made of carefully selected quality parts and accessories, with special focus on easy operating, portability, high accuracy, stability of performance and workable price. Therefore MEC has become well known during the last years in manufacturing innovative medical microelectronic and development of hardware and software-based cardio respiratory devices combined or contained into computers.

Products description

Lung function range to help patients with asthma, chronic obstructive pulmonary disease

- Full range of spirometers with many options (MIP/MEP, Rocc, etc)
- Pulmonary Function Testing systems: Bodyplethysmography, Diffusion, Stress Test
- Tailored solutions for respiratory equipment

Gastro range to help patients with bacterial overgrowth and carbohydrate malabsorption

- Breath test monitors H2 CH4 & CO2 monitors

Technology description

MEC Variable Orifice Membrane Flow Sensor has a perfect linearization and an excellent reproducibility.

Gas analyzers take advantage of the most advanced technologies at the hardware and software levels to serve your top priorities: fast, accurate and long lifetime.

Services description

Development, production, distribution and technical service.

Research & Development (R&D)

Continuous program development in respiratory and gastro-enterology.

**Rue Prévinaire, 64/68
B - 1070 Brussels (Belgium)**

Phone: +32 2 558 00 60

Fax: +32 2 558 00 69

www.mecbelux.com

Contact person

Jean-Yves MOENS

E-mail

info@mecbelux.com

Date of establishment

1984

Number of employees

5

Market

- Physicians/Doctors (lung specialists and gastro-enterologist).
- Hospital, sleep laboratories, rehabilitation department, Sports Medicine
- Aerospace
- Research

Activities in Brussels

Headquarter
Manufacturer
Production
Distribution
Research & Development (R&D)



**Square J. Algoet, 5
B - 1070 Brussels (Belgium)**

Phone: +32 2 527 16 93

Fax: +32 2 527 18 00

www.medatec.be

Contact person
Eric DRIESSENS

E-mail
ed@medatec.be

Date of establishment
1988

Activities in Brussels
Headquarter
Production
Distribution
Research & Development
(R&D)

Corporate description

A 100 % Belgian company, **MEDATEC** sprl started developing and producing sleep labs and neurophysiology systems back in 1988.

Through its continued development efforts and investments in new technologies, **MEDATEC** became an European market leader in digital polysomnography, home sleep monitoring, EEG and Evoked potential systems.

Technology description

Medatec develops and builds medical devices, and is complying with the most stringent quality requirements available: MEDATEC is certified to ISO 13485 (the equivalent of ISO 9001 in the medical world). All MEDATEC products—software and hardware—bear the required CE marking, your guarantee for a safe and reliable system.

Products description

- Sleep labs and EEG systems. European market leader in digital polysomnography and EEG registration
- Brainnet 3 : network based 78 channels sleep lab with extended EEG possibilities
- Brainnet 4 : 40 channels paperless EEG concept
- Dreamscan : ultra-miniature wireless long term sleep screening system
- Dream: wireless Ambulatory Sleep lab
- Brainwalker 3: wireless ambulatory EEG and 24 hour EEG system
- P8 evoked potential system

Innovative aspects

Quality and constant innovation are the driving forces behind our company, and benefit to all our customers through our lifetime free software upgrade program.

COMMUNICATION AND INFORMATION TECHNOLOGIES: COMPUTER SOFTWARE, DATA BASES, ELECTRONIC PATIENT RECORD (EPR), INTERNET/ON-LINE SERVICES, SECURE HEALTHCARE COMMUNICATION AND INTEGRATION PLATFORMS

Corporate description

MediBRIDGE was founded in 1994 and established itself quickly as the market leader of healthcare related secure messaging, communication and integration, based on its unique data-encryption and security expertise. In 2004 MediBRIDGE became part of the UBM group which has operations all over the globe.

Today, all Belgian hospitals and laboratories use MediBRIDGE, as well as over 12 000 users in the primary care (GPs, nurses, physiotherapists ...) either directly or through its wide and growing partner network, enabling secure communication and data services through its proprietary technology in a heterogeneous health ecosystem .

Technology description

The main features of the MediBRIDGE technology are reliability and consistency, and are based on open source (Java) and Microsoft technologies.

Solutions and services

The main solutions and services are:

- **MediMail:** the market leading secure messaging system for the healthcare
- **MediPath:** a new xml-based care path platform solution
- **DIS (Medidrugdata):** the most complete drug information service available in Belgium
- **Prescribe:** the prescription software for GPs and specialists

Innovation

Based on its proprietary technology, MediBRIDGE bridges the technology gap between different stakeholders in the healthcare sector.

**Rue du Bourdon, 100
B - 1180 Brussels (Belgium)**

Phone: +32 2 333 34 11

Fax: +32 2 527 30 13

www.medibridge.be

Contact person

Diederick GEERINCKX

E-mail

diederick.geerinckx@be.cmpmedica.com

Date of establishment

1994

Number of employees

9

Market

Army
Healthcare Organization
Homecare
Hospitals, nursing homes
Physicians/Doctors

Distribution

Direct (own sales force)
Indirect (independent dealer)

Activities in Brussels

Headquarter
Research & Development (R&D)
Service company
Supplier/Distributor



MEDICAL DEVICE WORKS

NON-ACTIVE IMPLANTABLE - SINGLE USE - DIAGNOSTIC AND THERAPEUTIC RADIATION TECHNOLOGIES:
INTERVENTIONAL RADIOLOGY CATHETERS, PERIPHERAL STENTS, INTERVENTIONAL ONCOLOGY, MINIMAL
INVASIVE SURGERY DEVICES, BALLOON CATHETERS, DRUG ADMINISTRATION DEVICES, STENT GRAFTS,
SINGLE-USE MEDICAL PRODUCTS, NON-ACTIVE, SINGLE-USE SHORT TERM IMPLANTABLE DEVICES,
PERCUTANEOUS LIVER ISOLATION AND PERFUSION, ORGAN ISOLATION AND PERFUSION

**Avenue Joseph Wybran, 40
B - 1070 Brussels (Belgium)**

Phone: +32 2 529 51 01

Fax: +32 2 529 51 05

**www.medicaldeviceworks.
com**

Contact persons

Joop FIERENS
Herbert KONTGES

E-mail

joop.fierens@
medicaldeviceworks.com
herbert.kontges@
medicaldeviceworks.com

Date of establishment
2004

Number of employees
14

Activities in Brussels

Headquarter
Manufacturer
Research & Development
(R&D)

Corporate description

Medical Device Works is a privately held company, founded in 2004 as a MBO from Abbott Vascular Devices. **MDW's** is pioneering the development of minimally invasive, interventional devices that allow diseased organs to be temporarily isolated from the systemic blood circulation and perfused with high drug concentrations. **MDW's** lead product is the Liver-PILP System. It consists of a set of proprietary, percutaneous catheters that enable temporary, complete separation of the liver from the systemic blood circulation and permit administration of physician selected chemotherapy drugs locally and at high concentrations directly into the isolated liver - under optimized pharmacokinetic conditions-, for the treatment of liver cancer or cancer metastases without systemic side effects. The isolation of the liver also permits control of perfusion parameters in the liver like temperature, flow rates, oxygen level, ortho versus retrograde perfusion flow etc, in short to adjust to operational parameters that permit the drug to function under optimal pharmacokinetic parameters and adjusted to the patient's condition. The system is presently in the clinical study phase. Addressed market segment is the nascent and strongly growing Interventional Oncology market. Besides development of the PILP System, MDW also performs development services and subcontract manufacturing of interventional radiology devices. MDW's organ isolation and perfusion technology is a "platform technology" that reaches beyond the present Liver-PILP to other organs e.g. lung, pancreas etc.

Market

Medical Device Works' lead product is the Liver-PILP System. It is a set of catheter based, percutaneous devices intended to be used, in combination with physician selected chemotherapy drugs, for the treatment of primary and secondary liver cancer. With the European regulatory approval (CE-mark) projected to be received in 2013, the company will first pursue market introduction in EU and seek regulatory approval in the US. Regulatory approvals in Japan and other Asian markets will be pursued with local partners. The potential market size for Liver-PILP is estimated at 240.000 patients in EU and US alone.

Our clients

Hospitals, nursing home, Physicians/Doctors.

Distribution

Indirect (independent dealer).

TECHNICAL AIDS FOS DISABLED - ORTHOPAEDIC TECHNOLOGIES: FOOT MEASUREMENT, INSOLES

Corporate description

Medida-Solutions is active in technological measurement solutions to obtain a precise measurement of the foot. MEDIDA is the Spanish word for "measure" (dimensions).

SOLUTIONS stands for "answers" where for our team is the clock round. The hyphen indicates that either objectives are committed to each other. In the first place, we stand for progressive, technological and qualitative measurement solutions to obtain an utmost precise measurement of the foot, de bases for the adjustment of the insole, after which the insole will be milled computer-controlled.

Technology description

Laser, light, pressure measurement (sensors), 3D modeling.

The podology, podotherapy, podoposturale therapy, sport sole manufacturer, safety shoes and comfort soles have created new techniques and therapies to treat feet. The leading aspect is the study of the feet in relation with the body structure.

Today we apply digital measurement systems. Not only to study the static, but mainly the dynamic pattern of the step. The feet are measured and the soles were digital manufactured. This digital information will be milled computer-controlled. This progressive process will give you, the treating specialist more time or your patient, which will result in a more efficient and more precise treatment of the patients need.

Market

Medida Solutions mills insoles for the podiatry, podo therapy, podo postural therapy, orthopaedics and sport sole manufacturer

Products description

Cad Cam systems for insole production Insole production.

Since not every sole manufacturing company can invest in a milling machine, Medida-Solutions mills insoles for the podiatry, podo therapy, podo postural therapy, orthopaedics and sport sole manufacturers.

A digital foot scanner, together with the software, can easily be placed at your company.

**Luikenaarstraat, 66
B - 1050 Brussels (Belgium)**

Phone: +32 2 646 95 10

Fax: +32 2 647 56 75

www.medida-solutions.com

Contact person

Virginie HAERYNCK

E-mail

vh@medida-solutions.com

Date of establishment

2005

Activities in Brussels

Headquarter

Production

Distribution

Research & Development (R&D)

MERCURA INDUSTRIES

HOSPITAL HARDWARE: MEDICAL FURNITURE AND EQUIPMENT (MEDICAL TROLLEYS, DOSSIER CARTS, BAG CARRIER, PHARMACY CABINETS AND LOGISTICS FOR HOSPITALS)

Rue Bois des Iles, 15
B - 1082 Brussels (Belgium)

Phone: +32 2 482 11 30

Fax: +32 2 468 18 48

www.mercura.com

Contact persons

Paul COUPEZ
Manu DELANGHE

E-mail

pc@mercura.com
md@mercura.com

Date of establishment
2003

Market

Rest homes
Hospitals
Clinics
Laboratories

Activities in Brussels

Production

Corporate description

Mercura Industries NV, established as a limited company on 10 June 2003, boasts unique experience in the development and production of aluminium trolleys for the healthcare sector. With 58 years of experience, this Brussels-based company offers the ideal solution for all internal logistics problems in the form of a comprehensive range of top quality trolleys.

In addition, our engineers are able to meet all the wishes and requirements of rest homes and hospitals by supplying customized products. A Mercura® trolley is an investment which will prove satisfactory for all users. Ergonomic, long-lasting, superb quality and environmental friendly, Mercura® trolleys are used in over a thousand buildings and more than eighty countries.

Technology description

Specific knowledge of the development of aluminium trolleys – medication trolleys with electronic badge systems for safety and registration.

Products description

Development, production and sale of aluminium trolleys for the health sector (RVT hospitals)

- Medical trolleys such as emergency, anaesthesia, drug distribution, etc
- Linen trolleys
- Dossier carts
- Bag carrier
- Trolleys for selective collection of dirty linen and waste, etc
- Pharmacy Cabinets & Logistics for hospitals

Innovative aspects

Over 58 years' experience of the manufacture of aluminium trolleys. New range with electronic applications currently being developed "Smart trolley".

Research & Development [R&D]

Development of a new range of medication trolleys with electronic lock and ergonomic applications such as electronically driven wheel system.



ELECTRONOMECHANICAL MEDICAL TECHNOLOGIES - HOSPITAL HARDWARE -
DIAGNOSTIC AND THERAPEUTIC RADIATION TECHNOLOGY - COMMUNICATION
AND INFORMATION TECHNOLOGY - RESCUE AND EMERGENCY EQUIPMENT

Corporate description

N.V. Philips Medical Systems was set up on 1/12/2003. For that time was the Medical Division part of Philips Professional Activities.

The history of Philips Medical Systems starts however earlier, approximately in 1896, at the production of the first X-Ray tube.

The health care and technology have gone strongly ahead since then and offer to Philips the best products concerning X-ray, magnetic resonance, CT, echography, monitoring, defibrillators, Nuclear medicine with CAP, CAP/ct and radio Therapy planning systems, ... thanks to the acquisitions of the last years (Marconi Medical Systems, Adac Laboratories, Healthcare department of Agilent Technologies and ATL) Philips Medical Systems becomes one of the largest suppliers of medical material.

Technology description

High technological equipment for medical diagnosis, mainly for medical representation and Cardiac monitoring.

Products description

Sales of Medical Systems, mainly Medical Imagery and Cardiac Monitoring Systems.

Market

- Private experts in cardiology, radiology and gynaecology
- Hospitals
- Polyclinic

Innovative aspects

Best picture quality for best diagnosis pathological deviations. Most sophisticated systems concerning ergonomics, exactitude and cost efficiency.

**Tweestationstraat, 80
B - 1070 Brussels (Belgium)**

Phone: +32 2 525 72 52

Fax: +32 2 525 65 45

www.medical.philips.be

E-mail
medical@philips.com

Date of establishment
2003

Activities in Brussels
Headquarter

**Rue Dodonée, 8
B - 1180 Brussels (Belgium)**

Phone: +32 2 340 17 10

Fax: +32 2 346 34 65

www.promodent.com

Contact person

Martin RAVETS

E-mail

info@promodent.com

Date of establishment

1984

Number of employees

2

Activities in Brussels

Parent company

Production

Distribution/Sales

Research & Development
(R&D)

Corporate description

Company producing mainly dental alloys intended for export throughout the world. Other products are currently being examined.

CMD is also linked with other companies:

PRO DENTAL, Pierre Ravets Organization

Established in 1972, active in the field of manufacture, creation and R&D of new dental alloys. Main products: Vio Ceram Ni, Vio Ceram Cr, Vio Chrome 35, ...

www.prodental.be

MAIL-DENT, dental diffusion

Established in 2001, active in e-business.

The Website allows:

- to consult the offers and innovations of various suppliers on only one site
- to obtain information on dental manufacturers and importers

www.onlinedental.net

CENTRALE MEDICO DENTAIRE S.A.

Established in 1947, active in the field of dental sector, import and export.

DENTEX INTERNATIONAL

Established in 1976, co-operative company organizing, in Belgium and abroad, fairs and seminars to inform on the medico-dental sector.

www.dentex.be

INTER MEDIC-ALL

Established in 1987, active in the field of manufacture of dental alloys for export.

www.ima.be

Market

- Dental medical equipments and products
- Dental alloys
- Dental implantology

DENTAL TECHNOLOGY: IMPLANTOLOGY, PROTHESIS ON IMPLANTS

Corporate description

The Prothetica laboratory is installed in Brussels since 1999 and meets the standards of ISO quality. Philippe Vandecandelaere, manager of the laboratory, is at the origin of a system of hook of skeletal out of white resin injected, the DentalD system.

The laboratory passed from 6 to 12 fulltime people working. A ceramist of talent and experiment, a team for the remo-vable one, another with the plaster and the reinforcements.

All make it possible to ensure a complete offer carried out in the house. With such a structure, Prothetica is committed guaranteeing a service which answers the current requests: guarantee on work, respect of the deadlines, a twice-daily withdrawal and parcel delivery, a service speed dental of repair in urgency, all that with competitive tariffs.

Each stage of work is carried out and controlled in the Prothetica laboratory which allow the company to grow quickly.

Technology description

- Modern
- Cad Cam computer-assisted with feeler of precision, work on zirconium and titanium
- Surgical guide, all in one, complex implantology, prosthesis on implants

Products description

- Dentures
- Implants
- Bridges

Innovative aspects

Technology, skills, Belgian know-how.

**Rue de Hal, 3/5
B - 1190 Brussels (Belgium)**

Phone: +32 2 512 00 62

www.prothetica.com

Contact person
Philippe VANDECANDELAERE

E-mail
prothetica@skynet.be

Date of establishment
1999

Market
Hospitals
Dentists
Medical centres

Activities in Brussels
Parent company
Production

Avenue Louise, 228
B - 1050 Brussels (Belgium)

Phone: +32 2 370 47 33

Fax: +32 2 370 47 30

www.remedpharma.com

Contact person

Axel BIART

E-mail

info@remedpharma.com

Date of establishment

1996

Number of employees

5

Market

Design, development and manufacturing of condoms, lubricating gels and oral hygiene products

Our clients

Consumer (mass market)
Healthcare Organization
Hospitals, nursing homes
Distributors worldwide

Distribution

Indirect (independent dealers)

Activities in Brussels

Parent company
Distribution/Sales
Research & Development (R&D)



Corporate description

Remed Pharma nv/sa is an independent company since 1996 after have been a subsidiary of Remed nv/sa, a well known company in the Pharmaceutical field since 1963. We produce our high quality brands of condoms PREVENTOR® and LOVE CONDOM®, water based lubricating gel as well as a new range of toothbrushes and dental floss PREVENTOR®.

The top quality and reliability of our products is our main priority: quality testing is made at different stages of the manufacturing process (100 % of our condoms are electronically tested) and there are also post manufacturing testing, in accordance with the ultimate norms in use in that sector worldwide.

Remed Pharma is certified as meeting the requirements of the Directive 93/42/CEE, and of the ISO 13485:2003 and ISO 9001:2008 norms.

Our objectives of continuous improvement and of being customer-oriented lead our company to be innovative in Research and Development: we developed a special formulation with a low level of chemicals added to the natural latex in order to make our condoms hypoallergenic.

Moreover our current R&D projects are the development of a new shape for condoms and the addition of specific substances to the condom.

Remed Pharma has a long term expertise in the condoms fields.

We are aware that we are a major player in eradicating the AIDS spreading worldwide. We are currently exporting our top quality condoms to 104 countries and are continuously increasing our distribution network in order to protect most people from AIDS and other sexually transmitted diseases.

Technology description

Manufacturing, design and development of condoms.

Products description

Male latex condoms, lubricating gels, toothbrushes, dental floss.

Innovative aspects

PREVENTOR® condoms: CLASSIC, TUTTI FRUTTI, RIBBED, DOTTED, SUPER DUPER, HOT HOT, PRET-A-PORTER, X'TRA STRONG, X'TRA LARGE

LOVE CONDOM® FRUITIES

PREVENTOR® ORAL CARE: CLASSIC, COMFORT, EXPERT, KIDS, DENTAL FLOSS

Corporate description

RENOL's view is to approach the idea of patient safety from a new angle and in a way we will describe as "progressive" such that the concept of the brace is perceived differently.

When the risks of falling and serious injury to which the patient is exposed are assessed objectively and the prevalence of the brace has been properly evaluated, we find it is not always necessary to immediately resort to so-called "strong" methods.

Consequently, solutions that are alternative, preventive and even often complementary to the immobilisation methods can be considered. For this reason **RENOL** has perfected a wide range of ergonomic and multi-functional positioning products designed to stabilise the patient in the chair or bed to anticipate any accident.

Cushions, various appropriate protective devices that are suited to a comfortable and optimal position, prove to be a fully fledged medical aid and a real help to the care dispensed by nursing staff.

When the situation is such that position holders are inevitable, these are preferably used alternatively with cushions or protective devices to make the patient as safe as possible but also to preserve his comfort (freedom of movement) and therefore his physical and mental integrity.

**Quai Ferdinand Demets, 23
B - 1070 Brussels (Belgium)**

Phone: +32 2 660 62 45

Fax: +32 2 675 48 65

www.renolcare.com

Contact person

Renaud JONCKERS

E-mail

renaud.jonckers@renolcare.com

Market

Hospitals, nursing homes
Homecare

Distribution

Indirect (independent dealer)

Activities in Brusels

Headquarter
Research & Development
(R&D)



HOSPITAL HARDWARE: FURNITURE AND EQUIPMENT, DESINFECTION
EQUIPMENT (SANITARY TAPS, SINGLE LEVER MIXER AND SHOWER

Avenue Général Dumonceau, 58
B - 1190 Brussels (Belgium)

Phone: +32 2 376 00 30

Fax: +32 2 332 08 54

www.rvb.be

Contact person

Daisy TAVARES GRACA

E-mail

dtg@rvb.be

Date of establishment

1935

Market

Consumer (mass market)
Hospitals, nursing homes

Distribution

Indirect (independent dealer)

Activities in Brussels

Headquarter
Manufacturer
Reserch & Development (R&D)



Corporate description

Created in 1935 by an enterprising and conscientious craftsman, the company of Gaston van Bastelaere, hence the initials of **rvb®**, has, over the time, acquired a good reputation for the quality and durability of its taps.

The rigorous selection of superb pure materials such as solid brass and the obsessional care with which the taps are manufactured and finished, ensure the quality, strength and pleasure of an rvb® tap.

Moreover, the quality demanded by the most-renowned university hospitals that use rvb®'s medical range constitutes a genuine reliability label in itself.

Technology description

Single lever mixer, handshower with pusher hygiene, bodyring

ELECTROMECHANICAL MEDICAL TECHNOLOGY - HOSPITAL HARDWARE -
IN-VITRO DIAGNOSTIC TECHNOLOGY - DIAGNOSTIC AND THERAPEUTIC
RADIATION TECHNOLOGY - COMMUNICATION AND INFORMATION
TECHNOLOGIES

Corporate description

Siemens Healthcare is one of the world's largest suppliers to the healthcare industry.

The company is a renowned medical solutions provider with core competence and innovative strength in diagnostic and therapeutic technologies as well as in knowledge engineering, including information technology and system integration.

With its laboratory diagnostics acquisitions, Siemens Healthcare is the first fully integrated diagnostics company, bringing together imaging and lab diagnostics, therapy, and healthcare information technology solutions, supplemented by consulting and support services.

Siemens Healthcare delivers solutions across the entire continuum of care: from prevention and early detection, to diagnosis, therapy and care.

Technology description

- Diagnostic Imaging & Therapy
- Healthcare Infrastructure
- Laboratory Diagnostics
- IT and performance solutions

Products description

Sales and services for Diagnostic Imaging and Therapy, Healthcare Infrastructure, Laboratory Diagnostics and IT and performance solutions.

Innovative aspects

Our innovations combine state-of-the-art laboratory diagnosis, imaging technologies and IT for an earlier prevention and more specific diagnosis thus enhancing patient care.

**Square Marie Curie, 30
B - 1070 Brussels (Belgium)**

Phone: +32 2 536 21 11

www.siemens.com/healthcare

E-mail

healthcare.be@siemens.com

Market

Hospitals
Polyclinic and private specialist
in medicine
Laboratories

Activities in Brussels

Headquarter

**Rue Romanie Van Dijck, 19
B - 1070 Brussels (Belgium)**

Phone: +32 2 520 19 48

Fax: +32 2 520 32 28

www.smdw.be

Contact person
Etienne MERTENS

E-mail
smdw@skynet.be

Date of establishment
1993

Market
Disabled person
Car dealers

Activities in Brussels
Parent company
Production
Distribution/Sales
Research & Development (R&D)

Corporate description

SMDW is an sprl (limited liability company) founded by Mr Etienne Mertens in 1993 with a view to play an active role in the reintegration of disabled people into society.

To this end, SMDW designed a revolutionary vehicle which enables André Malherbes, several times world motocross champion, to drive a vehicle in the Shell eco marathon using his head during the 1994, 1995 and 1996 events and to achieve impressive performances. SMDW aims to perfect all sorts of adaptations in order to facilitate daily life for disabled people and to distribute certain machines and accessories.

Moreover, SMDW is developing new concepts, such as the patented Hemilead transmission system (wheelchair propulsion system for hemiplegics) and an engine driven by this system with a view to breaking records, driving a car using a joystick or an off-road electronic wheelchair.

Technology description

Adaptable and customized mechanics and motorization.

Products description

Adaptation of automotive vehicles for disabled persons.

Hemilead®: to enhance the mobility for hemiplegic people, SMDW developed Hemilead, the unilateral control stick with double effect (forward as well as backward arm movements propel the wheelchair for optimal efficiency). The control of the wheelchair is also simplified: moving forwards and backwards, slowing down and turning can be done by using only one hand. Sales and after-sales service of manual and electronic wheelchairs.

Research & Development (R&D)

SMDW is currently developing a number of projects:

- Car driven using a joystick
- Perfecting and production of an off-road electronic wheelchair
- Ramer bike



HOSPITAL HARDWARE: STERILIZATION AND DESINFECTION EQUIPMENT:
 AUTOCLAVES, HOT-AIR STERELISERS DISTILLERS, PURE STEAM GENERATORS,
 PURIFIED WATER INSTALLATIONS, LIQUID EFFLUENT DECONTAMINATION
 UNIT, FREEZE DRYERS

Corporate description

STERITEC is since 1986 specialized in the development and commercialization of sterilization and decontamination equipment offering integrated solutions for the pharmaceutical and biotechnology industries, healthcare, and laboratories. The steady growth and the solid financial resources of the company makes of STERITEC the solid, trustable and experienced partner with highly qualified personnel and an extended technical department.

The basic features of the company are Service, Technical support and Quality. STERITEC holds a quality management system and is ISO 9001:2008 certified.

The company's activities may be divided into five groups:

1. **Pre sales services** : Assistance to customers and engineers in basic design and design phase of the project.
2. **Project services**
 - Supervising of the deliveries, mechanical completion of the equipment in the plants.
 - Qualification and validation of the equipments following cGMP and ISO standards
3. **After sales service**
 - Maintenance and repairs by 8 multidisciplinary and experienced technicians (within 24 hours in Belgium)
 - Upgrades, retrofits and modifications on customer's request
 - Spare parts available in our warehouse in Brussels
4. **Trainings**
 - Dedicated trainings according to specific customer's needs
5. **Testing activities**

For the Benelux, STERITEC is your distributor of :

- **FEDEGARI AUTOCLAVI SPA** (Industrial sterilizers, Bio-Waste Decontamination Systems, Low temperature decontamination systems (dry fog and VHP), Contamination reduction equipment)
- **FEDEGARI AUTOKLAVEN AG** (Laboratory sterilizers)
- **TECNINOX** (Pharmaceutical Process Plants)
- **PHARMAREX** (Stainless steel laboratory furniture)

For Belgium, STERITEC is your distributor of :

- **STILMAS** (Purified water systems, WFI distillation plants, Pure steam generators)

**Avenue Joseph Wybran, 40
 B - 1070 Brussels (Belgium)**

Phone: +32 2 520 11 50

Fax: +32 2 520 19 99

www.steritec.be

Contact person

Patrick VAN HECKE

E-mai

steritec@steritec.be

Date of establishment

1986

Market

Pharmaceutical industry
 Laboratories
 Hospitals

Activities in Brussels

Parent company
 Production
 Distribution/Sales
 Research & Development (R&D)

ELECTROMECHANICAL MEDICAL TECHNOLOGY: ELECTROCARDIOGRAPHY (ECG), CARDIO-RESPIRATORY EQUIPMENTS (SPIROMETRY, ...), GLUCOMETER, WEIGHT SCALE, BLOOD PRESSURE, ... - COMMUNICATION AND INFORMATION TECHNOLOGY: DIAGNOSTIC AND TELEMEDICINE, ELECTRONIC PATIENT REPORTED OUTCOMES (EPRO)

**Rue Prévinaire, 64
B - 1070 Brussels (Belgium)**

Phone: +32 474 96 39 24

www.teleclin.com

Contact person
Gregory SZCZESNY

E-mail
gszczesny@teleclin.com

Date of establishment
2011

Market
Hospitals / Nursing homes
Biotech / Pharma companies
Physicians/Doctors
Homecare

Activities in Brussels
Headquarter
Manufacturer
Research & Development

Corporate description

TeleClin is a Belgian consortium combining the medical technology expertise from 3 companies.

TeleClin has developed the 'remote patient monitoring tablet', a platform that answers simultaneously the needs of different market segments such as hospitals, clinical trials, home care and telemedicine.

The 'RPM-Tablet' currently consists of a tablet PC, fully touch sensitive, equipped with an ECG, a spirometer and an electronic patient reported outcome system. It has provisions to connect all kinds of medical equipment such as blood pressure recorder, glucometer, weight scale, etc.

Through this mobile platform, patient data are recorded using the various sensors, transmitted through Ethernet, wireless LAN or even mobile phone technology (3G), to a secure and protected central server and made available in various formats to the medical staff in charge of managing the patient. The system is extremely mobile and user-friendly.

TeleClin also provides all necessary services adapted to your needs. Our staff will help you refine your needs and translate these needs into technical specifications that will be implemented in TeleClin technology. TeleClin takes care of all deployment activities including training, technical support, helpdesk and/or hosting of patients data. TeleClin has deployed a server architecture that centralizes data and allows authorized personnel to view and exploit data through a web browser.



SINGLE USE TECHNOLOGY: MEDICAL DEVICES FOR PREVENTION, HEALTH AND HYGIENE (CONDOMS, LUBRICANTS, REGRESHING TOWELS, ALCOHOL PADS AND TOWELS, HYGIENE BAGS, ETC)

Corporate description

Terpan Laboratories designs, manufactures and sells hygiene and infection prevention products. It was founded in 1986 by a former biologist. Since then, we have drawn on our practical experience and the trust of our customers to bring out a range of reliable products whose quality you can count on every step of the way from the drawing board to the consumer.

We are one of the standard bearers in the fight against STI (Sexually Transmitted Infections) thanks to our male condoms, female condoms (Femidom®, for which we are the original distributor in France) and intimate lubricants.

We are ISO 9001 and ISO 13485 certified, which makes us ideally placed to deliver the standards expected from these products and guarantee you the quality you are entitled to receive.

Year 2010 was marked for Laboratory Terpan by the acquisition of the Belgian brand SMILE from its creator, in a continuation of our prevention efforts, in particular among young people. Four new products now swell the rank of the range of products TERPAN: SMILE classic and FUN&SMILE banana, mint and vanilla.

With our extensive experience in the field, we are also able to provide customized products such as custom pouches of condoms, cardboard packs of 3, 5, 12 or 24 condoms for retail or even hygiene kits containing upon request toothbrush, toothpaste, soap, cup, glove, comb...

Committed to prevention in all areas, we also provide clean consumption utensils to drug users associations, breathalysers, ear plugs, etc.

**Avenue Jules Bordet, 68
B - 1140 Brussels (Belgium)**

Phone: +32 2 6 17 46 58 43

www.terpan.fr

Contact person

Yvon PAWLAK

E-mail

terpan-yvon@organge.fr

Date of establishment

2010

Number of employees

1

Market

Consumer (mass market)
Healthcare Organization
Wholesale distributors

Distribution

Direct (own sales force)
Indirect (independent dealer)

Activities in Brussels

Manufacturer
Supplier/Distributor



ELECTROMECHANICAL MEDICAL TECHNOLOGY: BLOOD FLOW MEASUREMENT EQUIPMENT, ELECTROCARDIOGRAPHY (ECG), THERMOMETER, SPIROMETER, OXYMETER, ULTRASOUND RESCUE AND EMERGENCY EQUIPMENT - COMMUNICATION AND INFORMATION TECHNOLOGIES: COMPUTER SOFTWARE, DATA BASES, DIAGNOSTIC & TELEMEDICINE, ELECTRONIC PATIENT RECORD (EPR)

**Rue Anatole France, 92
B - 1030 Brussels (Belgium)**

Phone: +32 2 772 78 70

Fax: +32 2 772 67 06

www.uni-com.eu

Contact person

Marc VAN ANDRLECHT

E-mail

mhva@uni-com.eu

Date of establishment

1998

Market

Army
Healthcare Organization
Homecare
Hospitals, nursing homes
MedTech companies
Physicians/Doctors

Distribution

Indirect (independent dealer)

Activities in Brussels

Headquarter
Manufacturer
Supplier/Distributor

Corporate description

PC based, electrocardiographs, spirometers, oxymeters, BP meter and ultrasound imaging systems with multiple file in/output possibilities (standard, open source..).

Highly portable, for Hospital, GP, Home Care, Battlefield, Emergency purpose.

We also provide tailor made medical ICT development integration and solution on request.

We offer distribution and/or EMR partnership.

With numerous new products in development and to be introduced, Uni-Com anticipates significant market share gain for the next 5 years.

History

Initially dedicated to communication: **UNI-COM** quickly expanded and engaged in the growing market of the computer based medical devices and information sharing.

Our experiences and capabilities are helping us to meet and match the real needs of the healthcare market in providing excellent diagnostic and interpretation of patient wellness.

Experiences

Involved in numerous partnership projects, UNI-COM is proud to have tested and delivered proven high performance solutions for difficult challenges and conditions, insuring continually the best quality and communication development to our valuable day to day users.

Main Market

Thanks to integration capabilities, our main market are currently all the physicians using Electronic Medical Record system for diagnostic, management, storage and sharing of their patient data.

Telemedicine is naturally the best example of those successful partnerships in information management.

Future

The Hospital and Medical service, local and remote future partnership are the challenge now.

Thanks to a proven successful history of success, we are confident and happy to offer our solution and expertise in these fields.





**COMPANIES
INVOLVED IN
BIOTECHNOLOGY
& PHARMA
FIELDS**

IMMUNE SYSTEM - INFLAMMATION - ONCOLOGY - NEPHROLOGY -
THERAPEUTICS: PROTEINS, DNA (GENE THERAPY, DRUG FORMULATION
REGULATORY AFFAIRS - MARKET ACCESS - MANUFACTURING SERVICES
(CMOS) - DATA MANAGEMENT FOR CLINICAL RESEARCH

**Avenue Ariane, 5
B - 1200 Brussels (Belgium)**

Phone: +32 2 775 27 11

Fax: +32 2 775 27 06

www.amgen.be

Contact persons

Ann DHOORE
Maureen KANTERS

E-mail

adhoore@amgen.com
mkanTERS@amgen.com

Date of establishment

1990

Number of employees

150

Market

Biotech or pharma companies

Distribution

Direct (own sales force)

Activities in Brussels

Research & Development
(R&D)
Supplier/Distributor

Corporate description

Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.

Commitment to Science on Behalf of Patients

Our commitment to science goes beyond the lab, clinic and manufacturing plant. We rely on the scientific method to drive continuous improvement in every aspect of our business. We value open inquiry and logical and rational processes; we seek to ask the right questions, collect and analyze the relevant data and make informed decisions. Amgen has research programs in inflammation, metabolic disorders and osteoporosis, neuroscience, oncology and hematology.

An Interdisciplinary Approach to R&D

We focus on pioneering treatments for serious illness. As part of that commitment, our R&D organization has cultivated expertise in multiple treatment modalities – large – molecule proteins, small molecules and antibodies – allowing us to choose the best target for attacking disease and to use the modality most likely to affect that target.

Amgen in Belgium

Amgen Belgium was established in 1989. Now with almost 100 staff members, and about 50 contract workers Amgen Belgium encompasses a wide range of business activities from clinical development to commercial operations. Belgian contribution in clinical research is high. In 2011 Belgium participates in more than 65 studies, which is the highest number of studies outside US, equal to France. In 2010, more than 1000 patients have been treated in Amgen studies, in approximate 300 sites. These activities in clinical development are to the benefit of Belgian patients and hospitals and contribute favorably to local employment. For 5 consecutive years (2007, 2008, 2009, 2010 and 2011), Amgen was named amongst the 'Best Companies to Work For' in Belgium, as determined by the Vlerick Management School. In addition, together with the Amgen affiliates in Greece, Poland and Spain, Amgen was placed 2nd in the Best Multinational Workplaces Europe.



MAKING THE MOST MEANINGFUL DIFFERENCE TO PATIENT HEALTH THROUGH
GREAT MEDICINE

Corporate description

We discover new medicines that are designed to improve the health and quality of life of patients around the world—medicines which are innovative, effective and which offer added benefits.

We also focus on getting the best from every medicine we make by exploring all the ways it can be used or improved.

At AstraZeneca, innovation is about more than just research. We aim to stimulate continued creativity throughout our organization by maintaining a culture in which our people feel valued, energized and rewarded for their ideas and contribution to our success ideas which can make a difference in all aspects of our business. And we support and encourage our people in discovering their own potential, through excellent learning and development opportunities that are available to them throughout their careers.

With a global business comes a global responsibility for consistently high standards of behavior worldwide. We aim to effectively manage that responsibility and help to find new ways of bringing benefit to society to ensure that AstraZeneca continues to be welcomed as a valued member of the global community.

We are committed to continued achievement in all of these areas to ensure a healthy future for our business so that we can continue to help improve the lives of, and add value for, all those who benefit from it.

**Rue Egide Van Ophem, 110
B - 1180 Brussels (Belgium)**

Phone: +32 2 370 48 11

Fax: +32 2 332 29 69

www.astrazeneca.be

E-mail

info.be@astrazeneca.com

Date of establishment

1999

Number of employees

177

Activities in Brussels

Subsidiary company

Distribution/Sales

Phase II to phase IV coordination

PROTEINS - DNA (GENE THERAPY) - CELL THERAPY - VACCINES - ANTIBODIES
 GENERICS/BIOSIMILARS - CELL CULTURE EXPERTISE - CONSULTING
 ACTIVITIES: DEVICE FOR THE BIOPHARMA SECTOR - ENGINEERING SOLUTIONS
 TECHNOLOGY PROVIDER

**Rue de Ransbeek, 310
 B - 1120 Brussels (Belgium)**

Phone: +32 2 264 18 80

Fax: +32 2 264 26 00

www.atmi.com/lifesciences

Contact persons

José CASTILLO
 Tejarti Mounia

E-mail

info@atmi-lifesciences.com

Date of establishment

1986

Number of employees

45

Market

Army
 Biotech or pharma companies
 Healthcare Organization

Distribution

Direct (own sales force)

Activities in Brussels

Headquarter
 Research & Development
 Service company
 Manufacturing
 Product design and
 development

Corporate description

ATMI LifeSciences is an acknowledged technology leader in the field of single-use bioprocess systems and consumables for the pharmaceutical and biopharmaceutical industries. Its innovative, market-leading portfolio of single-use disposable storage systems, mixers and bioreactors is driving bioprocess efficiency and delivering value for biopharmaceutical companies around the world.

ATMI's mission is to continue delivering exciting new products that meet or exceed the expectations of our most demanding biotech industry users. When it comes to manufacturing single-use products for the biopharmaceutical industry, one thing is critical: to have an intimate knowledge of film and the means to produce it correctly. That begins with a fundamental understanding of polymers, specially selected resins and control of the film extrusion process and environment to insure optimal integrity and performance. As a global performer in film production, it is evident that manufacturing with film has been at the heart of ATMI's capabilities for 25 years.

Today, **ATMI** leads the way in the manufacturing and delivery of film-based products for very demanding industries, including notoriously-stringent semiconductor markets. With cleanroom-based manufacturing facilities in Hoegaarden, Belgium and Bloomington, Minnesota, ATMI LifeSciences builds on this expertise to create leading single-use bioprocess vessels, mixers and bioreactors for the biopharmaceutical industry. ATMI develops and manufactures innovative solutions using additive-free resins, in-house-extruded film and Class 100 cleanroom areas.



THERAPEUTICS : CELL CULTURE EXPERTIZE - DIAGNOSTIC TOOLS - DIABETES

Corporate description

BETA-CELL is a privately owned biopharmaceutical company that develops novel cell therapy and other products related to Diabetes.

The company is a spin-off from the Brussels Free University Diabetes Research Center (VUB-DRC), established in 1998. The DRC is a leader in the biology of insulin-producing beta cells and its use as platform for novel methods in the diagnosis and treatment of diabetes. It has particular expertise in cell isolation and quality control, stem/precursor cell characterization and differentiation, preparation of standardized beta cell grafts and organization and funding of multi-center clinical trials in diabetes patients. DRC is an internationally recognized center of excellence in the field of diabetes. BETA-CELL's technology platform is based on prior, current and future work at the DRC. It has acquired proprietary technology for a first product line, with BetaGRAFT as a lead, and has an agreement on its first right of refusal on all diabetes related Intellectual Property (IP) generated at DRC.

Technology description

BETA-CELL occupies a unique position in the development of beta cell grafts with wide application using patented, validated and stringently tested products. Key features of the commercial BetaGRAFT are its ability to survive, function and grow in a selected microenvironment that includes a biocompatible barrier that protects the grafted cells from rejection and the host from possible side effects. In the meantime, BetaCELL co-develops BetaSCREEN (a drug screening and discovery platform) and BetaREG (beta cell regeneration).

Innovative aspects

Beta-Cell is a spin-out from the Diabetes Research Center affiliated with the Free University of Brussels. DRC houses about 100 scientists, students and technicians devoted to the study of all the biological and medical aspects of diabetes and is also a major coordination center for human islet transplantation in Europe.

Research & Development

3 projects in R&D and pre-clinical stages:

- BetaGRAFT: cell therapy products in preclinical development
- BetaSCREEN: screening technology ready for demonstration on lab-scale
- BetaREG: R&D phase

Laarkeeklaan, 103

(Building E)

B - 1070 Brussels (Belgium)

Phone: +32 2 477 43 49

Fax: +32 2 477 43 50

www.beta-cell.com

Contact person

Sven ANDREASSON

E-mail

sven.andreasson@beta-cell.com

Date of establishment

1998

Number of employees

8

Activities in Brussels

R&D: research

R&D: pre-clinical development

R&D: clinical development



POLLUTION TREATMENT - MANUFACTURING SERVICES (CMO) - ORGANIC & NATURAL PRODUCTS FOR CLEANING AND DEGREASING

Rue Konkel, 105/107
B - 1150 Brussels (Belgium)

Phone: +32 2 772 40 70

Fax: +32 2 772 30 65

www.bioremediation.com

Contact person

Jean-Luc PLEUNES

E-mail

bioremediation@skynet.be

Date of establishment

2001

Number of employees

2

Activities in Brussels

Headquarter
R&D: research
Manufacturing
Marketing
Distribution

Corporate description

Bioremeridation

A recent technique, bioremediation uses the biological potential to induce and stimulate the natural degradation processes.

Either by potentiating the natural capacity of soil and water to purify themselves, or by using products from biology to prevent and solve pollution problems.

Bioremediation Europe sa: the Alternatives

The company is the realization of the project that its founding fathers have developed since 1996, convinced of the relevance and the exceptional potential of this approach.

The aim is: to seek and provide alternatives for the prevention and solution of environmental problems.

Industry and consumers in general have long hesitated to test these new products, despite a trend reflected in the search for solutions to replace chemicals by organic products.

Today, two phenomena modify this behavior: on the one hand, the awareness of having to save the planet and its natural resources, and, secondly, the establishment of the European REACH Law, which aims to better protect the user and his environment.

At the start of a new revolutionary concept of cleaning and bioactivating solutions, achieved by "simple" fermentation of an extract of Icelandic seaweed, the company markets new products and processes:

- on the one hand, at the service of sectors like metallurgical industry, catering, wastewater treatment facilities, public transport, or in terms of depolluting harbor and port water, and soils
- secondly, and most recently, for the consumer in two areas: household cleaning and vehicle cleaning

Our Values

- Respect and improve the environment
- Create and market effective, useful products with a positive environmental impact
- An ongoing commitment to the company and its stakeholders.

CARDIOVASCULAR DISEASES - CNS - DIABETES - ONCOLOGY - RESPIRATORY
DISEASES - HIV



Corporate description

The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies.

Headquartered in Ingelheim, Germany, it operates globally with 138 affiliates in 47 countries and 41,300 employees.

Since it was founded in 1885, the independent, family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine. In 2008, Boehringer Ingelheim posted net sales of 11.6 billion euro while spending one fifth of net sales in its largest business segment Prescription Medicines on research and development.

Research & Development

Molecules in development

Avenue Ariane, 16
(Vesalius Science Park)
B - 1200 Brussels (Belgium)

Phone: +32 2 773 33 11

Fax: +32 2 773 33 00

www.boehringer-ingelheim.be

Contact person

Stefan JUNQUE

E-mail

junque@bru.boehringer-ingelheim.com

Date of establishment

1961

Number of employees

120

Market

Physicians/Doctors

Activities in Brussels

R&D: clinical development

Marketing

Distribution & Sales

THERAPEUTIC: PROTEINS - DRUG FORMULATION - DRUG DELIVERY - CELL
CULTURE EXPERTIZE - DRUG DISCOVERY/SCREENING - CONSULTING
ACTIVITIES - LEGAL SERVICES TO BIOTECH - DIABETES

**Rue Forestière, 1 b7
B - 1050 Brussels (Belgium)**

Phone: +32 2 644 37 23

Fax: +32 2 644 14 49

www.brabantbiotech.com

Contact persons

Sydney SCHREIBER
Michaël BRODY

E-mail

sydney.schreiber@
brabantbiotech.com
michael.brody@
brabantbiotech.com

Date of establishment
2005

Number of employees
1

Activities in Brussels
Headquarter

Corporate description

Brabant Biotech's mission is to incorporate new strategies for improved oral and transdermal delivery of peptide based drugs, by utilizing recombinant protein methods and outsourced laboratory, clinical and manufacturing activities.

Research & Development

One project in pre-clinical stage.



THERAPEUTICS: PROTEINS, ANTIBODIES - ANALYSIS LABORATORY - IMMUNE SYSTEM - INFECTIOUS DISEASES - HAEMOSTASIS - ALBUMIN

Corporate description

Central Department of Fractionation of the Red Cross (CAF-DCF): a mission in healthcare with the goal to improve the safety of supply in Europe of plasma-derived medicinal products from unpaid voluntary blood donors. **CAF-DCF** is a not-for-profit organization producing stable plasma derivatives such as clotting factor concentrates, immunoglobulin products, and albumin, destined for the treatment of diseases such as coagulation factor disorders, immunological diseases, and disturbances of the internal fluid balance. CAF-DCF has longstanding expertise in fractionation of plasma proteins. It manufactures medicinal products meeting the highest efficacy and safety standards.

Technology description

Human plasma is the source material for manufacturing plasma products for therapeutic use under life-threatening conditions. Plasma derivatives are produced according to "state-of-the-art" pharmaceutical and biotechnological methods, including sophisticated purification techniques like chromatography and virus inactivation methods like nanofiltration. Biotechnology advances are implemented so as to meet the most stringent quality, safety, and efficiency requirements. In particular, virus testing is done by PCR (HIV, HBV, HCV, HAV, and erythrovirus (former parvovirus) B19. Patients suffering from rare disorders due to a lack of active plasma proteins (Factor VIII, Factor IX, fibrinogen, von Willebrand Factor, C1-inhibitor, IVIG, etc) can be treated efficiently with our plasma products.

Market

- Plasma products derived from plasma collected from Belgian donors are dedicated to Belgian patients
- Products derived from other countries are internationally distributed

Production facilities

Since 2004, a new "state-of-the-art" plant with a capacity of more than 700,000 litres of plasma, to be fractionated into intermediate bulk fractions, has been in activity in Brussels-North.

CAF-DCF fractionates plasma collected in Europe and in the US in addition to all the plasma collected by Belgian transfusion centres.

CAF-DCF is FDA approved after two extensive inspections in 2007 and 2008.

**Avenue de Tyras, 109
B - 1120 Brussels (Belgium)**

Phone: +32 2 264 64 11

Fax: +32 2 262 27 31

www.caf-dcf-redcross.be

Contact person

Ruth LAUB

E-mail

ruth.laub@caf-dcf-redcross.be

Date of establishment

1998

Number of employees

183

Activities in Brussels

Headquarter

R&D: research

R&D: pre-clinical development

R&D: drug discovery

R&D: clinical development

Manufacturing

Marketing

Distribution

Toll plasma fractionation

THERAPEUTICS: SMALL MOLECULES, CHEMICAL MOLECULES, DRUG
DISCOVERY/SCREENING - CONSULTING ACTIVITIES: TECHNOLOGY PROVIDER

**Route de Lennik, 802
B - 1070 Brussels (Belgium)**

Phone: +32 2 529 00 12

Fax: +32 2 529 81 41

www.chemcom.be

Contact person

Christian VAN OSSELAER
Renaud DE HEMPTINNE

E-mail

info@chemcom.be

Date of establishment

2000

Number of employees

21

Market

Consumer (mass market)
Biotech or pharma companies
Homecare
Hospitals, nursing homes

Distribution

Indirect (independent dealer)

Activities in Brussels

Headquarter
R&D: research
R&D: pre-clinical research
R&D: drug discovery

Corporate description

Since 2000, unravelling olfactory G-protein coupled receptors (GPCR) mode of action in both humans and animals has been the focus of **ChemCom** with a major interest on human olfaction. Positive results have led to the creation in 2007 of TecnoScent a spin-off and joint venture between ChemCom and Givaudan, the world leader in the Flavor & Fragrance industry.

ChemCom is unique in its ability to screen large libraries of compounds using proprietary cell-based assays for identifying new properties for odorants, i.e.: blocking and other modulating property, from which various blockers are already available. Not solely masking but also blocking malodours would be a major breakthrough in the Fragrance Industry and would offers perfumers new ranges of freedom in their art. Beyond the fragrance industry, our products and services also impact and better sectors like food, cosmetic, agriculture, pharmaceutical and biomedical industries.

Past deorphanisation campaigns have led to new discoveries that will be valorised by ChemCom in partnerships with companies primarily interested in the discovery of blockers towards specific malodours and off-notes as well as the discovery of modulators for olfactory receptors expressed in cancer cells.

Our approach in understanding of human olfaction will be transposed to other organisms e.g. mammals (for pet care) and insects (as new pest management solutions). ChemCom's innovations will revamp the agricultural sector to consider integrated pest management as the norm rather than an alternative to the conventional use of pesticides.



MICROARRAY, ELISA, BIOMARKERS, PCR, QPCR, GENE PROFILING, IN VITRO DIAGNOSTIC, PROTEIN, RNA, DNA MULTIPLEXING ASSAY DEVELOPMENT...

Corporate description

ClinEuroDiag is an innovative company specialized in Molecular Diagnostics, genetic signatures analysis (DNA / RNA) and isolation of new genetic markers. ClinEuroDiag's main objective is to become the market leader in genomics applications and to extend their activities in the area of molecular diagnostics in Europe by means of the design, development and commercialization of new diagnostic applications with its innovative in vitro diagnosis platform, "ClinDiag Arrays". ClinEuroDiag manufactures, and markets Microarrays that perform genetic analysis, including DNA and RNA analysis, for the clinical genetic assessment, biothreat, and life sciences markets. ClinEuroDiag's Microarray service provides complete MicroArray solutions, from probe design, oligonucleotides production, PCR amplification and Microarray manufacturing to complete gene profiling service including cDNA synthesis and labelling, hybridisation and data analysis, for academic and industrial customers. Through collaborations with academic laboratories and European consortiums (Galar fungal, Garnish, StrepSec), our DNA array service has developed MicroArrays for bacterial and fungal niche (H.Pylori, B. subtilis, N. meningitides, L. lactis, C. albicans, S. cerevisiae, S. pombe, Y. Lypotica,...). Services: pharmacogenomics, genotyping, functional genomics, genomic MicroArray, production of catalogue DNA microarrays.

Market

Current molecular diagnostics are primarily single-analyte tests involving the detection of a single gene or protein. However, many disease-related processes are multifactorial, involving the abnormal expression of multiple genes or proteins. Second-generation molecular diagnostics are anticipated to utilize novel detection technologies and multiplexing platforms to allow the measurement of a large number of analytes simultaneously.

These innovations will increasingly utilize multiplexing platforms such as DNA microarrays that perform parallel biomarker analyses. There are indications that the next advance will involve measuring several biomarker types simultaneously. Such innovations relate to constructs, such as DNA/antibody microarrays capable of assaying proteins and nucleic acid test simultaneously.

ClinEuroDiag targets laboratory-based immunoassay and nucleic acid test such as hospitals and clinical laboratories.

**Clos Chapelle aux Champs, 30
BP 30.46**

B - 1200 Brussels (Belgium)

Phone: +32 2 764 31 56

Fax: +32 2 764 39 59

www.clineurodiag.com

Contact person

Driss TALIBI

E-mail

driss.talibi@clineurodiag.com

Date of establishment

2009

Activities in Brussels

R&D: research
Manufacturing



SKINS DISEASES (ACNE, PSORIASIS, ECZEMA)

**Chaussée d'Anvers, 6
B - 1000 Brussels (Belgium)**

Phone: +32 2 213 60 30

Fax: +32 2 213 60 39

www.seaderm.com

Contact person

Guillaume-Henri HUREL

E-mail

export@seaderm.com

Market

Hospitals, nursing homes
Biotech or pharma companies
Pharmacies

Activities in Brussels

Headquarter
Research & Development
Service company
Supplier/Distributor

Corporate description

Dermo Expert Group is constantly creating and innovating new dermo-cosmetic products to best meet consumer demand.

Our brand is “**Laboratoires SEADERM**”. Indeed, our pharmacists and experts in marine dermo-cosmetology are mobilized to create new formulas and seek the most effective ingredients.

Our products are offered to both women and men. They are made from marine ingredients and minerals. SEADERM brand consists of three ranges: face, body and dermatology. All our products meet the specific needs of the skin. We sell almost 35 references to our network of pharmacies and drug stores, as well as our new web site.

Our team consists of R&D department, marketing department, purchasing department and sales department.

The R&D department is always looking for innovations and new approaches, highlighting the cosmeto-vigilance.

The marketing department is constantly creating packaging design, the brand image. This service also handles the POS in our many outlets.

The production department purchases the raw materials at the best price and creates the POS, manages inventory and follows the order status until the delivery to our costumers.

The sales department responds to specific requests in the Benelux and abroad. The main tasks of this service are prospecting for new customers worldwide, the implantation of the brand in foreign markets, the negotiation with distributors and ensure a good relationship with our partners.

During the past 3 years, the brand SEADERM has continued to grow, we have created and developed new means of communication. The marketing department has created the website and facebook page. These communication channels are updated daily to inform our customers, distributors and prospects. In 2011, we launched a European platform for selling products online. Moreover, the marketing department and sales creates sales brochures, book lets medical (in collaboration with the R&D service), materials: display, POP displays, posters for all new SEADERM brand products. The marketing department updates our communication. It is always looking for new concepts.



THERAPEUTICS: SMALL MOLECULES - DRUG DISCOVERY/SCREENING -
MOLECULES SUPPLIER - CONTRACT RESEARCH ORGANIZATIONS (CRO)
TECHNOLOGY PROVIDER - CNS - DIABETES - DIGESTIVE DISEASES -
INFLAMMATION

Corporate description

Euroscreen is a privately held preclinical-stage biopharmaceutical company based in Brussels Belgium, focused on the discovery and development of small molecule drugs for unmet medical needs. Founded in 1994, as a spin-off of the "Université Libre de Bruxelles", initially developing and commercializing G Protein-Coupled Receptors (GPCR) reagents, Euroscreen is now developing a pipeline of preclinical candidates targeting proprietary GPCR, such as GPR43 or CCR5, as well as several preclinical-stage collaborations with partners, using its worldwide recognized expertise on this critical class of drug targets.

Euroscreen pursues a dual business model strategy of combining:

- Its internal programs on high value targets (Euroscreen DRUG DISCOVERY)
- With its fully dedicated Business Unit (Euroscreen FAST) providing GPCR customized screening and other services for biotech and pharmaceutical companies around the world

Euroscreen has also developed a broad target portfolio for licensing intellectual property rights to pharmaceutical companies for the development of therapeutic drugs that act through these targets, including CCR5, Chemerin receptor, GPR43, GPR7/8, ORL1-R, FPRL2, purinergic receptors (P2Y4, P2Y11 and P2Y13) and SHIP2.

Euroscreen has discovery and licensing partnerships with Alchemia, AstraZeneca, Boehringer-Ingelheim, Cephalon, GNF, Grunenthal, HGS, ICOS owned by Lilly, Medarex, Novartis and Pfizer.

Technology description

GPCR expert, track-record on New Chemical Entities drug discovery for unmet medical needs.

Euroscreen give access through partnership to its novel and proprietary drug candidates, and Euroscreen Fast Business Unit is providing GPCR customized screening and other services for biotech and pharmaceutical companies around the world.

Services description

Euroscreen Fast Business Unit providing customized screening, profiling and assay development on all the GPCRs including orphans.

Products description

Novel and proprietary chemical series for unmet medical needs.

**Route de Lennik, 802
B - 1070 Brussels (Belgium)**

Phone: +32 71 348 500

Fax: +32 71 348 519

www.euroscreen.com

Contact person

Jean COMBALBERT

E-mail

info@euroscreen.com

Date of establishment

1994

Number of employees

49

Market

Partnership with pharmas worldwide

Activities in Brussels

Headquarter

MOLECULAR PRODUCTS: DNA, RNA, PROTEINS, ANTIBODIES, SMALL MOLECULES - CELL CULTURE EXPERTISE - IN-VITRO DIAGNOSTICS

**Avenue de l'Armée, 68
B - 1040 Brussels (Belgium)**

Phone: +32 2 732 56 88

Fax: +32 2 732 44 14

www.gentaur.com

Contact person

Lieven GEVAERT

E-mail

lieven@gentaur.com

Date of establishment

1999

Activities in Brussels

Headquarter

Distribution

Corporate description

GENTAUR is supplier in life sciences reagents, services, storage and invoicing, we occupy 1200 m² fulfillment in Brussels airport.

Technology description

GMP E.coli recombinant human IL-4, GM-CSF, TNF- α , IL-1B, IL-6 CD40L for dendritic cell culture, IL-2, HIV, p24 ELISA, Melanomax for melanocytes culture, Vitotox, synoviocytes, chondrocytes, Cholera toxin, immunohistomax, antibodies production, protein purification, mouse caspases, Pt7pol plasmid & tissue arrays.

Services description

Provider/Supplier

Innovative aspects

Personalized online ordering and web based access to sample storage -80C°, -20C° and 2-8C°.



POLLUTION TREATMENT

Corporate description

Since 1996, **IDRABEL** is an European biotechnology company which develops and supplies products to treat all industrial and municipal organic pollution in water. With more than 100 references in area as diverse as sewage network, lakes, canals, environmental, food, paper and petrochemical industries, our technical team have a long experience to work in collaboration with our customers to design specific solution to reach concrete and measurable results.

Technology description

IDRABEL offers a range of natural biotechnological products covering the full waste water treatment based on a process called Biofixation which fixes natural micro-organisms on mineral supports. An efficient, economical and environmentally friendly approach. The advantages of the Biofixation are to: have a high percentage of micro-organism reactivation: protects the micro-organisms in highly polluted environment, increase their growth, improve the effectiveness, rehabilitate a viable ecosystem, enable a mix of micro-organisms in order to obtain specific products

Services description

Idrabel provide a range of integrated services to private and public sector. Our effective and sustainable approach of wastewater treatment and environment management includes: research, development, consultancy, training, testing, supervision, operation, maintenance.

Products description

BIO-COL: treatment of all municipal wastewater & sewage, the sewer networks and collectors.

BIO-VASE: degradation of organic sludge, biodregging of canal, river, lakes, and marine ports, harbors and lagoons.

BIO-EPUR: treatment of all municipal and industrial wastewater treatment plant.

**Rue St Denis, 51
B - 1190 Brussels (Belgium)**

Phone: +32 2 345 42 53

Fax: +32 2 345 64 81

www.idrabel.com

Contact person

Frédéric DESWATTINES

E-mail

f.deswattines@idrabel.be

Date of establishment

1996

Number of employees

6

Activities in Brussels

Headquarter
R&D: research
Manufacturing
Marketing
Distribution

POLLUTION TREATMENT - PRODUCER OF MICROBIAL CONSORTIUM FOR ENVIRONMENTAL TECHNOLOGY

**Avenue Joseph Wybran, 40
B - 1070 Brussels (Belgium)**

Phone: +32 2 526 73 71

Fax: +32 2 526 73 88

www.imbp.be

Contact person

Alain DURIEUX

E-mail

a.durieux@meurice.ubt.be

Date of establishment

2002

Activities in Brussels

Headquarter

Corporate description

Created in 2002, IMBP is a spin-off of the Meurice Institute (Biotechnology Unit). IMBP activities (production, R&D) are subcontracted to the non-profit association of the institute, Meurice R&D. The owners are Meurice R&D and researchers from the Meurice Institute.

Market

Environmental technology involving bioaugmentation.

Type of clients

Industrial partner dealing with biological products for environmental technology developer of formulations for septic tank treatment and waste-water treatment manager of wastewater treatment plant.

Products description

The purpose of IMBP is the production and marketing of micro-organisms specific to environmental technology ("bioaugmentation"). IMBP has developed highly concentrated and stabilized micro-organisms (Bacillus spores, Pseudomonas, etc) formulations for waste water treatment. Spores of Bacillus have been successfully tested in septic tank treatment, wastewater treatment plants and composting. Technical collaboration is sought with industrial partners dealing with biological products and ideally possessing mixers and packaging units. The company is proposing three preparations including spores of Bacillus: two solid (powdered or encapsulated) and a liquid one.

The spores concentrations are certified in the formulations as follows:

- for liquid formulation: $2.10 \text{ E}+10 \text{ CFU/ml}$
- for dry formulation: $1.10 \text{ E}+11 \text{ CFU/g}$
- for encapsulated formulation $1.10 \text{ E}+9 \text{ CFU/g}$

These natural and biodegradable products present a very high-concentration biomass and their viability is maintained at 100% for extended periods (shelf life up to 5 years) when compared to traditional solutions. According to their specific bioactivity, these products accelerate the biodegradation rates up to 20%.

Moreover, the advantage of encapsulation is the delaying effect of bacterial action. Thanks to encapsulation, bacteria are gradually released, which is particularly recommended for devices that need continuous maintenance.



THERAPEUTICS: ALLERGY, DIGESTIVE DISEASES, INFLAMMATION, RESPIRATORY DISEASES, CHEMICAL MOLECULES, DRUG FORMULATION - CONSULTING ACTIVITIES: TECHNICAL ADVICES, CONTRAT RESEARCH ORGANIZATIONS (CROS), ANALYSIS LABORATORY, MANUFACTURING SERVICES (CMOS) - LOGISTICS FOR CLINICAL RESEARCH, ENGINEERING SOLUTIONS, TECHNOLOGY PROVIDER

Corporate description

Labima, a 100% family owned company, created in Brussels (Belgium) in 1952.

Labima is a pharmaceutical company of which the main activities are:

- Manufacturing packaging of pharmaceutical specialties: i.e. tablets, caps, solutions and emulsions, according to GMP Standards, ISO 13485 and ISO 9001
- Storage & distribution of products according to GDP
- Distribution & promotion to pharmacists, as well as to the medical profession, in BeLux
- Development of new galenic formulations. Packaging of Hospital Unit Doses
- Packaging, labelling, release storage and distribution of investigational products for clinical trials according to annex 13 and directive 2001/20/EC

Mission

- Develop, manufacture and supply products with a permanent care for quality, total service, respect for the persons in conformity with national and European standards, and in a profitable way.

Labima has 4 axes of development:

- 1 Through his own set of products both in Belgium and abroad (inside and outside EU)
- 2 Through outsourcing services for products on the market (Belgium and abroad): i.e. Production, Packaging, Storage, Distribution, etc
- 3 Through UnitDose packaging for both directly to hospitals or other pharmaceutical companies.
- 4 Through GMP services to third parties for product in clinical trial phases (I up to IV)

Market

Healthcare organizations

Biotech and Pharma

Hospitals, nursing homes

Belgian, EU and non EU pharmacists and wholesale

Other pharmaceutical organizations from SME up to large international companies

CRO's, Biotech and Pharma Research Organizations

**Avenue Van Volxem, 328
B - 1190 Brussels (Belgium)**

Phone: +32 2 349 0315

Fax: +32 2 345 30 48

www.labima.com

Contact persons

Paul-Adrien SLEGGERS

Jacqueline SIMEONS

E-mail

pas@labima.com

js@labima.com

Date of establishment

1952

Number of employees

18

Activities in Brussels

Headquarter

Manufacturing

Marketing

Distribution



THERAPEUTICS: CARDIOVASCULAR DISEASES, CNS, DIABETES, IMMUNE SYSTEM, INFECTIOUS DISEASES, INFLAMMATION, ONCOLOGY, RESPIRATORY DISEASES, VACCINATION, PROTEINS, DNA (GENE THERAPY), RNA, CELLS (CELL THERAPY), VACCINES, ANTIBODIES, SMALL MOLECULES, CHEMICAL MOLECULES, GENERICS/BIOSIMILARS, DRUG FORMULATION, DRUG DELIVERY, CELL CULTURE EXPERTISE, DRUG DISCOVERY/SCREENING, MOLECULE SUPPLIER - CONSULTING ACTIVITIES: REGULATORY AFFAIRS, CONTRATC RESEARCH ORGANIZATIONS (CROS), ANALYSIS LABORATORY, DATA MANAGEMENT FOR CLINICAL RESEARCH, BIOMARKERS, BUILDINGS

**Boulevard de la Plaine, 17
B - 1050 Brussels (Belgium)**

Phone: +32 2 554 62 11

Fax: +32 2 554 66 60

www.pfizer.be

Contact person

Daniel VAN BELLINGHEN

E-mail

daniel.vanbellinghen@pfizer.com

Date of establishment

1952

Number of employees

500

Activities in Brussels

Headquarter

In-Licensing

Out-licensing

Research & Development

Research on contract basis

Subsidiary

Supplier/Distributor

Corporate Description

Pfizer was founded in 1849 when Charles Pfizer and Charles Erhart decided to open a fine-chemicals business. A modest red-brick building in the Williamsburg section of Brooklyn, New York, serves as office, laboratory, factory, and warehouse.

The company's first product is Santonin - a palatable antiparasitic which is an immediate success.

Using deep-tank fermentation, Pfizer is successful in 1944 in its efforts to massproduce penicillin and becomes the world's largest producer of the "miracle drug" Most of the penicillin that goes ashore with Allied forces on D-Day is made by Pfizer. This is the start of Pfizer's pharmaceutical activities and international expansion.

Our purpose is helping people live longer, healthier, happier lives. Our route to that purpose is through discovering and developing breakthrough medicines; providing information on prevention, wellness, and treatment; consistent high-quality manufacturing of medicines and global leadership in corporate responsibility.

Every day we help 38 million patients, employ more than 100,000 colleagues, utilize the skills of more than 10,000 medical researchers, and work in partnership with governments, individuals and other payers for healthcare to treat and prevent illnesses-adding both years to life, and life to years.

Market

Healthcare organizations

Homecare

Physicians/Doctors

Biotech or pharma companies

Hospitals, nursing home

Distribution

Direct (own sales force)

Indirect (independent leader)



THERAPEUTICS: CARDIOVASCULAR DISEASES, DIABETES - DRUG
FORMULATION - DRUG DELIVERY



Corporate description

Pharco was created in 2003. The company is focused on the OTC and OTC Market. We are specialized in the nutritherapy. We are active in Benelux, France, Austria, Morocco, Lithuania.

In Belgium we have a sale force of 13 people. We are producer of more than 25 products covering the most important pathologies of the OTC market. All our product are made in Belgium, France and Italy (ISO 22000).

We are looking to expand our commercial activities on the CEE, Russia and the maghreb.

Market

Specialized in OTC and OTC market.

**Avenue Latérale, 143
B - 1050 Bruxelles**

Phone: +32 2 648 78 08

Fax: +32 2 648 91 38

www.pharco.be

Contact persons

Guy WYVEKENS
François MOTTE

E-mail

guy.wyvekens@pharco.be
francois.motte@pharco.be

Date of establishment

2003

Number of employees

15

Market

Consumer (mass market)
Hospitals, nursing homes
Physicians/Doctors
Distribution
Direct (own sales force)

Activities in Brussels

Headquarter
Manufacturer
Research & Development
Research on contract basis

THERAPEUTICS: FERTILITY - RNA - DRUG FORMULATION - CONSULTING
ACTIVITIES: MANUFACTURING SERVICES (CMOS)

**Rue de l'Association, 40/42
B - 1000 Brussels (Belgium)**

Phone: +32 2 880 82 20

Fax: +32 2 880 82 21

www.sasmar.com

Contact person

Jules VANHOEBROUCK

E-mail

jvanhoebrouck@sasmar.com

Date of establishment

2009

Market

Consumer (mass market)
Healthcare Organization

Distribution

Direct (own sales force)
Indirect (independent dealer)

Activities in Brussels

Headquarter
Manufacturer
Supplier/Distributor

Corporate description

SASMAR is a multinational pharmaceutical company with a focus on women's health and family planning. The company was founded in Sydney, Australia in 2005 and now has its global headquarters located in Brussels, Belgium.

SASMAR (commonly written in capitals) is a manufacturer and major supplier of personal lubricants to governmental aid organizations in HIV/AIDS prevention and awareness programs in third world and developing countries. The company was the first lubricant manufacturer globally to provide silicone based lubricant to the mass market through the supermarket and pharmacy channels. And today have an extensive range of product formulations within the family planning category.

SASMAR is also highly regarded for its OTC fertility product, 'Conceive Plus' launched in 2009. Conceive Plus fertility lubricant is available in multiple delivery methods through hospitals, fertility clinics, supermarkets, pharmacies and online retailers, helping coupled to conceive naturally in more than thirty countries globally.

SASMAR manufacture a large range of formulation both under our own brands OEM/Private labels for a growing number of brands and major retailers within Europe and internationally.

The group has operations based in Sydney Australia, London United Kingdom, Chicago United States and has a presence in more than thirty countries through a network of distribution partners.

SASMAR has a number of novel products in development and today is set for continued rapid growth globally.



THERAPEUTICS: CARDIOVASCULAR DISEASES, DIABETES, DIGESTIVE DISEASES, INFECTIOUS DISEASES, INFLAMMATION, RESPIRATORY DISEASES
 DRUG FORMULATION - DRUG DELIVERY - CONSULTING ACTIVITIES:
 REGULATORY AFFAIRS

Corporate description

Laboratoires SMB S.A is a private Belgian pharmaceutical company, specialized in Research & Development of advanced drug delivery systems and fixed dose combinations of active ingredients for oral and lung administration.

The activities of Laboratoires SMB SA and its partners involve R&D, clinical testing, registration and production of pharmaceutical products. Not less than 10 new projects based on our technology platforms are currently in development. SMB also co-develops fundamental research projects in collaboration of various Belgian universities.

Thanks to its R&D results, SMB is internationally recognized in the field of human healthcare in various high tech areas such as: sustained release pellets, Lidose® (semi-solid oral formulation), dry powder inhalers (DPI), effervescent tablets.

Laboratoires SMB obtained in early 2011 via Central Procedure the European approval of the first fixed-dose combination Fibrate-Statins (PRAVAFENIX) for the treatment of patients at high cardiovascular risks presenting mixed dyslipidemia.

As a scientific driven company, we are looking for licensee and distributors worldwide with a strong marketing culture and reputation in the medical community.

**Rue de la Pastorale, 26/28
 B - 1080 Brussels (Belgium)**

Phone: +32 2 411 48 28

Fax: +32 2 412 09 91

www.smblab.be

Contact person

Frédéric BESANCON

E-mail

fbesa@smb.be

Date of establishment

1978

Number of employees

49

Market

Biotech or pharma companies

Distribution

Indirect (independent dealer)

Activities in Brussels

Headquarter

R&D: research

R&D: clinical development

Marketing



GENERICS - DRUG FORMULATION

**Avenue de Scheut, 46/50
B - 1070 Brussels (Belgium)**

Phone: +32 2 524 39 66

Fax: +32 2 521 60 71

www.sterop.be

Contact person
Luc EYKERMANN

E-mail
info@sterop.be

Date of establishment
1947

Number of employees
80

Activities in Brussels
Headquarter
Research & Development
Production
Distribution/Sales



Corporate description

STEROP is well placed in the pharmaceutical sector thanks to its experience and its management team. Created in 1947, Sterop presents 65 years of experience in the manufacturing of liquid forms and 30 years in manufacturing of dry forms pharmaceuticals, is an unique asset and irrefutably confirms the quality of the products manufactured by STEROP. Sterop proposes a large portfolio of products marketed in more than 35 countries. More than 260 drug formulations are manufactured by STEROP, under:

- Liquid forms: injectable solutions in glass or plastic ampoules, external use solutions, eye and ear drops, ointments, syrups, etc
- Dry forms: powder for external use, tablets, coated or uncoated, pills, etc

The product line is extensive:

- Anaesthetics (lidocaine, procaine, morphine), atropine, methylene blue, caffeine, ephedrine, isoniazide, levorenine, papaverine
- Hormones: progesterone
- Minerals: calcium, magnesium, potassium, sodium salts, iron dextran, phosphates
- Narcotics: morphine, pethidine, methadone
- Psychotropics: sodium Phenobarbital, diazepam
- Vitamins: A, B1, B2, B6, B12, C, K, and PP

Technology description

Plastic and glass ampoules for injection, coated tablets, regulatory and registrations.

Products description

Injectables, oral medicines, nutriments, medical devices.

Innovative aspects

260 formulations registered for medicines, medical devices and nutriments.

Research & Development

Anti-age products, health products.

CEO : Sophie Eykerman

CFO : Valérie Eykerman

Export : GCC : Belaid Louahrani

Europe, South America : Vanessa Menendez

Pharmacobel Biogam : Luc Eykerman

DRUG DELIVERY • DRUG FORMULATION

Corporate description

The Therabel Group, a privately owned pharmaceutical laboratory, sets itself apart from the highly diversified pharmaceutical industry through the quality of the men and women it employs, the way they work in close cooperation and the desire they share to move forward both in taking charge of their own futures and in helping build Therabel's future.

Therabel promotes a spirit of enterprise, volutarism and enthusiasm through its "human" dimension.

Every one of us at Therabel works in an environment in which valuable people are allowed to give the best of themselves to the company. The company's only goal is to focus all of its strenghts and talents on its know-how to be at the service of the medical field of patients by providing innovative prescription drugs.

Therabel is not guided by quarterly and stock market results. It focuses on five-year projects and on long-term objectives. This has enabled the company to position itself for the long run since 1945 leading it to strong and to a threefold increase in turnover in 10 Years.

After 60 years in business, first in Belgium then in France, the Netherlands and Italy, Therabel intends to become a European pharmaceutical group. It will extend its presence to all major European Community countries while maintaining the human scale of its organization, its spirit, ethics and freedom of action.

Innovative aspects

In addition to its talent-based culture, other facets of Therabel separate it from the pharmaceutical industry majors:

Therabel does no basic research. It invests in phase 3 clinical studies of new molecules created by trusted partners and in the development of new indications and galenic formulations of existing molecules.

Therabel does not rely on an array of production centres specialized in a variety of chemical and pharmaceutical forms. It has a single, modern plant flexible enough to produce different types of dry pharmaceutical products. Therabel also works with contractors.

**Rue Egide Van Ophem, 108
B - 1180 Brussels (Belgium)**

Phone: +32 2 370 46 11

Fax: +32 2 370 46 90

www.therabel.com

Contact person

Gabriël VERHELLE

E-mail

generalities@pharma-therabel.com

Date of establishment

1945

Number of employees

80

Activities in Brussels

Headquarter

R&D: clinical development

Marketing

Promotion of pharmaceutical products

HUMAN USE DRUGS - FOOD SUPPLEMENTS - NUTRIENT

**Avenue Dolez, 480/482
B - 1180 Brussels (Belgium)**

Phone: +32 2 347 02 53

Fax: +32 2 374 68 81

www.trenker.be

Contact person
Rodolphe TRENKER

E-mail
info@trenker.be

Date of establishment
1933

Number of employees
38

Market
Consumer (mass market)

Activities in Brussels
Headquarter
Production
Distribution/Sales



Corporate description

Trenker Laboratories S.A. was founded in 1933 by Rodolphe Henri Trenker. We have been independent ever since and this has helped us remain very responsive. Our high performance equipment and highly qualified staff have enabled us to offer a wide range of innovative and effective drugs and nutritional supplements. Our Production and Quality Control departments meet the strictest European Standards (GMP and GLP) and are, certified by the Belgian Ministry for Public Health.

Our Research & Development department works closely with the best universities in the country, leading to the development of new, ever-improving entities for increased patient satisfaction.

Although our nutritional supplements are not drugs, they are produced and controlled according to pharmaceutical standards. This provides a guarantee for patients regarding the quality and purity of the ingredients used, their analysis and traceability, and ensures that principles of "good practices" applied in the pharmaceutical industry are strictly adhered to during the production process.

For more information, do not hesitate to visit our website:
www.trenker.be

ANTIBODIES - CHEMICAL MOLECULES

Corporate description

UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 000 people in about 40 countries, the company generated revenue of EUR 3.2 billion in 2011. UCB is listed on Euronext Brussels (symbol: UCB).

Products description

Main products are for the treatment of epilepsy, Parkinson disease, Crohn's disease, Rheumatoid arthritis, Systemic Lupus Erythematosus.

Research & Development

Investment in R&D (2011 : €780 million).

A world leader in antibody research:

- SLAM technology to rapidly isolate functionally active antibodies
- Biological scaffolds to create more tolerable antibody-based therapies
- Pegylation to enhance the specificity and cost efficiency of biologics
- Unique and patented expertise in targeting the SV2A protein
- A large library of proprietary chemicals to unravel the role of SV2A in epilepsy and other diseases

2 Research Centres of Excellence:

- Braine-l'Alleud (Belgium) covering CNS disorders
- Slough (UK) covering oncology/immunology

Over thirty major R&D partnerships: includes Amgen (anti-sclerostin for bone loss disorders).

An intellectual property estate of a large number of patent families

**Allée de la Recherche, 60
B - 1070 Brussels (Belgium)**

Phone: +32 2 559 99 99

Fax: +32 2 559 99 00

www.ucb.com

Contact person

MALHERBE Didier

E-mail

contactucb@ucb.com

Date of establishment

1928

Number of employees

(in Brussels) 409

Market

Biotech or pharma companies
Direct (own sales force)





COMPANIES INVOLVED IN EXPERTISE & SERVICES FIELDS

**Rue de la Régence, 58
B - 1000 Brussels (Belgium)**

Phone: +32 2 548 36 36

Fax: +32 2 548 36 45

www.alexionpharma.com

Contact person

Jordi BADIA CAMPOS

E-mail

badiaj@alxn.com

Date of establishment

2008

Number of employees

14

Market

Hospitals, nursing homes
Physicians/Doctors

Distribution

Direct (own sales force)

Activities in Brussels

Subsidiary

Corporate description

Alexion is a global biopharmaceutical company that combines ground-breaking science with a steadfast commitment to meeting the needs of patients living with severe, life-threatening and often ultra-rare diseases. Alexion scientists are among the first in the world to unlock the therapeutic potential of inhibiting terminal complement, a group of proteins that play an important role in the body's immune response and can destroy healthy tissue in certain patients.

Alexion discovered and developed Soliris® (eculizumab), a first-in-class terminal complement inhibitor. Today, Soliris is approved in more than 35 countries as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH), and in the United States and European Union as a treatment for patients with atypical hemolytic uremic syndrome (aHUS). Alexion is working urgently to investigate Soliris and additional product candidates as treatments for patients with other rare and severe diseases.

Further information about Alexion Pharmaceuticals, Inc. can be found at: www.alexionpharma.com.

Corporate description

1883, that was the year when Gustaf de Laval founded the company that today is Alfa Laval. Its success was based on his brilliant invention of the continuous separator. Since then we have added heat transfer and fluid handling to our expertise in separation. We grow by helping our customers to grow. It's a fruitful partnership.

Alfa Laval is a leading global provider of specialized products and engineered solutions. Our equipment, systems and services are dedicated to helping customers to optimize the performance of their processes. Time and time again. We help our customers to heat, cool, separate and transport products such as oil, water, chemicals, beverages, foodstuffs, starch and pharmaceuticals. Our worldwide organization works closely with customers in almost 100 countries to help them stay ahead.

Technology description

Centrifugal Separation

The need to separate different liquid phases and solids from each other is part of practically every industrial process. Alfa Laval has more than one hundred and twenty years of experience in meeting this requirement using either decanter or disc stack centrifuge technology, and our products perform this crucial function exceptionally well.

Filtration

Alfa Laval is the world leader in technologies for the mechanical separation of liquids. Alfa Laval is committed to develop our portfolio of filtration products in line with our goal to optimize the performance of your processes time and time again.

Fluid Handling

A reliable and continuous process flow is the key to consolidating your competitive edge. Through reliable fluid handling equipment that flow will be under your control.

Heat Transfer

Heating and cooling are essential parts of most industrial processes. The demand is for these applications to be carried out with the least energy consumption. Heat exchangers provide an efficient technology for heating and cooling.

**Avenue de Bâle, 5
B - 1040 Brussels (Belgium)**

Phone: +32 2 728 39 77

Fax: +32 2 728 38 03

www.alfalaval.com

Contact person

Frédéric MOUSTY

E-mail

frederic.mousty@alfalaval.com

Date of establishment

2000

Number of employees

50

Market

Consumer (mass market)
Biotech or pharma companies

Distribution

Direct (own sales force)
Indirect (independent dealer)

Activities in Brussels

Service company



CONSULTING ACTIVITIES - CONTRACT RESEARCH ORGANIZATION (CRO) -
SERVICE PLATFORMS

**Rue Saint Lambert, 141
B - 1200 Brussels (Belgium)**

Phone: +32 2 774 11 00

Fax: +32 2 774 11 99

**www.businessdecision-
lifesciences.com**

Contact person

Nicole RENSONNET

E-mail

nicole.rensonnet@
businessdecision.com

Date of establishment

2007

Number of employees

131

Market

Biotech or pharma companies
MedTech companies

Distribution

Direct (own sales force)

Activities in Brussels

Headquarter
R&D: clinical development
Consulting, Services platforms

Corporate description

Business & Decision Life Sciences is an international contract research organization (CRO) with offices in nine countries across Europe, North America, Asia and North Africa. It supports its clients in the pharmaceutical, medical device, biotechnology, food and cosmetics industries in the conduct of their clinical research and development activities.

Services include clinical study management, laboratory management, regulatory affairs, data management, electronic data capture (EDC), CDISC conversion and implementation, statistical programming, biostatistics, scientific writing, pharmacovigilance, quality assurance, system and process validation.

Clients engage Business & Decision life Sciences' expertise through one of three delivery models:

- 1. Consultancy services: specialized expertise and/or additional resources provided at the client's site.
- 2. Contract Research Organization: conducts end-to-end clinical studies or serves as a functional services provider.
- 3. Dedicated service platforms: a dedicated team of experts supports the client remotely from the Business & Decision Life Sciences offices, using the client's SOPs and systems, providing increased flexibility to the client.



SERVICE PROVIDER - STERILE MANUFACTURING

Corporate description

Catalent Pharma Solutions is one of the leading providers of advanced dose form and packaging technologies, and development, manufacturing, packaging and printing services for pharmaceutical, biotechnology and consumer healthcare companies in nearly 100 countries. Catalent applies its local market expertise and technical creativity to advance treatments, change markets and enhance patient outcomes.

Technology description**Catalent Group****Development**

Catalent offers a full range of development services, such as pre-clinical support, API development, analytical services, drug delivery development, clinical manufacturing and packaging services.

Manufacturing

We provide manufacturing for nearly every major dose form on the market today. Along with our proprietary dose forms, we also manufacture traditional oral, sterile and inhaled dose forms. We also produce biologics for pre-clinical and clinical studies.

Packaging

Catalent is the largest provider of packaging services to the pharmaceutical industry. Our packaging services include commercial packaging for all dose forms and the supply of printed components. We specialize in new product launch support and are the recognized leader in the packaging of biotechnology products, and the design and development of innovative compliance packaging and novel unit-dose formats.

Services description**Catalent Belgium (Brussels)**

- Sterile compounding of pharmaceutical products
- Sterile pre-filled syringe filling 0,520 ml
- Terminal sterilization
- Secondary packaging

**Font Saint Landry, 10
B - 1120 Brussels (Belgium)**

Phone: +32 2 788 50 00

Fax: +32 2 788 39 59

www.catalent.com

Contact person

Jerôme DETREILLE

E-mail

sales@catalent.com

Number of employees

395

Activities in Brussels

Development
Sterile manufacturing
Secondary packaging
Distribution

COMMUNICATION AND INFORMATION TECHNOLOGIES: INTERNET ON-LINE SERVICES

**Rue des Cottages,, 152
B - 1180 Brussels (Belgium)
Phone: +32 484 50 58 71**

www.mikrono.com

Contact person
Gaël FALEZ

E-mail
info@mikrono.com

Date of establishment
2011

Market
Physicians/Doctors
Healthcare organization

Distribution
Direct (own sales force)
Indirect (independent dealer)

Activities in Brussels
Headquarter

Corporate description

Mikrono is an online appointment management service dedicated to health professionals and including:

- on-line appointment scheduling
- appointment reminders via email and sms
- waiting list management
- automated notification of customers in case of a delay

It allows:

- substantial time saving
- efficient follow up of appointments
- cost reduction through the reduction of missed appointments
- increase of customer satisfaction through a better time management

CONSULTING ACTIVITIES: REGULATORY AFFAIRS - TECHNICAL ADVICES

Corporate description

Since 2005, **De Valck Consultants** exclusively focuses on delivering Quality Assurance consulting services. With more than 130 consultants and 5 offices in Europe, we are the European partner for the Life Sciences industry: Pharma & Biotech, Medical Technologies and Health & Nutrition.

De Valck Consultants is the dedicated brand to Quality Assurance of the Altran Group for the Life Sciences Industry.

Technology description

Consulting servicesService provider

Services description

Pharmaceutical and biotechnology consulting services:

- Quality Assurance
- Audit
- From Engineering to Validation

**Avenue de Tervuren, 142/144
B - 1150 Brussels (Belgium)**

Phone: +32 2 737 68 68

Fax: +32 2 737 68 88

www.devalckconsultants.com

Contact person

Fabrice DEKONINCK

E-mail

pharma@devalckconsultants.com

Date of establishment

2005

Number of employees

130

Activities in Brussels

Headquarter

TRAINING & COACHING OF PROFESSIONALS IN CLINICAL RESEARCH & DEVELOPMENT (R&D) - ALL AREAS OF CLINICAL OPERATIONS - REGULATIONS AND SOFT SKILLS

**Keizer Karellaan, 576 b4
B - 1082 Brussels (Belgium)**

Phone: +32 2 464 39 55

Fax: +32 2 465 56 23

www.eccrt.com

Contact person

Veerle BULTINCK

E-mail

info@eccrt.com

Date of establishment

2000 as a part of HRC Benelux

2009 as an independent company

Activities in Brussels

Headquarter

Training & Coaching for professionals in clinical R&D

Corporate description

The “**European Centre for Clinical Research Training**” (ECCRT) is a division of the Harrison Clinical Research Group and the primary focus is to serve as a training centre for professionals in the pharmaceutical, biotechnological and academic clinical research environment.

The courses offered are tailored to every level of experience and are divided into modules ranging from an introduction course over clinical research and monitoring, to current regulatory requirements of clinical trials and specific medical research areas such as the development of vaccines or understanding the ECG trace in cardiology trials.

In addition, ECCRT also provides tailored courses, specifically designed to company training needs and given on-site at the company or institution.

Market

Over the last ten years the company has provided training all over the world, for small and global companies and for different levels of profiles.

The customers of the European Centre for Clinical Research Training (ECCRT) are pharmaceutical, biotech, medical device and nutraceutical companies, as well as private persons, freelancers, academics, researchers and hospital staff.

Technology description

Recent Training Techniques such as Interactive Voting Software, etc.

Services description

Service in Clinical Research: training & coaching .

Products description

- Training and Coaching Services on Clinical Operations
- Clinical Operations Related Topics and Soft Skills for Professionals in clinical R&D

Innovative aspects

- Dedicated & professional trainers
- Interactive trainings



DRUG DELIVERY - MANUFACTURER OF CAPSULE FILLING - LOADING -
COATING - BLISTERING DEVICES

Corporate description

For decades **Feton**, a small and dynamic company, serves the pharmacist's expertise. Inventor of the small capsule filler, Feton has developed a complete processing system for hard gelatin capsules. With Feton, one can load, fill, coat and blister pack capsules.

Feton manufactures and distributes pharmaceutical and par-pharmaceutical products such as:

- Feton Capsule Filling and Loading machines, enabling the filling of empty capsules in series of 60, 100, 120, 200, 300 or 400 capsules
- Feton enteric coater, enabling the preparation of gastro-resistant capsules
- Feton empty capsules sizes 000, 00, 0E, 0,1,2,3,4 and 5
- Owing to a highly specialized network, Feton International is the leader in the field of empty capsules distribution in Belgium.

Feton International enjoys an excellent reputation due to the superior quality of its products and its excellent service both in Belgium and Internationally. Feton's international activities are backed by a distribution network characterized by longlasting and efficient commercial partnerships with foreign importers, wholesalers and distributors.

Technology description

Semi-automatic, user friendly kits for capsule filling, coating and blistering

Innovative aspects

Easy to use, low maintenance, high level material, fast and economic way to fill small batches of capsules.

**Rue Gabrielle Petit, 4 b9
B - 1080 Brussels (Belgium)**

Phone: +32 2 420 52 00

Fax: +32 2 420 61 61

www.feton.com

Contact person

Richard VAN ELEWIJCK

E-mail

fetonrve@netscape.net

Date of establishment

1973

Number of employees

5

Activities in Brussels

Manufacturing

Production

Distribution/Sales

COMMUNICATION AND INFORMATION TECHNOLOGIES: DATA WAREHOUSING,
PATIENT MANAGEMENT, FINANCIAL MANAGEMENT.

**Lenniksebaan 788 b1
B - 1070 Brussel**

Phone: +32 2 894 42 21

Fax: +32 2 529 58 92

www.forcea.be

Contact persons

Kris OOSTERLINCK
Frank SWAELENS

E-mail

kris.oosterlinck@forcea.be
frank.swaelens@forcea.be

Date of establishment

2006

Number of employees

35

Market

Biotech or pharma companies
Healthcare Organization
Hospitals, nursing homes
Medtech companies

Distribution

Direct (own sales force)

Activities in Brussels

Headquarter
Service company

Corporate description

Forcea is IBM Business Analytics Partner of the year and has received the prestigious global IBM award for 'Outstanding Business Analytics Innovation'.

Forcea PharmaReport is a business analytics solution focused on pharmaceutical sales & marketing transformation. Forcea PharmaReport provides following capabilities:

- One version of the truth
- Transparent analysis integrating ERP, CRM (SFA) and IMS data
- Meaningful dashboards for the mobile sales force
- Integrated information to enable Key Account Management
- Powerful simulation and planning to support key business decisions

Besides Forcea PharmaReport for the Sales & Marketing function, Forcea develops solutions to support the Finance, Human Resources and Supply Chain functions within a pharmaceutical company

CONTRACT RESEARCH ORGANIZATION (CRO) - DATA MANAGEMENT FOR CLINICAL RESEARCH - SCIENTIFIC CONSULTANCY - QUALITY SERVICES - MEDICAL WRITING TRAINING - OUTSOURCING SERVICES - CONSULTING ACTIVITIES: REGULATORY AFFAIRS - TECHNICAL ADVICES - CLINICAL OPERATIONS - TRANSLATIONS - IMP SERVICES - STATISTICAL ANALYSIS

Corporate description

Harrison Clinical Research Benelux nv is part of the Harrison Clinical Research Group founded in 1987 by Dr Francisco Harrison.

The company offers a full service solution for clinical research projects, both globally and locally. The activities range from phase I – IV studies and trials are conducted in accordance with all international and local regulatory requirements.

Market

Over the last twenty-three years the company has conducted studies covering all major therapeutic areas and all classes of products.

The clients of Harrison Clinical Research are pharmaceutical, biotech, medical device and nutraceutical companies. Harrison Clinical Research is represented by own local offices in Belgium, Germany, France, UK, Austria, Italy, Spain, Poland, Ukraine, Russia, Israel and the US. The headquarters in Munich (Germany) has its own Phase I Unit, available for early phase clinical development.

Services description

Harrison Clinical Research offers the following services for clinical research: clinical operations (including CRA, PM and CTA outsourcing services), Regulatory and Scientific Advice, International Project management and Monitoring Services, Quality Management, Auditing, Data Management, Biometrics, Training, Medical Writing and Translating.

Innovative aspects

Harrison Clinical Research is an international CRO offering a full service solution for clinical research projects, focusing on achieving the highest quality by constantly providing training to the staff and by implementing lean operations concepts. This approach resulted in a successful audit of the headquarters by the FDA in 2009.

**Keizer Karellaan, 576
B - 1082 Brussels (Belgium)**

Phone: +32 2 464 39 00

Fax: +32 2 465 56 23

www.harrisonclinical.com

Contact person

Rafaël HOEBRECHTS

E-mail

rafael.hoebrechts@harrison.be

Date of establishment

1996

Number of employees

45

Activities in Brussels

R&D: clinical operations including project management and global monitoring Outsourcing, Regulatory Affairs, Quality Services and Medical Writing, Training, Translations, IMP Services

CONSULTING ACTIVITIES: REGULATORY AFFAIRS, MARKET ACCESS,
TECHNICAL ADVICES - ALL THERAPEUTICS FIELDS

**Avenue Joseph Wybran, 40
B - 1070 Brussels (Belgium)**

Phone: +32 2 2 529 58 62

Fax: +32 2 461 03 03

www.hm3a.eu

Contact person

Marc CZARKA

E-mail

m.czarka@hm3a.eu

Date of establishment

2008

Number of employees

4

Market

Pharmaceuticals and Medical
Devices

Activities in Brussels

Headquarter
Consultancy

Corporate description

Based in Brussels, Belgium, in the heart of Europe, **HM3A** is an independent specialist consultancy specialized in market access for pharmaceuticals and medical devices. We are committed to deliver value and quality through objective and effective advice to clients on all matters related to obtaining and maintaining access to market in Europe.

Our small core of four partners, accrued, together, more than 100 years of experience and expertise. We work with a few very experienced consultants. Through our network we work with leading experts in strategically important fields.

HM3A is a one-stop shop to bring you and your products to market from A to Z!

Services description

- Medical, regulatory, market access and commercialization strategy
- Regulatory Affairs
- Governmental and Public Affairs
- Early market access
- Pricing and Reimbursement by Public Health Insurance
- Business development

SERVICES: PRODUCT DESIGN AND DEVELOPMENT

Corporate description

iol Strategic Design has evolved from a design platform to an industrial design consulting agency.

iol Strategic Design is specialized in design and development of new products, mainly technical (e.g. Medical products).

Studies by iol are always requested by professional customers, from self-employed to big companies and cover the full cycle of product development from the first creative phase until final production.

The aim of the agency by developing these studies is not only to formalise an idea, but to increase sales and profit.

Since 1988, iol Strategic Design has studied and created many new products in various fields of competences. The team concentrates on developing its know-how across an ever increasing diversity of sectors, and enriching its knowledge at the same time, with its development methodology as a guide line.

Its developed experiences can however be classified according to the following categories: Medical product (Laser applications, intraocular lenses, cosmetic surgery, phototherapy, presso-therapy, pulsated light, etc), industrial machines, child welfare, electro, equipment, consumers, interface.

Description of the technology

iol's designers work in-house using the CAD software Top Solid. Some designers also have the knowledge of Pro Engineer, Catia V6 and Inventor [external consultancy possible].

The agency has also built a diverse and reliable subcontractor network (for additional services in engineering, prototyping, manufacturing, etc).

R&D (Research & Development) – Fields & Projects

- Medical product: Ambulatory equipment, diagnostic instrument, laser applications, ophthalmic industry, cosmetic surgery, equipment for beauty centers, etc
- Industrial machines
- Child welfare
- Electro
- Equipment
- Consumers
- Interface

**Rue de l'Autonomie, 14
B - 1070 Brussels (Belgium)**

Phone: +32 2 500 57 75

Fax: +32 2 511 93 67

www.iol.be

Contact person
Ariane TYDGADT

E-mail
ariane@iol.be

Date of establishment
1998

Number of employees
2

Activities in Brussels
Design office

ANALYSIS LABORATORY - CONSULTING ACTIVITIES; REGULATORY AFFAIRS,
MARKET ACCESS, TECHNICAL ADVICES

Avenue Jean Jaurès, 46
B - 1030 Brussels (Belgium)

Phone: +32 2 215 04 01

Fax: +32 2 216 01 53

www.lca.be

Contact persons

Jean-Antoine DE MUYLDER
Seppe DE GELAS

E-mail

j.a.demuylder@lca.be
seppe.degelas@lca.be

Date of establishment

1983

Number of employees

11

Market

European and non-European
pharmaceutical companies

Activities in Brussels

Headquarter
Laboratory control

Corporate description

LCA Ltd is, since 1983, a testing laboratory as well as a service and consultancy company located in the Brussels area.

LCA Laboratory

The LCA laboratory follows the ISO 17025 and is active in the chemical, physicochemical, bacteriological and toxicological fields.

This quality system allows LCA to be registered in various domains:

- by the Department of Pharmacy Inspection of the Ministry of Health, for drug testing in Belgium and Europe
- by the Ministry of Health, for the control of biocides (hospital and surface disinfectants)

LCA Consultancy

As a consultancy company, LCA has developed her activity in the following domains:

- Within the pharmaceutical field, in Regulatory Affairs (R.A.), by helping Belgian and foreign pharmaceutical companies in administrative, pharmaceutical and clinical steps for the working-out and follow-up of drug dossiers, according to both the Belgian and European Procedure
- Within the scope of pharmaceutical engineering, through counseling and support in accordance with Good Manufacturing Practice (GMP) and the validation of pharmaceutical premises or manufacturing processes
- In the field of cosmetics and foodstuffs by helping in the information, training, audit, and follow-up of companies in HACCP plan
- Control of content of specifications including technical, scientific and legal aspect for great distribution

Vision

To implement all its services and tasks, LCA has set up a team and a laboratory structure where pharmacists and scientists work under the responsibility and control of heads of departments and of a Quality Assurance Adviser.

Ethics

Our duties are achieved based on confidentiality (Secrecy agreement) which guarantees discretion to our customers as required by the Belgian law of 22/09/66.



Corporate description

Design and manufacturing of clean rooms, laboratories and operating rooms.

Design and production of agro-food hygiene rooms.

Design and manufacturing of pet lab for research and development.

We are the representatives in Belgium of:

- Plasteurop, for sandwich panels
- Octanorm, for bi-panel
- Ics, for interlock and interlock system
- Ditec, for motorized doors in the pharmaceutical sector and hospitals
- Duffay, for pharmaceutical furniture hpl and Pass Box
- LSB Att, for hpl doors and technical hpl (H2O2 resistance)

Market

Our main customers

In Belgium:

- Pharma: Baxter, UCB, GSK, Eurobiotech, Quality Assistance, Bone Therapeutics, Cerva
- Hospital: Citadel Liège, Luxembourg Clinic South, Thieu, Namur, Charleroi
- Agro-food: Friesland Campina, Enzybel, LVH

Overseas

Sanofi Aventis, Macopharma, Bagtech, EFS (Northern France).

We are part of the group Pi-instal (cleanroom in Europe and Africa).

We are part of the distributors and installers group Plasteurop.

**Avenue Brugmann, 563
B - 1180 Brussels (Belgium)**

Phone: +32 2 469 13 73

Fax: +32 2 469 13 73

www.lsb-att.be

Contact person

Serge DELAUDE

E-mail

serge.delaude@lsb-att.be

Date of establishment

2005

Number of employees

12

Market

Consumer (mass market)

Hospitals, nursing home

Biotech or Pharma companies



COMMUNICATION & INFORMATION TECHNOLOGIES: ELECTRONIC PATIENT RECORD (EPR)

**Rue General Thys, 12 b4
B - 1050 Brussels (Belgium)**

Phone: +32 2 476 24 10 86

Fax: +32

www.mimedication.com

Contact person

Mitchell SILVA

E-mail

Mitchell@mimedication.com

Date of establishment

2011

Number of employees

3

Market

Homecare
Hospitals, nursing homes
Physicians/Doctors
Homecare

Distribution

Direct (own sales force)

Activities in Brussels

Headquarter

Corporate description

miMedication stands for monitoring individual Medication and offers a platform to manage medical data and a service to develop algorithms on this data. These algorithms can be used to trigger early warning signals and get an insight in the individual reaction on medication.

An initial product is a webtool that enhances self-management for chronically ill people with a focus on asthma and COPD (Chronic Obstructive Pulmonary Disease). A key ingredient is the personal electronic health record.

Via a secure login, users can access their personalized health record where they can store their medical history and contact details of healthcare providers, keep a diary, register what medication they are taking, log physiological parameters (such as blood pressure and weight), log activities (such as number of hours of sleeping or sports) and score their symptoms on a zero to ten scale (such as coughing, wheezing and headache).

All the parameters can be visualized in a graph. For example, one can plot his medication consumption on top of his blood pressure and symptoms. In this way interactions can become visible.

These graphs can be exported in pdf or a spreadsheet and sent to a family member or physician. The data can be used to develop smart algorithms to trigger early warning signals.

Medical electronic devices such as spirometers or weighing scales will be coupled to the database to minimize manual input.

An important pillar is also patient education. It is only by combining this with a personal health record that patients can make the step to self-management.

miMedication can be used by individual patients or by clinical partners involved in patient reported outcome.



CONSULTING ACTIVITIES: TECHNICAL ADVICES, BUILDINGS

Corporate description

MODULO architects has an extensive experience in architectural services for pharmaceutical and biotechnological buildings. The type of constructions varies from low-budget spin-off laboratories and incubator buildings to state of the art cleanroom production areas and large research facilities.

Clients range from universities (KULeuven, Ugent, UA, UMH, UCL, ULG, ...) and spin-offs (CropDesign, Starlab, Eurobiotec Brussels, BLSI, ...) to established multinational firms (GlaxoSmithKline, Inbev, Janssen Pharmaceutica, etc).

Market

- Pharmaceutical cleanrooms
- Biotechnological laboratories
- Research Centres
- Interior and exterior architecture
- Permits

Services description

Architectural services

- Conceptual design
- Building Permit
- Procurement
- Technical detailing
- Site supervision
- Envelope and finishings validation
- Project team collaboration

Innovative aspects

- Creativity of solutions
- Design synergies
- Quality of service and product
- Efficiency
- Communication Comfort
- Energy efficiency
- Sustainable solutions

**Chemin des Deux Maisons,
69 b5
B - 1200 Bruxelles**

**Phone: +32 2 776 81 00
Fax: +32 2 776 81 09**

www.modulo-architects.be

Contact persons

Didier HOLEMANS
Olivier BARRE

E-mail

d.holemans@modulo-architects.be
o.barre@modulo-architects.be

Date of establishment

2000

Number of employees

20

Market

Biotech or pharma companies
Healthcare Organization
Hospitals, nursing homes
University

Distribution

Direct (own sales force)

Activities in Brussels

Service company



LEGAL ADVICE FROM IP TO REGULATORY AND FROM CONTRACTS TO
FINANCIAL - FULL RANGE OF TRANSACTIONAL, ADVISORY AND LITIGATION
SERVICES - REGULATORY AFFAIRS - MARKET AFFAIRS

**Chaussée de la Hulpe, 120
B - 1000 Brussels (Belgium)**

Phone: +32 2 566 88 00

Fax: +32 2 566 88 01

www.nautadutilh.com

Contact person

Jo VANWITTENBERGH

E-mail

jo.vanwittenbergh@
nautadutilh.com

Date of establishment

1994

Number of employees

130

Market

Biotech or pharma companies
Healthcare Organization
Hospitals, nursing homes
Medtech companies

Distribution

Direct (own sales force)

Activities in Brussels

Legal advice, from IP to
regulatory and from contracts
to financial.

We provide a full range of
transactional, advisory and
litigation services tailored to
meet your requirements.

Corporate description

NautaDutilh is an independent law firm, focused on Belgium, the Netherlands and Luxembourg, with clients ranging from start-up ventures to industry leaders, whether in biotech, pharma, medical devices or diagnostics, and also the leading trade associations representing these industries in the Benelux and Europe. What they all have in common is their confidence in the way we work, in our knowledge and experience of their sector and in our ability to provide innovative and practical solutions.

Life sciences companies have to cope with everchanging day-to-day economic cycles in a highly regulated marketplace. That's why we build our legal services around the product's and company's life cycle. And we cover every aspect of this from commercial and licensing agreements to financing and mergers & acquisitions, and from patent litigation and marketing authorization procedures to pricing & reimbursement. In other words, we provide a full range of transactional, advisory and litigation services tailored to meet your requirements.

Our strategy is not about being the biggest in the market or having the broadest range of services or even having the largest turnover. It is about doing what we do consistently well: understanding the unique needs and challenges of every key sector and client, thus providing a tailor made legal and client service. We believe that success in our business will only come through the consistent delivery of quality, value and service to our clients.

We are the only law firm in Belgium with a sector dedicated team that shares business and legal know how on a regular basis and provides the complete range of legal services.

SERVICES: EUROPEAN AUTHORIZED REPRESENTATIVE SERVICES - CONSULTING

Corporate description

Obelis provides European Authorized ("E.A.R.") representative services (Directive 93/42/EEC): classification and identification of proper regulation; technical documentation review, keeping and updating; labeling compliance and language requirements; incident reporting and complaint handling; guidance on post-marketing surveillance; regulatory advice; European regulatory strategy; pre-market notification to EU authorities (Class I devices).

The designation of a E.A.R. is mandatory for manufacturers not established within the European Union – this profession was first created by the "New Approach" Directives in the late 90' and early 2000'. Today, there are very few professional E.A.R. who understood the definitions and responsibilities and took it upon themselves to spread out the "word of the EU Parliament" in reference to safety and EU conformity, towards Non-EU manufacturers.

Obelis is an active participant at major discussions in reference to the new definitions on the E.A.R., supporting EU legislators through position papers, professional presentations, workshops and seminars allowing the profession & service of a E.A.R. to be correctly structured in the coming new European legislations.

Obelis is also one of the few E.A.Rs that is ISO 9001: 2008 & ISO 13485 certified.

For the last 15 years, we met with manufacturer's associations, ministries of health, chambers of commerce, standard institutes and other institutions in Europe & all over the world; conducted workshops and seminars worldwide and we have enlarged our client base to represent over 40 countries around the world.

**Boulevard Général Wahis, 53
B - 1030 Brussels (Belgium)**

Phone: +32 2 732 59 54

Fax: +32 2 732 60 03

www.obelis.net

Contact person
Gideon ELKAYAM

E-mail
mail@obelis.net

Date of establishment
1988

Number of employees
9

Market
Medical Device Manufacturers

Activities in Brussels
Headquarter.

LABORATORY EQUIPMENT - IN-VITRO DIAGNOSTIC TECHNOLOGY: DIGITAL
HOLOGRAPHIC MICROSCOPY

Rue Engeland, 555
B - 1180 Brussels (Belgium)

Phone: +32 2 600 50 90

Fax: +32 2 600 50 45

www.ovizio.com

Contact person

Philip MATHUIS

E-mail

philip.mathuis@ovizio.com

Date of establishment

2009

Number of employees

5

Market

Hospitals, nursing homes
Biotech or Pharma companies

Distribution

Direct (own sales force)

Activities in Brussels

Headquarter
R&D: research
Marketing
Distribution

Corporate description

Spin-off of the ULB specialized in imaging systems and sensors based on Digital Holographic Microscopy (DHM). The company designs and markets optical instruments and adapted services primarily for the Life Sciences industry. DHM is the technology of acquiring and processing holographic measurement data, typically via a CCD camera or a similar device.

The product is composed of a microscope device (optical hardware) and advanced software for image capturing, processing and analysis. USP's and advantages: Partially coherent light: high quality images in harsh environments for real time analysis of particles in fluids and transparent objects.

Real Time:

- high acquisition speeds of "microscopic holograms" offer dynamic supervision of industrial processes
- Large depth of focus: observing large volumes bring reliable counting and analyses of particles in fluids out of the narrow focus plane
- Multimodal: fluorescence, bright field (regular imaging), dark field in both transmission and reflection mode in a single device
- Fluorescence: fluorescent holograms allow for full analyses of the observed volume
- LED light: high power LED's lead to cost effective and robust optical devices.

4 versions of the technology:

- oLine: desktop device for research and lab use
- pLine: portable device for field research
- iLine: industrial Holographic device for in-line monitoring
- mLine: extension unit for classical optical microscopes.

Ovizio's unique real time high quality 3D imaging technology of microscopic particles allows our customers to obtain detailed data and images of samples, breaking the barriers between the traditional speed of flow cytometry and the resolution of classic microscopy.



SERVICES IN FIELD OF INTELLECTUAL AND INDUSTRIAL PROPERTY PROTECTION:
PATENTS, TRADEMARKS, MODELS, COPY RIGHTS, ...

Corporate description

Pronovem-Office Van Malderen belongs to the pronovem group which has offices in Belgium (Brussels, Liège, Gent), Luxembourg and France (Lille) protect the commercial and technological innovations of their clients through patents, tradeMarks, designs, plant-breeder rights, domain names and copyrights filing and registration.

Our experienced European, Belgian, Luxembourg, Benelux and French patent and trademark attorneys provide IP services including but not limited to :

- prior art search
- patents drafting, filing and prosecution
- trademarks and designs filing and prosecution
- freedom to operate analysis
- litigation before national courts and before the European office

Market

All fields of technology.

**Avenue Jossé Goffin, 158
B - 1082 Brussels (Belgium)**

Phone: +32 24263810

Fax: +32 24263760

www.pronovem.com

Contact person

Eric VAN MALDEREN

E-mail

brussels@pronovem.com

Date of establishment

2000

Number of employees

25

Market

Consumer (mass market)
Biotech or pharma companies
Healthcare Organization
Hospitals, nursing homes
Medtech companies
Physicians/Doctors

Activities in Brussels

Headquarter
Service company

PEPTIDE APIS CGMP MANUFACTURING - THERAPEUTICS: SMALL MOLECULES, CHEMICAL MOLECULES, GENERICS/BIOSIMILARS

**Rue de Ransbeek, 310
B - 1120 Brussels (Belgium)**

Phone: +32 2 264 17 10

Fax: +32 2 264 34 70

www.peptisyntha.com

Contact persons

Johan DEVENYNS

Marc FOUASSIER

E-mail

johan.devenyns@solvay.com

marc.fouassier@solvay.com

Date of establishment

1987

Number of employees

45

Market

Biotech or pharma companies
Healthcare Organization

Distribution

Direct (own sales force)

Activities in Brussels

Headquarter
Research & Development
(R&D)
Manufacturer
Service company



Corporate description

Peptisyntha is a globally recognized cGMP manufacturer of clinical and commercial peptides.

With peptides dedicated laboratories, kilolabs, pilot and commercial scale manufacturing units (for chemical synthesis, for HPLC purification and for lyophilisation), Peptisyntha offers the advantage of a single point of contact for R&D, process development and production of peptide APIs, therefore supporting its pharmaceutical and biotechnological clients throughout the entire lifecycle of their peptide product.

With two GMP manufacturing facilities in USA and Belgium, Peptisyntha masters all peptide manufacturing technologies (SPPS, LPPS and hybrid approaches) at all scales.

Based on its rich expertise and technical know-how in peptide synthesis, Peptisyntha has also ventured into adjacencies beyond APIs over the past few years. Currently, Peptisyntha is working on two projects based on advanced peptide biomaterials using the self-assembling properties of peptides:

- 1. peptide hydrogel for cell culture
- 2. peptide-based biomaterials for controlled release of drugs.



COMMUNICATION AND INFORMATION TECHNOLOGIES: COMPUTER SOFTWARE
(DATA MANAGEMENT, STATISTICAL ANALYSES, EDC, MANAGEMENT OF
CLINICAL STUDIES)

Corporate description

S-CLINICA provide advanced technologies and professional expertise for real-time management of clinical studies. We offer IVRS services, data management, biostatistical analyses, statistical consultancy and scientific writing. Our preferred provider relationships with several international pharmaceutical and biotechnology companies bear witness to our reputation.

Technology description

With S-IVRS

- Clinical trial management is performed in real time
- Recruitment is initiated and locked promptly
- Recruitment target is reached rapidly
- Study participants – Sponsor, Monitors, Investigators, Data Managers, Pharmacists, Laboratories – cooperate in real time
- Data is accurate

With our Treatment Logistics

- Clinical Trial Kits are used with a minimum of waste

With our Data Management

- Data validation is prompt and accurate
- CRF data is managed by means of web-technology
- CRF pages are traced in real-time

With our Bio-Statisticians

- Statistical analyses and reporting of results are excellent
- Randomisation method is tailored to each study
- Treatment allocation process is monitored

Services description

IVRS services (central randomisation, treatment supply management, e-diaries) - Data management - Statistical analyses - EDC.

Innovative aspects

We provide services compliant with FDA 21 CFR Part 11, Good Clinical Practice and ISO 9001. Our Biometry, IVRS and IT professionals ensure you excellent services and assistance throughout your study. The Quality Assurance department ensures that our operating procedures comply with required standards. Internal, external and client auditing regularly evaluates the quality of our services. We protect data with a highly secure backup.

**Chaussée de Boondael, 6 b12
B - 1050 Brussels (Belgium)**

Phone: +32 2 645 05 55

www.s-clinica.com

Contact person

Irena SEREDINA

E-mail

info@s-clinica.com

Date of establishment

1997

Market

Clinical trials

Activities in Brussels

Headquarter
Research & Development
(R&D)

SERVICES: CE MARKING - CERTIFICATION BODY

Internationalelaan, 55
gebouw D
B - 1070 Brussels (Belgium)

Phone: +32 2 556 00 20
Fax: +32 2 556 00 36

www.be.sgs.com/cebec
www.sgs.com/en/life-sciences/medical-devices.aspx

Contact person
Bart MERSSEMAN

E-mail
bart.mersseman@sgs.com

Number of employees
50

Activities in Brussels
- Service company
- Headquarter
* Product Certification
* Quality Management
- System Certification and CE Certification in Antwerp

Corporate description

The SGS Group Belgium is a group of companies whose mission consists of monitoring and improving the quality of goods (eg. Medical Devices), products, services and systems, as well as the environment.

Technology description

In the therapeutic, diagnostic and telemedicine activity field we provide market access for medical devices through:

CE certification (div. S&SC)

- Notified Body with identification number 1639
- BELAC accredited
- Medical Device Directive 93/42/EEC conformity assessment

Quality Management System certification (div. S&SC)

- ISO 9001 (Generic quality system standard)
- (EN) ISO 13485 (Medical device quality system standards)

Product testing and certification (div. Cebec)

- EN 60601-1 (Medical Devices) + national deviations
- Worldwide CB Test Certificates according to IEC 60601-1
- Inside Test laboratory (ISO 17025 compliant)
- CEBEC-marking

With 50.000 customers worldwide, SGS is the world's preferred certifying body. We share with our customers the wealth of 125 years of experience in certification, testing and verification across most major industries in the world, and provide them with innovative services to build a leading competitive edge and succeed in today's and tomorrow's competitive markets.

Innovative aspects

Accredited by the Belgian authorities (BELAC) and notified to the European Commission (MDD 93/42/CEE). Belgian organization for conformity assessment and certification under the Directive "Medical Device" for the broad range of active and non-active medical devices.

Market

- Conformity assessment and CE-certification of Medical Devices under the European Directive 93/42/CEE /Belgian Royal Decree of 18 March 1999
- Quality management systems certification according to ISO 9001 and ISO 13485 (Medical Devices-Quality management systems-Requirements for regulatory purpose)



ALLERGY - CARDIOVASCULAR DISEASES - CNS - DIABETES - DIGESTIVE DISEASES IMMUNE SYSTEM - INFECTIOUS DISEASES - INFLAMMATION - ONCOLOGY - RESPIRATORY DISEASES - CONSULTING ACTIVITIES: MARKET ACCESS

Talos Health Solutions (THS) has developed and created a 3D web platform replicating the ergonomic layout of a convention center (healthwebevents.com).

This technology is a starting point for the development of a wide range of services to Patients, PAGs, Health Professionals, Pharmaceutical Companies and Government.

THS's concept and business model has been developed to address several challenges that link to the economic situation affecting present and future patients.

THS strategy goes beyond simply providing basic web events:

- Our primary strength is to propose web strategies to strengthen compliant relationships between patients, Health professionals and pharma companies through high valued Healthwebevents.
- Secondly, THS has created "TalosHealthAnalytics" to bring intelligence to our web events data collection with actionable dashboard designs.

**Chaussée de Saint Job, 145
B - 1180 Brussels (Belgium)**

Phone: +32 2 496 58 72 19

www.thaloshealthsolutions.com

Contact person

Jérôme PRADIER

E-mail

jpradier@taloshs.com

Date of establishment

2011

Market

Consumer (mass market)
Hospitals, nursing homes
Biotech or Pharma companies
MedTech companies
Physicians/Doctors
Homecare
Healthcare organizations
Patients

Distribution

Direct (own sales force)

Activities in Brussels

Headquarter
Service company



CONSULTING ACTIVITIES

**Rue du tabellion, 64
B - 1050 Bruxelles**

Phone: +32 288 091 75

**www.thebiotechqualitygroup.
com**

Contact persons

Yvan GOUTTEBELLE
Fabrice DEKONINCK

E-mail

ygo@tbqgroup.com
fdk@tbqgroup.com

Date of establishment
2011

Number of employees
12

Market

Biotech or pharma companies
Medtech companies

Distribution

Direct (own sales force)

Activities in Brussels

Headquarter
Research & Development
Service company.

Corporate description

The Biotech Quality Group advises biopharmaceutical and medtech industries in their Quality Assurance strategy and operations.

BQG philosophy towards its customers is enforced through reactive and transparent processes, leading to measurable results:

- Reactiveness, through a close monitoring of our activities
- Transparency, involving straight relationship with our clients
- Commitment to results by implementing best practices and setting the right priorities.

BQG is also involved in the development of innovative solutions, in order to provide answers to key challenges faced by the bio-pharmaceutical industry, in the area of Production, Quality & Engineering.

Along with our customers, we are committed to the ethical and regulatory responsibility of developing safe and effective medicine. Collectively and individually, we commit ourselves in sharing the responsibility of delivering innovative and efficient solutions aiming at improving Quality Systems and Processes Sharing responsibilities (TM)





INCUBATORS

BLSI (BRUSSELS LIFE SCIENCE INCUBATOR)

**Clos Chapelle-aux-Champs, 30
b1.3030**

B - 1200 Brussels (Belgium)

Phone: +32 2 880 62 00

Mobile: +32 497 16 25 53

www.blsincubator.be

Contact person

Caroline TEUNISSE

E-mail

c.teunisse@blsiincubator.com

Brussels Life Science Incubator (BLSI) is the new biosciences incubator of the Brussels-Capital Region. BLSI offers a dynamic and stimulating environment for entrepreneurs and young innovative companies developing their activities in the biotech, medical devices and e-health sectors.

Our offer

High quality furnished offices and fully flexible laboratories BLSI offers a 2.350 m² gross area distributed in 30 office/lab modules established on 2 floors and connected with a modern and convivial lounge area. Furthermore, common areas, as well-equipped meeting rooms, cafeteria with catering services, copying and scanning facilities are shared within the BLSI entrepreneurial community.

Proximity to an extensive knowledge base

BLSI is at the heart of the Brussels campus of the "Université catholique de Louvain" and is surrounded by the faculty of medicine and its research institutes like the "de Duve Institute" (5.500 students and 1.000 teachers/researchers), the "Cliniques Universitaires Saint-Luc" (900 beds and 4.700 employees) various high schools (7.000 students) and famous research centers such as the European Organization for Research and Treatment of Cancer (EORTC - 200 employees). BLSI proximity allows hosted companies to rely on a pool of highly-skilled human resources and to benefit from a wide range of services offered by the UCL laboratories such as a privileged access to scientific equipment.

Business support and mentoring

BLSI provides young entrepreneurs and start-up companies with professional business support such as:

- access to a specialist
- business support network, business information and networking events
- assistance with grants and fundraising
- assistance in recruitment (operational & board level)

Location

BLSI is situated on the UCL campus in Brussels, at the heart of Europe and close to the European institutions. BLSI is ideally connected to the main highways reaching Brussels with a bus station and a subway station at the door and is only a 5-minutes-drive away from Brussels National Airport.



EEBIC (ERASMUS EUROPEAN BUSINESS & INNOVATION CENTER)

EEBIC (Erasmus European Business & Innovation Center), the Brussels Capital Region business and innovation centre was created in 1992. It has a comprehensive administrative infrastructure which enables you to start up your business under the best possible conditions.

EEBIC has very strong connections with academic partners who call upon its expertise in order to create spin-offs.

The ULB has a 30 % stake in the SA EEBIC and is thus positioned as a privileged and active share-holder.

The 6.600 m2 building which houses start-ups and where the EEBIC manages its activities is also the university's property.

Academic research resulting from the ULB's laboratories can be developed through the creation of university spin-offs. EEBIC owes its reputation in this field to the number of spin-offs thus created and the successful managerial orientation of the spin-offs conducted by its team and network of experts.

The EEBIC team is assisted by legal, scientific and management experts, in order to assess and support pioneering projects, which require specific skills.

Our scientific experts unsparingly offer their precious advice on emerging technologies:

- Biotechnology
- Chemical engineering
- Micro-electronics
- Positioning, management consultancy, patenting, etc

EEBIC provides you with a whole range of resources so that your project has the greatest possible chances of success. Apart from the preparation of a "business plan", EEBIC offers assistance with regard to strategic positioning, day-to-day management, intellectual property protection, etc.

**Avenue Joseph Wybran, 40
B - 1070 Brussels (Belgium)**

Phone: +32 2 529 58 11

Fax: +32 2 529 59 11

www.eebic.be

Contact person

Jean VAN NUWENBORG

E-mail

jvn@eebic.be

Rue de Ransbeek, 310
B - 1120 Brussels (Belgium)

Phone: +32 2 264 29 83

Fax: +32 2 264 34 20

[www.solvay.com/en/
innovation/
home.aspx](http://www.solvay.com/en/innovation/home.aspx)

Contact person
Thierry CARTAGE

E-mail
innovation.world@solvay.com



Welcome to the Innovation World

Solvay Campus is opened to "start-ups".

The initiative by Solvay Campus fits perfectly with the objectives of the European Commission and of the Brussels-Capital Region by encouraging R&D within small-sized creative promising and ambitious companies which if their project succeed can become the real drivers of new industrial activities.

In order to enable the start-ups to match their ambition and devote themselves to their core competences, Solvay Research and Technology is offering the access to technology resources. The selected companies receive research premises and back-up support and particular favorable rental conditions for a two year period.

The initiative is unique: a large research centre of a world size group, a leader in its spheres of activity is supporting and encouraging research in chemistry, materials, plastics on the frontiers of existing activities in which the start-up retains full autonomy and full ownership rights to its research.

Solvay Campus is located ideally to the north east of Brussels, close to the ring, within an easy distance from the International Airport in a 22 hectares parc with 120.000 m² of labs, offices and workshops, where the young entrepreneurs have the opportunity to meet 600 scientists, engineers, technologists of Solvay.

Solvay Campus offers among others :

- Technical building management services with assembly teams, electricians, IT, etc
- Documentation department with access to worldwide databases and the advice from Intellectual Property experts
- Analytical services with up-to-date know-how and equipment
- A "process engineering" department specialized in the design and technical economic assessment of pilot and industrial production facilities.





BRUSSELS SUPPORT ORGANIZATIONS



Tour & Taxis
Avenue du Port, 86c b211
B - 1000 Brussels (Belgium)

Phone: +32 2 422 00 24

Fax: +32 2 422 00 43

www.bea.irisnet.be

Contact person

Pierre LAMY

E-mail

pla@bea.irisnet.be

The Brussels Enterprise Agency's mission

The Brussels Enterprise Agency (BEA) is a key strategic regional partner for Brussels based businesses.

Information

BEA offers high-quality, timely and appropriate business information and tools to foreign investors, local start-ups and SMEs and provides them with support in areas such as starting up, financing, public grants, town planning regulations, environmental permits and other formalities.

With its extensive knowledge of all business support services in Brussels, BEA is the main gateway to find the suitable public or private partner.

The Brussels entrepreneurs may obtain the information free of charge by calling the 1819, Bea is the central operator of this regional call number.

Coaching

BEA also encourages business competitiveness through innovation and internationalization and gives intensive support to promising entrepreneur projects or businesses or that are of critical or extreme importance to the Brussels-Capital region, in particular in the areas of life technologies, ICT, green technologies and sustainable construction.

BEA's advice and services are free of charge and independent.

BEA is publicly funded by the Brussels Regional Government and is also known as the "Agence bruxelloise pour l'Entreprise or ABE (French name) or "Brussels Agentschap voor de Onderneming" or BAO (Dutch name).

The Brussels LifeTech Cluster is a non-profit initiative of the Life Technologies Business Unit of the Brussels Enterprise Agency (BEA).

The Brussels LifeTech Cluster's mission is to support the life science sector in the Brussels-Capital Region. Our objective is to ensure that the life sciences remain a strong driver of economic growth in the region, attracting new R&D companies, investors, and service & technology providers.

The Brussels LifeTech Cluster brings together companies with innovative, R&D-driven activities in the life sciences (active in the biotechnological, pharmaceutical or medical technologies sectors) that are based in Brussels but also academic research institutes and support organisations.

The main objective of the cluster is the visibility of the Brussels know-how, stimulating innovation, encouraging international partnerships and generating synergies between the players.

Mission

The mission of the Brussels LifeTech Cluster is to:

- Stimulate, accelerate and develop the competitiveness of the companies and "start-ups" mainly on our priority thematic
- Promote and facilitate international marketing of the cluster members.
- Stimulate "added value" interactions between the cluster members to create synergies, complementarities and all relevant collective initiatives.
- Create, with all regional partners, an adequate environment for innovation and the development of the sector.

Tour & Taxis
Avenue du Port, 86c b211
B - 1000 Brussels (Belgium)

Phone: +32 2 422 00 24
Fax: +32 2 422 00 43

www.bea.irisnet.be

Contact person
Pierre LAMY

E-mail
pla@bea.irisnet.be

Tour & Taxis
Avenue du Port, 86c b211
B - 1000 Brussels (Belgium)

Phone: +32 2 422 00 21
Fax: +32 2 422 00 43

www.brusselsnetwork.be

Contact person
Mathilde VIVOT

E-mail
mvi@bea.irisnet.be



Helping small businesses with the challenges that go beyond their familiar context: that is what the European Commission offers with the **“Enterprise Europe Network” (EEN)**.

Young and very small companies often do not have the means or the time to stay informed about the different European support programmes. Neither can they fully exploit the new technological and commercial opportunities, especially outside their usual scope of action and local markets.

The **“Enterprise Europe Network”** wants to close precisely this gap. Building on an experience of more than 15 years, this network has been launched by the European Commission in 2008 as the one-stop shop where entrepreneurs can get information, advice and a vast array of personalized supporting services.

With its 500 local contact points and 4000+ experienced staff active in more than 51 countries, this is simply the biggest International service network for companies.

Even though it is open to companies and institutions of varying size and activities, the network is mainly focused on SMEs. Thanks to the network, entrepreneurs have the opportunity to:

- Promote, acquire and use innovation in the company
- Become faster and more efficiently active on an international level
- Get information and advice on European policy, law and norms
- Find quality partners across borders for commercial, innovation or research projects
- Get access to European projects and financing

In Brussels, the network is represented by **“Enterprise Europe Brussels”**, a collaboration between the Brussels Enterprise Agency (BEA) and Brussels Enterprises Commerce and Industry (BECI).

“Enterprise Europe Brussels” helps companies and researchers of all sectors of industry and research, including in the field of medical technologies.

These services are free of charge

BRUSSELS invest & export is the foreign trade and investment agency of the Brussels-Capital Region. It aims to promote the internationalization of the Brussels economy.

Brussels is not only the Belgian and European capital, home of NATO and EU headquarters, but it is also a large business centre at the heart of the European market.

BRUSSELS invest & export assists Brussels companies operating in foreign markets. Almost ninety economic and trade commissioners across all continents provide free guidance to SMEs, target potential local prospects and partners, organise matchmaking visits... Concrete initiatives in Brussels and abroad include trade missions, contact days, buyers' invitations and collective stands at international trade fairs. Brussels exporters are listed in a database, www.brussels-exporters.be, which can be accessed by all foreign companies searching for partners.

Another mission of **BRUSSELS invest & export** is to attract foreign companies to Brussels and to provide them with support, should they decide to locate their business in the Region.

To enable investors to assess the benefits of establishing in the capital, **BRUSSELS invest & export** offers them a "Welcome Package" which includes equipped office space at no cost for a three-month period.

To support the above mentioned activities, **BRUSSELS invest & export** has developed a trade counseling service to help companies individually with their internationalization process as well as a competitive and economic watch service to monitor and inform on international trends and opportunities.

**Avenue Louise, 500 b4
B - 1050 Brussels (Belgium)**

www.brusselsinvestexport.be

E-mail

info@brussels-export.irisnet.be

Contact persons

Ghislain BREYDEL

Phone: +32 2 800 40 84

Emmanuel DE BEUGHEM

Phone: +32 2 800 40 64

E-mail

gbreydel@mrbc.irisnet.be

edebeughem@mrbc.irisnet.be

**Boulevard A. Reyers, 80
B - 1030 Brussels (Belgium)**

Phone: +32 2 706 80 02

www.agoria.be

Contact person

Carole ABSIL
Agoria Medical Technologies

E-mail

carole.absil@agoria.be

Agoria is the federation for the technology industry. Agoria is Belgium's largest employers' organization and trade association and is financed by member contributions.

Our members are our driving force

Agoria is the partner of more than 1.600 companies in the technology industry. The federation's 230 employees provide the members with information, services and advice.

Our members are our strength

Agoria doesn't let the strength of its member companies go to waste. We help to shape policy at regional, Federal and European level in a bid to improve the social and economic climate for companies in the technology industry.

The health sector is an important market for about 170 Agoria's member companies.

Those companies manufacture, develop and sale:

- Electromedical devices and medical technologies
- ICT solutions (eHealth)
- Industrial solutions for the pharma and labo industry
- Commodities and consumer goods

Agoria has developed various initiatives in order to help those members finding new opportunities and developing new products, services and/or solutions adapted to the health sector. Those activities are focussing on both the national and international markets.

BeCRO is the Belgian Association of CROs (Contract Research Organization).

BeCRO was founded by a group of 19 Belgian CROs in January 2010, BeCRO asbl/vzw is a non-profit organization established in Brussels. To-date, BeCRO counts over 30 members.

The BeCRO mission is to:

- Represent and defend the interests of such companies to health authorities, companies, institutions and organizations operating in and regulating the health sector
- Be recognized as an authorized spokesperson by health authorities, professional bodies and national or international associations and/or federations
- Establish required operating practices, with respect to the highest quality rules and GXP's
- Develop training programs for its members
- Promote Contract Research in Belgium

Rue Saint Lambert, 141
B- 1200 Brussels (Belgium)

www.becro.be

Contact person
Philippe VAN DER HOFDSTADT

E-mail
info@becro.be

**Diamant Building
Boulevard A. Reyers, 80
B - 1030 Brussels (Belgium)**

Phone: +32 2 238 98 47

Fax: +32 2 231 13 01

www.bio.be

Contact person

Johan VANHEMELRIJCK
Manager

E-mail

cb@essenscia.be

The “Belgian Association for the Biotechnology Industry” (Bio.be)

was founded in January 2006 and is now an integrate in essenscia, the Belgian chemical and life sciences federation.

Bio.be represents companies and professionals involved in research, development, tes-ting, production or marketing of biotechnology applications, as well as those servicing the bio-technology community.

BIO.BE ACTIVITIES

The association stimulates, promotes and defends biotechnological innovation and entrepreneurship as an essential factor of economic growth, of more and better employment and of an expanded science and skills base.

In the Belgian federal state Bio.be represents the interests of the biotechno-logy industry by anticipating, shaping, steering and correc-ting our regulatory environment and by interacting or allying with other stakeholders such as patient groups and other intermediate or final users, media, policymakers or fund providers. In addition, Bio.be represents its members towards relevant trade, industry, business or academic organizations in Belgium, Europe and worldwide.

Bio.be’s members are offered support for rai-sing their standards, by finding or creating the tools, introductions and networks required for reaching their full potential.

Bio.be pays particular importance to the specific needs of our entrepreneurial members, whose success will determine the future of biotechnology in Belgium.

EDMA (EUROPEAN DIAGNOSTIC MANUFACTURERS ASSOCIATION)

EDMA (the European Diagnostic Manufacturers Association) represents national associations and major companies engaged in the research, development, manufacturing or distribution of In Vitro Diagnostic (IVD) tests in Europe. Through its membership, EDMA represents in total more than 500 companies (or over 700 legal entities) across Europe. The mission of EDMA is to raise awareness of the importance, usefulness and added value that diagnostic information can provide to healthcare. For this purpose, EDMA cooperates with European institutions, patients groups, trade associations, health professionals and academia to support an appropriate regulatory system, to work towards a realistic economic environment for healthcare in Europe and to be an effective voice in globalisation.

Description of the technology

Laboratory testing, In Vitro diagnostics.

Activities in Brussels

EDMA's Brussels-based office monitors EU initiatives and actively contributes to European policies of interest to the IVD industry and the overall healthcare industry.

Activities in other countries

EDMA represents 21 National Association Members and 43 Corporate Associate Members from across Europe. Members are engaged in the research, development, manufacture and distribution of IVD products in Europe.

Fields of action

The main activities of EDMA include promoting the value of In Vitro testing in healthcare, supporting appropriate regulatory systems and improving the economic conditions in the market in order to ensure the continued supply of high quality, cost effective products. Through its activities, EDMA aims to create a level of awareness and business environment that ensures a leading role for IVDs in healthcare.

**Place des Maîtres, 2
B - 1150 Brussels (Belgium)**

Phone: +32 2 772 22 25

Fax: +32 2 772 23 29

www.edma-ivd.eu

Contact person

Madeleine LAFFONT
Director Public Affairs &
Communications

E-mail

edma@edma-ivd.eu

EHTEL

(EUROPEAN HEALTH TELEMATICS ASSOCIATION)

**MEPS - Rue d'Arlon, 50
B - 1000 Brussels (Belgium)**

Phone: +32 2 230 15 34

Fax: +32 2 230 84 40

www.ehtel.org

Contact person
Marc LANGE

E-mail
info@ehtel.org

EHTEL (European Health Telematics Association) provides to its members a platform for information communication, representation, networking and co-operation in support of the implementation of information and communication technologies (ICT) in health and social care in Europe.

EHTEL believes that using ICTs in health and social care in Europe offers an unparalleled opportunity to revolutionize:

- The quality of health and social care services provided to patients and citizens
- The speed and ease of access to those services
- Their efficiency and cost effectiveness

The association brings together under one roof all of the constituencies with an interest in ICTs in health and social care:

- National and regional health authorities and systems
- Hospitals and other health institutions
- Public and private insurance providers
- Health professionals
- Health managers and executives
- Patients, citizens and consumers
- Industry
- Researcher and academics
- National and regional member-based organizations

Our Members benefit from exclusive and individualized EHTEL added values like:

- Networking within the EHTEL supported Working Groups
- Exchanging views with other stakeholder groups (ministries, health professionals, industry, insurers, patients, academics, etc)
- Getting briefing papers for them influencing policies related to priority themes as addressed by EHTEL Task Forces
- Gaining visibility in the eHealth arena by:
 - * Securing speaking slots in conferences
 - * Putting papers forward in professional publications
 - * Sponsoring EHTEL events
- Sharing field experience in eHealth deployment
- Obtaining individualized support in seeking for information

EUCOMED represents the medical technology industry in Europe. Our mission is to make modern, innovative and reliable medical technology available to more people.

Eucomed members include both national and pan-European trade and product associations as well as medical technology manufacturers. In total we represent around 22,500 designers, manufacturers and suppliers of medical technology used in the diagnosis, prevention, treatment and amelioration of disease and disability.

The industry we represent employs more than 500,000 people, turns over €95 billion per year in Europe and encompasses some 500,000 different medical technologies from sticking plasters and wheel chairs through to pacemakers and replacement joints.

Eucomed promotes a balanced policy environment that enables our industry to meet the growing healthcare needs and expectations of our stakeholders. We maintain a close dialogue with them and demonstrate the value of medical technology through health-economic research, data collection, membership services and clear communications.

Our secretariat comprises some 30 experts who are in continuous contact with EU stakeholders, and we and our members are committed to ensure that fundamental collaboration with healthcare professionals adheres to the highest ethical and professional standards

**Place des Maieurs, 2
B - 1150 Brussels (Belgium)**

Phone: +32 2 772 22 12

Fax: +32 2 771 39 09

www.eucomed.org

Contact person
Ingmar DE GOOIJER

E-mail
info@eucomed.be

**Rue des Sols, 8
B - 1000 Brussels (Belgium)**

Phone: +32 2 515 08 81

Fax: +32 2 515 09 39

www.healthcarebelgium.com

Contact person
Herwig FLEERACKERS

E-mail
herwig.fleerackers@
healthcarebelgium.com

Healthcare Belgium is an official Belgian non-profit organisation established in 2007 by 11 top Belgian hospital groups.

The organisation receives substantial support from Agfa Healthcare, the Federation of Enterprises in Belgium (VBO-FEB), Ion Beam Applications (IBA) and VK Group amongst others.

Objective

Internationalisation of the Belgian medical sector Belgium ranks in the top in Health in The Global Competitiveness Report published by the World Economic Forum : Nr.1 in 2010-2011 and Nr.2 in 2011-2012.

In order to develop new areas of international cooperation, Healthcare Belgium achieves breakthroughs in the medical sector, establishing relationships and collaboration with public and private partners worldwide.

Healthcare Belgium offers unique collaboration opportunities:

Academic & Clinical Knowledge Transfer

- Training
- Fellowships
- Education

Health Technology Implementation

- Management of Hospital
- Digitisation of hospital administration
- Design and construction of hospitals

Patient Treatment

- Telemedicine, teleradiology services
- Treatment of patients
- Remote Medical Opinions/ Second Opinions

Indutec has been created on the initiative of the 4 Brussels Industrial Engineering Institutes to provide a common and complementary technology transfer office (interface) to Brussels businesses.

The four Institutes represented are:

- ECAM – Haute Ecole Leonardo da Vinci
- EHB (Erasmushogeschool Brussel) Industrial Sciences & Technology
- IM (Institut Meurice Chemistry Biochemistry) Haute Ecole Lucia de Brouckère
- ISIB (Institut Supérieur Industriel de Bruxelles) Haute Ecole Paul-Henri Spaak

Through InduTec, more than 200 professors and researchers put their scientific know-how at the companies' service, drawing as well on various research centres or associated organizations/ bodies.

Acting as an external R&D centre for Businesses and Entrepreneurs, InduTec works in both directions:

- Finding industrial/business partners for technological innovations initiated in one of the Institutes when it becomes necessary
- Responding to any requests for research and/or consulting work from the industrial world through contractual research, industrial sub-contracting, collaborative Research and embedded labs

In addition to Biotechnological sciences, the Institutes offer the following area of expertise available to research program and consulting services: Agro-food technologies, Electronics and ICT, Electromedical equipments, Industrial and Material technologies, Medicine & Human health, Physical sciences & Measurements, Protecting man and Environment, Rational use of energy, and Transport technologies.

InduTec welcomes all collaboration, from the private inventor to the long standing companies, and acts in: Engineering processes, Technological assessment, Economical assessment IPR support, R&D funding evaluation, Technical prototype building, Commercial prototype development, Marketing plan, Business plan.

At InduTec, we match our engineers' potential and know-how with Industry's needs.

**Avenue Nellie Melba, 73
B - 1070 Brussels (Belgium)**

Phone: +32 2 534 33 79

Fax: +32 2 434 33 95

www.indutec.be

Contact person
Cédéric DOUTRELEPONT

E-mail
info@indutec.be



**Domaine Latour de Freins
Rue Engeland, 555
B - 1180 Brussels (Belgium)**

Phone: +32 2 600 50 34

Fax: +32 2 600 50 47

www.innoviris.be

INNOVIRIS Director
Claude MAY

E-mail
cmay@innoviris.be

Contact person
Xavier HULHOVEN

E-mail
xhulhoven@innoviris.be

INNOVIRIS is a funding organization that encourages, promotes and supports scientific research and technological innovation at companies, universities and higher education institutes located in the Brussels-Capital Region. The main goal of the Institute consists in increasing the economic activity of the Region and in developing local excellence.

INNOVIRIS actions in favour of SMEs and large companies

INNOVIRIS launches one to two call(s) for proposals a year. In this framework, INNOVIRIS grants subsidies and repayable loans to support ambitious research or pre-competitive development projects. To benefit from this action, companies have to submit a proposal in which they present their project. This proposal is reviewed by experts (INNOVIRIS scientific advisers and/or academic experts). Their reviews serve as basis for the funding decision.

Additional actions dedicated to SMEs

Beyond the R&D-funding, SMEs can benefit from regional funds if they want to delegate the carrying out of a feasibility study to a university, a higher education institute or a research centre. The aim of this action is to enable SMEs to evaluate the industrial potential of an innovation before starting a more ambitious research or development program. Finally, SMEs can benefit from regional funds for the deposition and enforcement of patent(s).

INNOVIRIS actions in favor of universities and higher education institutes

In the framework of the "impulse" action, INNOVIRIS funds cooperative research programs with a midterm economic goal. The research consortia are composed of teams of highest standard belonging to the universities, institutions of higher education and/or collective research centres located in the Brussels-Capital Region.

The "strategic platforms" program is in the continuity of the "impulse program". It aims to strengthen the attractiveness and the potential of the regional economic activities in areas of priority that are the Environment, Information and Communication Technology (ICT) and Life-Sciences.

Three actions are currently in progress:

- the "strategic platform" Environnement
- the "strategic platform" ICT
- the "strategic platform" Life-Sciences

MIM (Belgian Society for Medical Informatics) was established in 1974 to promote and develop medical information science and technology in Belgium. It is a national bilingual (French and Dutch) society consisting of about 150 members, all involved or interested in the use of computers and telematics in the health-care environment. The administrative board includes 15 members (physicians, engineers and computers specialists) from academic institutions, hospitals, computers and the software industry.

The “MIM” is a scientific society. Its major activities focus on improving communication among researchers and developers in the field of medical computing and telematics. It is also the place of choice where problems related to the role of medical informatics in society and its ethical aspects are discussed.

International related medical informatics societies:

- The MIM is the Belgian member of EFMI (European Federation for Medical Informatics) and of IMIA (International Medical Informatics Association). As such, the MIM is involved in the setting up of whose congresses, scientific events and publication.
- The MIM cooperates closely with the Dutch (VMBI), French (AIM) and Swiss (SSIM) medical informatics societies to organize annual scientific meetings: the “Medish Informatica Congres” (MIC) and the “Journées Francophones d’Informatique Médicale” (JFIM) .

**Avenue Hypocrate, 10 b47.11
B - 1200 Brussels (Belgium)**

Phone: +32 2 764 32 62

Fax: +32 2 764 31 83

www.bmia.be

Contact person

Dr Etienne DE CLERCQ
Chairman
Health System Research

E-mail

Etienne.Declercq@uclouvain.be

UCL-ESP

Clos Chapelle aux Champs 30.41
B - 1200 Brussels (Belgium)

**Chaussée de la Hulpe, 166
B - 1170 Brussels (Belgium)**

Phone: +32 2 661 91 06

Fax: +32 2 661 91 99

www.pharma.be

Contact person

Christine VANORMELINGEN
Communication Director

E-mail

cvo@pharma.be

pharma.be is the General Association for the Medicine Industry in Belgium. Its role is to represent its member companies to Belgian society and the Belgian health care partners in all areas related to human and veterinary medicines (i.e. regulation, information, budget, reimbursement, etc).

pharma.be, the General Association for the Medicine Industry (AGIM) was founded in 1966.

- pharma.be combines 130 pharmaceutical companies based in Belgium and has a staff of 20 experts in the juridical & deontological, economic and health scientific field.
- As a partner to the general public, patients, doctors, pharmacists, hospitals, authorities and other stakeholders, pharma.be ensures the promotion of the best available healthcare treatment in the field of medicines through therapeutic innovation.
- The priority of pharmaceutical laboratories and health professionals is to offer patients access to the best suited , medicine, according to his or her personal characteristics.
- pharma.be favours a policy which, through branded medicines, permits the funding of research and development costs for the medicines of the future, thanks to a budget which matches real healthcare needs.

pharma.be represents a dynamic, innovative and responsible sector with an essential synergy between small, medium and large (bio) pharmaceutical research companies, universities, biotech spin-offs and hospitals. Not in the least to maintain the important activities in clinical research and clinical trials in Belgium.

The association emphasizes the public and animal health contribution made by the industry through new medicine research and development with a focus on the societal importance and responsibility of the sector and medicines on one hand, and the importance to the economy of research, clinical trials and medicine production on the other hand.



UDIAS

(PROFESSIONAL ASSOCIATION OF DISTRIBUTORS AND PRODUCERS OF LABORATORY EQUIPMENT)

UDIAS, the Professional Association of Distributors and Producers of Laboratory Equipment, was founded in 1936.

Now **UDIAS** is a non-profit organization that represents over 90 companies. With their products, services and specialities they contribute to the development of the Belgian market, the quality of our environment, our healthcare, the quality of our food and the development of new technologies.

| Product Categories | Areas of application |
|--|------------------------------|
| Equipment | Environment |
| Peripherals | Food and beverage |
| Reagents | Biotechnology |
| Analytical Instruments | Pharmaceutical industry |
| Chemical Products | Health sector |
| Automation Systems Industrial Medicine | Industrial medicine |
| Laboratory Equipment | Energy Sector ^(*) |
| On-line analysis | Polymers and composites |
| | Metallurgy |
| | Space research |
| | Transport |
| | Recycling and waste material |
| | Criminology |
| | Sports and sports medicine |

(*) gas, electricity, nuclear industry

UDIAS also organises Laborama, trade show for the laboratory sector, as well as the UDIAS Prize and the Analyst of the Year. Both these prizes reward young upcoming talents in the scientific community. The UDIAS Prize rewards master students and the Analyst of the Year rewards bachelors. For more info, please consult www.udias.be. UDIAS also developed the career website for the laboratory sector: Labojobs (www.labojobs.be).

The members of UDIAS are multinational companies as well as small and medium sized companies that distribute laboratory equipment in Belgium. The equipment includes instruments and apparatus for analysis, fermentation, chromatography, spectrometry, optical equipment, balances, centrifuges, thermostatic baths, shakers and stirrers, titration equipment, reagents, consumables. In short the full equipment for a laboratory.

**Z.1 Researchpark, 310
B - 1731 Zellik (Belgium)**

Phone: +32 2 481 00 50

Fax: +32 2 463 17 06

www.udias.be

Contact persons

Willy STELZER
Myrjam PANIS

E-mail

info@udias.be



**Avenue Roi Albert 1er, 64
B - 1780 Wemmel (Belgium)**

Phone: +32 2 257 05 90

Fax: +32 2 252 43 98

www.unamec.be

Contact person

Richard VAN DEN BROECK

E-mail

r.vandenbroeck@unamec.be

UNAMEC is the only notified professional association in Belgium that represents manufacturers, importers and/or distributors of medical devices. What are medical devices? All the products and equipment falling under the scope of the European directives on 'Medical Devices' 93/42/ACC and 'Active Implantable Medical Devices' (90/385/ECC). It concerns a very large scope (range of products of application, that covers disposables as well as implants to anesthetic equipment).

UNAMEC was founded on 6 March 1959, as a recognized professional association. In 1987, it was transformed into a non-profit organization with the right to employ staff. This professionalization led to increased effectiveness and impact, generating a rapid rise in membership. UNAMEC's 200 members represent 1.5 million of references and a turnover of 3.4 billion € on the Belgian market and employ about 18000 people.

UNAMEC represents the sector towards the concerned authorities in order to promote the essential role and the added value from our industry for the public healthcare.

Our members invest in up-to-date medical technologies and systems, including quality survey and training, so they ameliorate the efficacy of the healthcare services.

As a partner UNAMEC contributes on a permanent and pro-active base to the evolution of a payable healthcare sector, to ensure the access for the patient to the best possible treatment.

Our 4 priorities:

- Access
- Quality
- Financing
- Ethics



INDEX

Research Area Landscape

| | |
|--|----|
| UCL (UNIVERSITE CATHOLIQUE DE LOUVAIN) | 12 |
| ULB (UNIVERSITE LIBRE DE BRUXELLES) | 14 |
| VUB (VRIJE UNIVERSITEIT BRUSSEL) | 16 |
| HAUTE ÉCOLE LUCIA DE BROUCKERE | 18 |
| HAUTE ECOLE PAUL-HENRI SPAAK | 20 |

Companies Involved In Medical Technologies Fields

| | | | |
|---|----|---|----|
| 2INGIS | 24 | MEC (MEDICAL ELECTRONIC CONSTRUCTION) R&D | 41 |
| BIOMEDICAL SYSTEMS | 25 | MEDATEC | 42 |
| BRACING CENTER | 26 | MEDIBRIDGE | 43 |
| CARDIONICS | 27 | MEDICAL DEVICE WORKS | 44 |
| CHEMICAL PRODUCTS R. BORGHGRAEF | 28 | MEDIDA SOLUTIONS | 45 |
| CMD (CENTRALE MEDICO DENTAIRE) | 29 | MERCURA INDUSTRIES | 46 |
| CYRPA | 30 | PHILIPS MEDICAL SYSTEMS | 47 |
| DATA INNOVATIONS EUROPE | 31 | PROMODENT | 48 |
| DDD (DIGIAL DENTAL DESIGN) | 32 | PROTHETICA | 49 |
| DUMONT INSTRUMENTS | 33 | REMED PHARMA | 50 |
| EPISEARCH | 34 | RENOL | 51 |
| FONDA-MENTAL | 35 | RVB SA/NV | 52 |
| FSE INTERNATIONAL | 36 | SIEMENS (HEALTHCARE SECTOR) | 53 |
| IDEAS (INFORMATION DEVELOPMENTS FOR EDUCATIONAL APPLICATIONS AND SYSTEMS) | 37 | SMDW | 54 |
| IMAGILYS | 38 | STERITEC | 55 |
| INPUT FOR YOU | 39 | TELECLIN | 56 |
| KISANO BELGIUM | 40 | TERPAN LABORATORIES | 57 |
| | | UNI-COM | 58 |



Companies Involved In Biotechnology & Pharma Fields

| | | | |
|----------------------------|----|----------------------|----|
| AMGEN | 62 | GENTAUR | 74 |
| ASTRAZENECA | 63 | IDRABEL | 75 |
| ATMI (ARTELIS SA) | 64 | IMBP | 76 |
| BETA-CELL | 65 | LABIMA | 77 |
| BIOREMEDIATION EUROPE | 66 | PFIZER | 78 |
| BOEHRINGER INGELHEIM | 67 | PHARCO | 79 |
| BRABANT BIOTECH | 68 | SASMAR | 80 |
| CAF DCF RED CROSS | 69 | SMB LABORATOIRES | 81 |
| CHEMCOM | 70 | STEROP LABORATORIES | 82 |
| CLINEURODIAG | 71 | THERABEL PHARMA | 83 |
| DERMO-EXPERT GROUP SEADERM | 72 | TRENKER LABORATORIES | 84 |
| EUROSCREEN | 73 | UCB SA | 85 |

Companies Involved In Expertise & Services Fields

| | | | |
|--|----|--|-----|
| ALEXION | 88 | HARRISON CLINICAL RESEARCH BELGIUM | 97 |
| ALFA LAVAL | 89 | HM3A | 98 |
| BUSINESS DECISION LIFE SCIENCES | 90 | IOL STRATEGIC DESIGN | 99 |
| CATALENT PHARMA SOLUTIONS | 91 | LCA (LABORATOIRE DE CONTRÔLE ET D'ANALYSE) | 100 |
| CSA SOFTWARE | 92 | LSB - ATT | 101 |
| DE VALCK CONSULTANTS | 93 | MIMEDICATION | 102 |
| ECCRT (EUROPEAN CENTRE FOR CLINICAL RESEARCH TRAINING) | 94 | MODULO ARCHITECTS | 103 |
| FETON INTERNATIONAL | 95 | NAUTADUTILH | 104 |
| FORCEA | 96 | OBELIS | 105 |

| | | | |
|--------------------------------|-----|----------------------------------|-----|
| OVIZIO IMAGING SYSTEMS | 106 | SGS BELGIUM (DIVISION SGS CEBEC) | 110 |
| PRONOVEM (OFFICE VAN MALDEREN) | 107 | TALOS HEALTH SOLUTIONS | 111 |
| PEPTISYNTHA | 108 | THE BIOTECH QUALITY GROUP | 112 |
| S-CLINICA | 109 | | |

Incubators

| | | | |
|---|-----|---------------|-----|
| BLSI (BRUSSELS LIFE SCIENCE INCUBATOR) | 116 | SOLVAY CAMPUS | 118 |
| EEBIC (ERASMUS EUROPEAN BUSINESS & INNOVATION CENTER) | 117 | | |

Brussels Support Organizations

| | | | |
|--|-----|--|-----|
| BEA (BRUSSELS ENTERPRISE AGENCY) | 122 | EUCOMED | 131 |
| BRUSSELS LIFETECH CLUSTER | 123 | HEALTHCARE BELGIUM | 132 |
| EEB (ENTERPRISE EUROPE BRUSSELS) | 124 | INDUTEC | 133 |
| BRUSSELS INVEST & EXPORT | 125 | INNOVIRIS | 134 |
| AGORIA | 126 | MIM (BELGIAN SOCIETY FOR MEDICAL INFORMATICS) | 135 |
| BECRO | 127 | PHARMA.BE | 136 |
| BIO.BE | 128 | UDIAS (PROFESSIONAL ASSOCIATION OF DISTRIBUTORS AND PRODUCERS OF LABORATORY EQUIPMENT) | 137 |
| EDMA (EUROPEAN DIAGNOSTIC MANUFACTURERS ASSOCIATION) | 129 | UNAMEC | 138 |
| EHTEL (EUROPEAN HEALTH TELEMATICS ASSOCIATION) | 130 | | |







BrusselsLifeTech
Powered by BEA

Tour & Taxis
Avenue du Port 86c B 211
B - 1000 Brussels (Belgium)
Phone +32 2 422 00 24
Fax +32 2 422 00 43
www.brussellslifetech.com



With the support of



BRUSSELS-CAPITAL REGION